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GENERAL INTRODUCTION
Sensitive non-invasive imaging in oncology may lead to earlier detection of (recurrent) 
cancerous tissue. Intraoperatively, real-time imaging methods may improve tumor 
visualization and prevent recurrences. Thus, imaging can improve both diagnosis and the 
outcome of therapy, and improve the prognosis of oncology patients. 
MOLECULAR IMAGING
Conventional imaging techniques, such as computed tomography (CT), magnetic resonance 
imaging (MRI) and ultrasound, provide the clinician with high resolution anatomical 
images. Molecular imaging can provide additional information about biological processes 
at the cellular or molecular level. In molecular imaging (i.e. nuclear imaging techniques 
or fluorescence imaging) the distribution of specific endogenous or exogenous molecules 
(contrast agents) can be assessed to visualize the underlying biology of the disease. 
SPECT/CT
Single photon emission computed tomography (SPECT) is a nuclear imaging technique that 
visualizes gamma rays using a collimator and a detection crystal. This may be combined with 
a CT scan for anatomical correlation of the radioactive signal. The advantage of SPECT over 
conventional gamma camera imaging, is that a 3-dimensional reconstruction of the images 
can be made. Well known examples of gamma camera imaging in clinical practice are a bone 
scan (99mTc-MDP) or a renogram (99mTc-MAG3)[1, 2]. 
PET/CT
For positron emission tomography (PET), radionuclides are used that emit positrons, which 
produce two 511 keV gamma rays after annihilation with an electron. The gamma rays 
travel in opposite direction and can be detected with a PET-scanner. After processing the 
collected data, 3-dimensional images of the distribution of the tracer in the body can be 
obtained [3]. Often, conventional CT imaging is performed for correlation to the anatomy 
and for attenuation correction of the radioactive signal. Imaging of glucose metabolism with 
Fluorine-18-fluorodeoxyglucose (18F-FDG) is probably the best known and most widely used 
type of molecular imaging in cancer [3]. Distinct advantages of PET as compared to SPECT 
are the superior resolution (for clinical scanners only), the shorter acquisition time for whole-
body 3D images, and the potential for quantitative analysis of tracer distribution. 
Fluorescence imaging
A technique that is rapidly gaining interest for molecular imaging is fluorescence imaging. A 
fluorophore can be excited by light of a distinct wavelength, which subsequently leads to the 
emission of a photon of a slightly longer wavelength. These emitted photons can be detected 
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with a fluorescence camera and converted to an image. Due to the limited penetration depth 
of light in biological tissue, fluorescence imaging can only be applied in specific settings, for 
instance during surgery.
TUMOR-TARGETED IMAGING
A specific form of molecular imaging consists of targeting tumor-associated antigens that 
are preferentially expressed by tumor cells. When coupling a radionuclide or a fluorescent 
dye to a molecule that specifically binds to the tumor-associated antigen, a tumor-targeting 
imaging probe is created. After injection of the probe, the primary tumor or metastases can 
be imaged with for example PET, SPECT, or fluorescence imaging. 
Targeting molecules
Various molecules, such as receptor ligands, peptides, monoclonal antibodies, or antibody 
fragments, can be used to target tumor-associated antigens. The advantage of monoclonal 
antibodies is that they bind with high specificity to their target and that their large size allows 
for coupling with a fluorescent label or a radionuclide, without significantly compromising 
their affinity for the target molecule or altering the in vivo targeting characteristics of the 
antibody. Major differences exist between the clearance of the different molecules. In general, 
smaller molecules, such as peptides or (engineered) antibody fragments (minibodies 80 kDa, 
diabodies 50 kDa, or single-chain Fv 25 kDa), have a short circulatory half-life, while intact 
antibodies, due to their large size (150 kDa) and recycling due to interaction of the Fc portion 
with the Brambell receptor (FcRn) on cells [4], have slower pharmacokinetics. The clearance 
determines the optimal interval between injection and imaging. For intact antibodies several 
days are needed to allow for sufficient accumulation in the tumor and clearance from the 
blood, while smaller molecules can allow for imaging on the day of injection [5]. Furthermore, 
small molecules that are below the limit for glomerular filtration (60 kDa) are cleared through 
the kidney [6], whereas intact antibodies are metabolized in the liver. 
Radionuclides
When selecting a radionuclide to label a tumor-targeting molecule, it is important that the half-
life of the radionuclide matches the pharmacokinetics of the targeting molecule. Commonly 
used radionuclides for PET imaging are Fluorine-18 (t1/2 109 minutes), Gallium-68 (t1/2 68 
minutes), or Zirconium-89 (89Zr, t1/2 3.2 days). For monoclonal antibodies, radionuclides with 
a longer half-life such as Zirconium-89 or Iodine-124 (t1/2 4.2 days) are needed. An important 
advantage of Zirconium-89 is its retention in the tumor cell after antibody internalization, 
whereas Iodine-124 is released by the cell. This results in an improved tumor-to-background 
contrast when Zirconium-89 is used compared to Iodine-124 [7]. A suitable radionuclide for 
SPECT imaging that matches the slow pharmacokinetics of antibodies is Indium-111 (t1/2 2.8 
days, 171 and 245 keV gamma rays).
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Fluorescent dyes
Several dyes are available that can be conjugated to targeting molecules (e.g. blue dye, 
IRDye800CW and FITC). Dye characteristics that may be considered when selecting a 
fluorophore are the quantum yield, stokes shift and excitation wavelength. Dyes that absorb 
light in the 400 to 700 nm range (e.g. blue dye) are visible to the human eye, but a disadvantage 
is that they change the appearance of the surgical field. When using dyes that absorb light 
in the near-infrared range (NIR, 700-1000 nm) an external light source and detection system 
are needed, since light of these wavelengths is invisible to the human eye. Advantages of 
NIR fluorescence imaging are that the dye does not change the appearance of the surgical 
field and that light in the NIR range has a slightly higher tissue penetration depth and lower 
autofluorescence than light in the visible light range [8]. This can be an advantage to trace 
the tumor during intraoperative fluorescence imaging.  The quantum yield is defined  as the 
number of photons emitted divided by the number of photons absorbed. A higher quantum 
yield leads, together with a higher molar absorption coefficient, to a brighter fluorescent 
signal [9]. The stokes shift is defined as the difference between the maximum wavelengths 
of the absorption and emission spectra of the fluorophore and a higher stokes shift leads 
to less interference between the excitation source and the emitted fluorescent light and 
consequently to a better signal-to-noise contrast [10]. It is important that the fluorescent 
properties of the fluorophore are conserved after conjugation and that the biodistribution 
and the tumor specific accumulation of the targeting molecule are not significantly changed 
by the fluorophore.
 In this thesis IRDye800CW is used for fluorescence imaging. The advantage of 
IRDye800CW-NHS ester is that it can easily be coupled to the amine groups of an antibody 
without losing fluorescent properties. 
Tumor-associated antigens
A prerequisite for a suitable target is that it is highly, homogeneously, and consistently 
expressed by tumor cells, and that expression in normal tissues is limited. Furthermore, 
the antigen or receptor should preferably be accessible on the extracellular part of the cell 
membrane. Examples of such antigens for several types of cancer are FRα, CEA, and CAIX.
Folate receptor 
The folate receptor α (FRα) is overexpressed in several malignancies, such as ovarian cancer, 
non-small cell lung adenocarcinoma and renal cell carcinoma [11]. The FRα binds folate, 
essential for cell division and homeostasis, and transports folate into the cell. Since more than 
90% of epithelial ovarian carcinomas overexpress FRα, it is a suitable receptor for targeted 
imaging of ovarian cancer [12]. Farletuzumab (MORAb-003) is a humanized monoclonal 
antibody that specifically recognizes FRα and can be used to target ovarian cancer [13-15]. 
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Carcinoembryonic antigen
Carcinoembryonic antigen (CEA or CEACAM5) is a membrane-bound glycoprotein and a 
cell adhesion molecule, and may promote tumor development. When released into the 
circulation, serum CEA can be used as a diagnostic marker for colorectal cancer (CRC) 
[16]. Considering the overexpression of CEA in more than 95% of CRC, CEA is the preferred 
biomarker for in vivo targeting of CRC [17]. Labetuzumab (hMN14) is a humanized monoclonal 
antibody that specifically recognizes CEACAM5 and previous studies have shown that it can 
be used to target colorectal cancer [18, 19].  
Carbonic anhydrase IX
Carbonic anhydrase IX (CAIX) is a transmembrane glycoprotein that is involved in intracellular 
pH by catalyzing the reaction CO2 + H2O ←→ HCO3- + H
+ [20]. In hypoxic conditions, CAIX is 
overexpressed due to accumulation of hypoxia-inducible factor-1 (HIF-1) and CAIX is 
considered to be a marker of hypoxia in several tumor types, such as cervical cancer and lung 
cancer [20]. In clear cell renal cell carcinoma (ccRCC) the mutational loss of the Von Hippel 
Lindau (VHL) protein leads to accumulation of HIF-1 and subsequently high and homogeneous 
expression of CAIX [20]. Considering the limited expression in normal tissue and the absence 
of CAIX in normal kidney parenchyma, CAIX has extensively been investigated as a target for 
imaging and therapy of ccRCC with the monoclonal antibody girentuximab [21-25].
TARGETED INTRAOPERATIVE IMAGING
In oncological surgery complete tumor resection is of utmost importance to prevent 
disease recurrence and to optimize prognosis of patients. Traditionally, only preoperative 
imaging is used to plan the surgical strategy and during surgery the surgeon has to rely 
mainly on experience, inspection and palpation to differentiate tumor from normal tissue. 
Intraoperatively, it can be challenging to distinguish tumor from normal tissue, especially in 
patients that have been treated with prior surgery or chemotherapy. A complicating factor 
in laparoscopic surgery is that the surgeon misses tactile feedback. Preoperative imaging 
may be used for surgical navigation in an augmented reality environment, but inadequate 
image overlay due to organ movement and tissue deformation often form a major drawback 
[26]. Sensitive real-time intraoperative imaging techniques can help to guide the surgeon to 
tumor tissue and facilitate complete tumor resection. Therefore, new techniques to image 
tumors and surgical margins intraoperatively have been studied during the last decades.
Intraoperative radiodetection
Although PET and SPECT imaging techniques are used to visualize the distribution of the 
radioactive tracer preoperatively, radioactive tracers can also be detected intraoperatively 
with for example a hand-held gamma probe. Due to the high tissue penetration depth of 
gamma rays, such gamma probes allow for the intraoperative localization of tumor lesions by 
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producing an acoustic signal [27, 28]. However, due to the background signal in surrounding 
organs, it can be difficult to detect small tumor lesions solely based on this acoustic signal. 
Adequate shielding of the gamma probe is needed to protect the detector from scattering 
gamma rays, but shielding options are limited in laparoscopic surgery. In clinical practice, 
accurate delineation of tumor tissues solely based on gamma probe detection is impossible. 
If accurate tumor delineation is needed, for example in organ-sparing surgery or evaluation 
of surgical margins, an additional signal would be preferred. Currently hand-held gamma 
cameras and SPECT systems are available, that can provide an image of the area of interest 
within several minutes [29, 30]. A real-time alternative to produce an image intraoperatively 
is fluorescence imaging. 
Fluorescence-guided surgery
Targeted fluorescence imaging can quickly provide the surgeon with fluorescence images 
that may be used to differentiate tumor from normal tissue. The intraoperative fluorescence 
view can be merged with the visible light view, avoiding the need to switch between 
visible and fluorescence settings. The first proof-of-principle study using this technique 
demonstrated that folate receptor α (FRα) targeted fluorescence imaging can be beneficial 
in staging and debulking of metastatic ovarian cancer patients [12]. Since then many efforts 
have been made to extend targeted fluorescence imaging to other tumor types [31, 32]. 
The main disadvantage of fluorescence imaging is the limited penetration depth of light in 
biological tissue. This limits the use of fluorescence imaging to superficially located tumors. 
However, in contrast to gamma probe measurements, fluorescence imaging does allow for 
accurate real-time tumor delineation. Therefore, it can be applied to guide tumor resection, 
to assess the surgical cavity for residual disease and to assess the resected specimen for 
positive surgical margins.  
Targeted dual-modality imaging
In general, it can be advantageous to use multiple complementary imaging techniques 
for tumor localization and delineation, for example to combine nuclear and fluorescence 
imaging. In such a dual-modality imaging setting both a radionuclide and a fluorophore 
are attached to the same targeting molecule. Monoclonal antibodies can be easily labeled 
with both a fluorophore and a radionuclide because of their size. The high tissue penetration 
depth of gamma radiation allows for preoperative imaging of the tumor lesions with SPECT/
CT or PET/CT and for intraoperative tumor localization with a gamma probe, while tumor 
delineation can be performed by fluorescence imaging. When considering SPECT/CT or PET/
CT as dual-modality imaging techniques, the term trimodal or multimodal imaging would be 
more appropriate for imaging using dual-labeled antibodies. However, in this thesis the term 
‘dual-modality imaging’ will be used. The advantage of injecting a dual-labeled probe over 
co-injection of a radiolabeled and a fluorescently labeled probe, is that both signals originate 
from the same targeting molecule. When co-injecting separate probes, the in vivo behavior of 
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both probes may differ slightly due to the radiolabel or the fluorophore.  When using a dual-
labeled probe, the radioactive signal can be used as an internal control for the fluorescence 
signal, and vice versa. This can be useful to differentiate possible autofluorescence (no 
radioactive signal detectable) from fluorescence due to accumulation of the dual-labeled 
probe (radioactive signal detectable). 
SPECIFIC SURGICAL CHALLENGES
In peritoneal carcinomatosis (PC) multiple tumor lesions are spread within the abdominal 
cavity. Tumors may be difficult to recognize due to shrinkage after previous chemotherapy 
or may be difficult to distinguish from scar tissue after previous surgery. Intraoperative 
imaging can be useful for the improved detection of tumor lesions and assist in complete 
tumor resection and avoid unnecessary resection of normal tissue. Two malignancies that 
often present with PC are ovarian cancer and colorectal cancer. In both the completeness 
of cytoreductive surgery is a major prognostic factor in patient survival [33, 34]. Since the 
FRα is highly overexpressed in ovarian cancer, targeted dual-modality imaging using the 
anti-FRα monoclonal antibody farletuzumab can be a successful strategy to improve surgery 
of ovarian cancer patients. Similarly, targeted dual-modality imaging with the anti-CEA 
monoclonal antibody labetuzumab may improve surgery of colorectal cancer patients. 
 In organ-sparing surgery the surgeon faces the problem to find the right compromise 
between avoiding positive surgical margins and avoiding the resection of excess normal 
tissue. Intraoperative imaging can be useful for tumor localization and to delineate tumor 
borders. In renal cell carcinoma surgery a trend is seen to treat larger and more complex 
tumors by nephron-sparing surgery. CAIX is a suitable antigen for targeted imaging of ccRCC 
with girentuximab. Targeted dual-modality imaging with dual-labeled girentuximab may be 
used to perform oncologically safe nephron-sparing surgery in ccRCC.  
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OUTLINE OF THIS THESIS
As explained above sensitive imaging methods are needed for better preoperative and 
intraoperative tumor visualization. The aim of the studies in this thesis was to translate 
tumor-targeted imaging and image-guided surgery using radiolabeled and fluorescently 
labeled antibodies to the clinic. With a suitable probe, tumor-targeted imaging can be used 
in any type of cancer. This thesis starts with preclinical studies on dual-modality imaging 
in different tumor models, describes the translation to the clinic for the CAIX-targeting 
dual-modality imaging probe, and finally presents a first in man study in ccRCC patients. It 
concludes with a clinical trial that demonstrates the diagnostic value of targeted imaging 
with 89Zr-girentuximab to evaluate ccRCC patients. 
PART 1 - PRECLINICAL
FRα-targeted dual-modality imaging can be a useful aid in the operating room to 
improve surgery of ovarian cancer patients. The feasibility of dual-modality imaging using 
111In-farletuzumab-IRDye800CW was first studied in mice bearing subcutaneous xenografts 
and next demonstrated in an intraperitoneal tumor model (chapter 2). Currently, 
preparations are made for a clinical trial with dual-labeled farletuzumab in ovarian cancer 
patients that are scheduled for cytoreductive surgery.
 To be of optimal benefit in the operating room, dual-modality imaging should be 
able to detect small lesions that could be missed with the naked eye. This concept was 
studied in a micrometastatic pulmonary tumor model with CEA-expressing tumors (chapter 
3).  Colorectal cancer micrometastases could be detected by using SPECT/fluorescence 
dual-modality imaging after injection of dual-labeled labetuzumab in a preclinical setting. 
These promising results have contributed to the initiation of a trial that studies targeted dual-
modality imaging during cytoreductive surgery of colorectal cancer patients with peritoneal 
carcinomatosis.
PART 2 – TRANSLATION TO THE CLINIC
Chapter 4 reviews the current state-of-the-art and upcoming intraoperative imaging 
techniques that can aid the urologist in achieving complete tumor resection in 
nephron-sparing surgery of renal cell carcinoma. The techniques that are discussed are 
ultrasonography, fluorescence imaging, dual-modality imaging, augmented reality, optical 
coherence tomography and ex vivo MRI. 
 Several challenges occur when results of preclinical studies are translated to 
the human situation. In chapter 5 dual-modality imaging was tested in a translational 
setting. After ex vivo perfusion of radical nephrectomy specimens, the accumulation of 
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111In-girentuximab-IRDye800CW in ccRCC tumor tissue could be visualized with both 
preclinical and clinical fluorescence imaging systems.  
 In chapter 6 the safety and feasibility of intraoperative targeted dual-modality 
imaging are shown in a first in man trial in ccRCC. The study shows that tumor-targeted 
dual-modality imaging using 111In-girentuximab-IRDye800CW is safe and can successfully be 
used for intraoperative guidance of ccRCC resection. This supports the clinical translation of 
targeted dual-modality imaging with dual-labeled antibodies in patients with other types of 
cancer. 
 In chapter 7 targeted imaging with 89Zr-girentuximab PET/CT in ccRCC patients is 
described. 89Zr-girentuximab PET/CT imaging can be used to detect ccRCC non-invasively 
and help to decide whether or not to perform surgery in patients suspected of ccRCC. The 
study shows that 89Zr-girentuximab PET/CT imaging is a valuable diagnostic tool that can 
guide clinical decision making in case of diagnostic dilemmas concerning ccRCC suspicion.
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ABSTRACT
Purpose: 
Complete resection of tumor lesions in advanced stage ovarian cancer patients is of utmost 
importance, since the extent of residual disease after surgery strongly affects survival. 
Intraoperative imaging may be useful to improve surgery in these patients. Farletuzumab is a 
humanized IgG1 antibody that specifically recognizes the folate receptor alpha (FRα). Labeled 
with a radiolabel and a fluorescent dye, farletuzumab may be used for the intraoperative 
detection of ovarian cancer lesions. The current aim is to demonstrate the feasibility of FRα-
targeted dual-modality imaging using 111In-farletuzumab-IRDye800CW in an intraperitoneal 
ovarian cancer model. 
Methods: 
Biodistribution studies were performed 3 days after injection of 3, 10, 30 or 100 µg of 111In-
farletuzumab-IRDye800CW in mice with subcutaneous IGROV-1 tumors (5 mice per group). 
In mice with intraperitoneal IGROV-1 tumors the nonspecific uptake of 111In-farletuzumab-
IRDye800CW was determined by co-injecting an excess unlabeled farletuzumab. 
MicroSPECT/CT and fluorescence imaging were performed 3 days after injection of 
10 µg of 111In-farletuzumab-IRDye800CW. FRα expression in tumors was determined 
immunohistochemically. 
Results: 
Optimal tumor-to-blood-ratios (3.4 – 3.7) were obtained at protein doses up to 30 µg. Multiple 
intra-abdominal tumor lesions were clearly visualized by microSPECT/CT, while uptake in 
normal tissues was limited. Fluorescence imaging was used to visualize and guide resection 
of superficial tumors. Co-injection of an excess of unlabeled farletuzumab significantly 
decreased tumor uptake of 111In-farletuzumab-IRDye800CW (69.4 ± 27.6 versus 18.3 ± 2.2 
% ID/g, p < 0.05). Immunohistochemical analyses demonstrated that the radioactive and 
fluorescent signal corresponded with FRα-expressing tumor lesions. 
Conclusion: 
FRα-targeted SPECT/fluorescence imaging using 111In-farletuzumab-IRDye800CW can be used 
to detect ovarian cancer in vivo and could be a valuable tool for enhanced intraoperative 
tumor visualization in patients with intraperitoneal metastases of ovarian cancer. 
FRα-targeted dual-modality imaging in ovarian cancer
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INTRODUCTION
Epithelial ovarian cancer is also called the ‘silent lady killer’, since clinical symptoms arise 
relatively late [1]. As a consequence, approximately 70% of patients present with disease 
extending to other structures within or outside the pelvis at time of diagnosis [1]. Ovarian 
cancer metastasizes primarily throughout the abdominal cavity and complete resection of 
tumor lesions is of utmost importance [2]. These patients can be treated by primary debulking 
surgery or by neoadjuvant chemotherapy followed by surgery (interval debulking) [2]. In both 
regimes, the extent of residual disease after surgery is one of the main prognostic factors for 
(progression free) survival [1-4]. Especially in patients previously treated with chemotherapy 
the distinction between tumor tissue and benign tissue can be challenging during surgery, 
since tumor lesions may shrink or visually disappear due to chemotherapy [2]. Intraoperative 
tumor-specific imaging may be useful to improve surgery of ovarian cancer patients as it may 
facilitate accurate and sensitive detection of tumor tissue. 
 Van Dam et al. have shown that FRα-targeted fluorescence imaging using folate-
FITC (EC17) can be beneficial in staging and debulking of metastatic ovarian cancer patients 
[5]. The FRα is overexpressed in approximately 90% of the ovarian carcinomas, while 
expression in normal tissue is limited [6, 7]. Furthermore, the expression of the FRα is not 
changed by chemotherapy [8]. Therefore the receptor has been proposed as an ideal marker 
for targeted therapies and targeted imaging in ovarian cancer patients [9, 10]. Farletuzumab 
(also designated as MORAb-003) is an intact humanized IgG1 antibody that specifically 
recognizes FRα and is investigated as a diagnostic as well as a therapeutic agent for ovarian 
cancer [11-13]. Phase I/II therapeutic clinical trials have shown no dose-limiting toxicities and 
a pilot clinical study has shown that single photon emission computed tomography (SPECT) 
after injection of 111In-farletuzumab can detect ovarian cancer and metastases [11, 12, 14, 15]. 
 Fluorescently-labeled farletuzumab may enable intraoperative imaging, but the 
limited penetration depth of light in biological tissues implies that only superficial tumor 
lesions can be detected. Therefore, the use of dual-labeled tracers might be advantageous: 
the radioactive signal can be used to detect deeply located tumors, while the fluorescent 
label allows for accurate real-time tumor delineation. Several preclinical studies have shown 
the feasibility of targeted dual-modality imaging using monoclonal antibodies [16-22]. 
 The aim of the current study is to show the feasibility of FRα-targeted dual-modality 
imaging in ovarian cancer using 111In-farletuzumab-IRDye800CW in an intraperitoneal tumor 
model.
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MATERIAL AND METHODS
Animals
Animal studies were performed after approval of the national committee on animal 
experiments (CCD) and the local animal welfare body (AWB). BALB/c nu/nu mice (6-8 weeks 
old) were obtained from Janvier (Le Genest-Saint-Isle, France) and acclimatized to laboratory 
conditions during one week. Mice were fed water and animal chow ad libitum. At least 48 
hours before the start of the image-guided surgery and biodistribution experiments, mice 
were fed a folate-free diet. Daily health monitoring was performed. Mice with i.p. tumors were 
weighed three times a week as part of their welfare assessment.
Dual-labeled antibody production
Dual-labeled farletuzumab was produced essentially as previously described [17]. In short, 
2.5 mg humanized farletuzumab (5 mg/ml, IgG1, Morphotek, Exton, PA) was incubated at room 
temperature during 1 h with 58 µg of IRDye800CW-NHS ester (LI-COR biosciences, Lincoln, 
NE) in 0.1 M NaHCO3, pH 8.5. Next, farletuzumab-IRDye800CW was incubated with 109 µg of 
ITC‐DTPA (Macrocyclics, Dallas, TX) in 0.1 M NaHCO3, pH 9.5. Unconjugated IRDye800CW and 
ITC-DTPA were removed by extensive dialysis against 0.25 M ammoniumacetate, pH 5.5. On 
average 1.7 molecules of IRDye800CW were conjugated per antibody (substitution ratio) as 
was determined with the Ultrospec 2000 UV/Visible spectrophotometer (Pharmacia Biotech, 
Sweden). The absorption and emission spectra of DTPA-farletuzumab-IRDye800CW and 
IRDye800CW were measured with a microplate reader (Infinite Pro 200, Tecan Austria GmbH, 
Groedig, Austria) (Figure 1). The immunoreactive fraction of dual-labeled farletuzumab 
was determined after 1 h 
incubation with IGROV-1 
cells as described by Lindmo 
et al.[23] and exceeded 
70%. DTPA-farletuzumab-
IRDye800CW was stored in the 
dark at 4 ˚ C until radiolabeling.
111InCl3 was purchased from 
Mallinckrodt Pharmaceuticals 
(‘s Hertogenbosch, The 
Netherlands). On the day of 
the experiments radiolabeling 
of DTPA-farletuzumab-
IRDye800CW with Indium-111 
was performed by 30 
minutes incubation at room 
temperature in 0.5 M MES 
Figure 1: 
Absorption and emission spectra of DTPA-farletuzumab-IRDye800CW 
and IRDye800CW as measured with a microplate reader (Infinite Pro 
200, Tecan Austria GmbH, Groedig, Austria).  
FRα-targeted dual-modality imaging in ovarian cancer
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buffer, pH 5.0. Radiochemical purity was determined by Instant Thin Layer Chromatography 
(ITLC) on silicagel strips, using 0.1 M sodiumcitrate buffer, pH 6.0 as mobile phase and always 
exceeded 95 %. To reach a specific activity of 1.25 MBq/µg for SPECT imaging, dual-labeled 
farletuzumab was purified after radiolabeling using a PD10 column with 0.5% BSA/PBS. 
After purification (ITLC > 95%), 79% of the original amount of protein was left and this was 
supplemented with unlabeled DTPA-farletuzumab-IRDye800CW to the desired protein dose. 
For the dose escalation studies an equivalent of 3 µg DTPA-farletuzumab-IRDye800CW per 
mouse was labeled with Indium-111 and subsequently supplemented to the desired protein 
dose with unlabeled DTPA-farletuzumab-IRDye800CW. Before i.v. injection, the injection 
volume was adjusted to 200 µL per mouse with 0.5% BSA/PBS . 
Dose escalation study (s.c. tumor model) 
To determine the optimal protein dose to perform dual-modality imaging a protein dose 
escalation study was performed in mice with s.c. IGROV-1 xenografts. Cells were cultured 
in RPMI medium enriched with 10% fetal calf serum and 1% glutamine. Mice were injected 
s.c. with 200 µl tumor cell suspension (107 cells) on the right flank. When tumors had grown 
to approximately 100 to 300 mm3, mice were injected i.v. with 10 µg 111In-farletuzumab-
IRDye800CW (0.5 MBq). After approximately 1.5 weeks of tumor growth, mice were injected 
i.v. with 3, 10, 30 or 100 µg of 111In-farletuzumab-IRDye800CW (5 per group, 0.5 MBq/mouse, 
200 µl/mouse). Three days after injection, fluorescence imaging was performed with the IVIS 
Lumina closed-cabinet fluorescence scanner (Excitation 745 nm, background correction 
excitation 640 nm, emission filter ICG, Field of view C, binning medium, f/stop 2). Additionally, 
biodistribution studies were performed (see below).
Dual-modality imaging and image-guided surgery (i.p. tumor model) 
To show the feasibility of fluorescence imaging and fluorescence-guided surgery in a setting 
relevant for ovarian cancer, an i.p. tumor model with IGROV-1 cells was optimized. As a pilot 
study to assess tumor growth twelve mice were injected i.p. with 106 or 5x106 IGROV-1 cells in 
500 µL RPMI (6 mice per group). Mice were injected i.v. with dual-labeled farletuzumab after 3, 
7 or 13 days of tumor growth (2 mice per time point per group). Three days later fluorescence 
imaging and biodistribution studies were performed (day 6, 10 and 16 respectively). 
 Next, the feasibility of dual-modality imaging and fluorescence-guided surgery 
was studied in 8 mice with i.p. tumors. Seven days after tumor inoculation (5x106 cells), 
mice received 10 µg dual-labeled farletuzumab (12.5 MBq/mouse, i.v.). To determine 
the nonspecific tumor uptake of dual-labeled farletuzumab, 3 out of the 8 mice were co-
injected with an excess of unlabeled farletuzumab (1 mg) to block the FRα in vivo. After 10 
days of tumor growth (3 days p.i.) dual-modality imaging and fluorescence-guided surgery 
were performed. Mice were euthanized by O2/CO2 suffocation. Then, SPECT/CT imaging 
was performed in the USPECT small animal scanner (Milabs, Utrecht, the Netherlands) 
using a 1.0 mm mouse pinhole collimator (2 x 15 min acquisition time, 28 bed positions). 
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SPECT/CT images were reconstructed using the MILabs software (Utrecht, The Netherlands. 
Reconstruction parameters 0.2 mm voxels, 16 subsets, 4 iterations, Gaussian filter 1.5) and 
subsequently analyzed using the Inveon Research Workplace (Siemens Healthcare, The 
Netherlands). Next, fluorescence images were obtained with the IVIS Lumina closed-cabinet 
fluorescence scanner (Caliper LifeSciences, Hopkinton, MA) after removal of the abdominal 
skin (excitation 745 nm, background correction excitation 640 nm, emission filter ICG, field of 
view B, binning small, f/stop 2). After resection of all visible tumor lesions, mice were imaged 
again with the IVIS Lumina to check for residual disease. Finally, biodistribution studies were 
performed (see below). 
 Five µm sections were cut from formalin-fixed and paraffin-embedded resected 
tumor tissue and analyzed autoradiographically. Sections were exposed for 2 weeks to a 
phosphor imaging plate and developed using the Typhoon FLA 7000 Phosphor Imager (GE 
Healthcare Life Sciences, Eindhoven, the Netherlands). Then, the fluorescent signal in the 
tumor sections was imaged with the Odyssey CLx flatbed fluorescence scanner (800 nm 
channel, recording time 1-5 min, focus 1.0 mm) (LI-COR biosciences, Lincoln, NE). Lastly, a 
standard Hematoxylin & Eosin-staining was performed, as well as a folate-receptor-alpha-
staining using the Folate Receptor alpha IHC Assay Kit (Morphotek, Exton, PA).  
Biodistribution studies
All studies were performed 3 days after injection of dual-labeled farletuzumab. For 
biodistribution studies samples of blood, muscle, heart, lung, spleen, kidney, pancreas, 
liver, stomach, duodenum, and tumor lesions were retrieved. Tissue samples were weighed 
and measured in a gamma counter (2480 WIZARD2, Perkin Elmer, Boston, MA) together with 
standards of the injected dose in triplicate. The accumulation of dual-labeled farletuzumab 
was expressed as percentage of the injected dose per gram of tissue (% ID/g) and values are 
represented as mean ± standard deviation (SD). 
 Statistical analyses were performed using IBM SPSS Statistics 22.0. In the dose 
escalation study a one-way ANOVA test with post-hoc Bonferroni correction was performed 
to test for significant differences in tumor accumulation between the different dose levels. 
Tumor uptake in the mice that received an excess unlabeled farletuzumab was tested for 
significance with an independent sample t-test. An alpha of 0.05 was used in all analyses, 
p<0.05 was considered significant. 
FRα-targeted dual-modality imaging in ovarian cancer
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RESULTS
Dose escalation study (s.c. tumor model)
The protein dose-escalation study revealed tumor-to-blood-ratios of 3.5, 3.4, 3.7, and 2.8 in 
the 3, 10, 30 and 100 µg dose levels, respectively. Tumor uptake was 43.6 ± 4.8, 39.9 ± 4.3, 39.3 
± 5.8 and 32.7 ± 3.2 % ID/g after injection of 3, 10, 30 and 100 µg dual-labeled farletuzumab 
respectively (Figure 2). Tumor uptake after injection of 100 µg of dual-labeled farletuzumab 
was significantly lower than tumor uptake after injection of 3 µg (p<0.05). No significant 
differences in tumor uptake between the 3, 10 and 30 µg dose levels were seen. Further 
studies were performed with a protein dose of 10 µg dual-labeled farletuzumab.
Figure 2: 
Biodistribution profiles of Indium-111-farletuzumab-IRDye800CW 3 days p.i. in BALB/c nu/nu mice with s.c. 
IGROV-1 tumors at four different protein doses. 
Dual-modality imaging and fluorescence-guided surgery (i.p. tumor model) 
Fluorescence imaging clearly visualized high uptake of dual-labeled farletuzumab in 
macroscopically visible tumor lesions as early as 6 days after tumor cell injection in 10 out of 
12 mice. Tumors were mainly located around the spleen, in the hepatic hilum and between 
the abdominal organs. Two mice that were injected with 106 IGROV-1 cells did not have visible 
i.p. tumors and in one mouse no tumors could be visualized with fluorescence imaging (only 
biodistribution studies were performed in the second mouse). No tumor lesions outside the 
abdominal cavity were observed during extensive macroscopic inspection and mice did not 
develop ascites.
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Uptake of 111In-farletuzumab-IRDye800CW was visualized by microSPECT/CT in multiple intra-
abdominal lesions in all 5 mice that were injected with 10 µg/12.5 MBq 111In-farletuzumab-
IRDye800CW (Figures 3a and 3b). After resection of the abdominal skin, the gross majority 
of these hotspots could be localized to macroscopic tumor deposits and were detectable 
with fluorescence imaging (Figures 3c and 3d). For superficial tumors microSPECT images 
matched with the corresponding fluorescence images (Figure 3). Intraoperative fluorescence 
imaging was used to guide resection of superficial tumor lesions (Figure 4). After shifting 
the organs, also deeply seated tumor lesions could be visualized with fluorescence imaging 
(Figure 5). However it is more difficult to trace back the location of deeply located tumors in 
the abdomen to their preoperative location on the microSPECT/CT. In addition, fluorescence 
imaging revealed multiple lesions throughout the abdomen, suggestive of submillimeter 
tumor deposits that are barely visible to the naked eye (Figures 3, 5 and 6). 
Figure 3: 
MicroSPECT/CT shows multiple intraperitoneal IGROV-1 tumors as small as 1 mm (A, coronal view, B, sagittal 
view). Due to the high tumor-to-normal tissue ratio and tumor-to-liver ratio, only uptake in tumor tissue is 
visualized. After resection of the abdominal skin, multiple tumor deposits were observed macroscopically (white 
circles in C) and were visualized with fluorescence imaging (D). Furthermore, fluorescence imaging identified 
additional tumor lesions that were barely visible with the naked eye (square in C). 
Figure 4: 
Detection of superficially located tumor lesions by fluorescence imaging (A) and fluorescence image-guided 
surgery of intraperitoneal IGROV-1 tumors (B). 
A
A
B
B
C D
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Figure 5: 
Fluorescence imaging visualizes 
multiple deeply located 
intraperitoneal IGROV-1 tumors (A, 
liver lift up). Ex vivo fluorescence 
imaging of resected organs (S: 
spleen, P: pancreas in B and bowel 
in C) reveals multiple focal lesions 
with high fluorescence intensity, 
suggestive for submillimeter tumor 
deposits that are barely visible to 
the naked eye. 
Figure 6: 
Autoradiography (A) and 
fluorescence imaging (B) of a 
tissue section of the mouse 
oviduct revealed an area with 
high accumulation of dual-labeled 
farletuzumab. H&E-staining (C) of 
this same tissue section showed 
that this area corresponded with a 
0.25 mm tumor lesion located near 
the oviduct. The FRα-staining on an 
adjacent tissue section confirmed 
that this lesion expressed FRα (D). 
Microscopic tissue studies demonstrated that the radioactive and fluorescent signal 
corresponded with FRα-expressing tumor lesions (Figures 6 and 7). The FRα-staining showed 
a very homogeneous FRα expression in the IGROV-1 tumors, but autoradiography and 
fluorescence imaging showed that the distribution of dual-labeled farletuzumab in tumor 
tissue was more heterogeneous (Figure 7). This difference may be due to differences in tumor 
vascularization. Co-injection of an excess unlabeled farletuzumab resulted in a significant 
decrease of dual-labeled farletuzumab in tumor tissue (69.4 ± 27.6 versus 18.3 ± 2.2 % ID/g, p 
< 0.05) (Figure 8), indicating that the accumulation of the dual-labeled antibody in the tumor 
was FRα-mediated.
A
A
C
B
B
C
D
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Figure 7: 
H&E-staining (A) demonstrated that tissues resected from the abdominal cavity were tumor lesions and the 
FRα-staining confirmed that tumors expressed the FRα (C). Co-localization was seen between the radioactive (B) 
and fluorescent signal (D) in tumor lesions.
Figure 8: 
A. Uptake of 111In-farletuzumab-IRDye800CW in i.p. IGROV-1 tumors was significantly decreased by co-injection 
of 1 mg unlabeled farletuzumab. xs = excess unlabeled farletuzumab. B,C. microSPECT/CT 3 days p.i. of 
111In-farletuzumab-IRDye800CW with excess cold (C) and without excess cold (B). 
A
A
C
B
B C
D
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DISCUSSION
This study shows the feasibility of FRα-targeted dual-modality image-guided surgery of 
ovarian cancer lesions using 111In-farletuzumab-IRDye800CW. Intraperitoneal IGROV-1 tumor 
lesions were clearly visualized with both microSPECT/CT and fluorescence imaging, and 
dual-modality imaging was used to guide complete tumor resection. These results support 
the clinical translation of dual-modality imaging using dual-labeled farletuzumab, where it 
could be a valuable tool to assist the surgeon in cytoreductive surgery in patients with FRα-
expressing tumors. 
 In the current study dual-modality imaging was optimized in mice with subcutaneous 
IGROV-1 xenografts. Biodistribution studies showed that optimal tumor-to-blood-ratios (3.4 – 
3.7) were achieved at protein doses up to 30 µg. The decreased tumor accumulation at higher 
protein doses probably relates to antigen saturation at higher protein doses as has been 
described previously [24]. The biodistribution and tumor accumulation (up to 43.6 % ID/g 
in the s.c. model) of 111In-farletuzumab-IRDye800CW was comparable to that of 111In-DOTA-
farletuzumab as previously reported by Smith-Jones et al (tumor uptake 32 % ID/g 4 days 
after injection) [14]. This finding is in accordance with our previous studies that indicated that 
conjugation of an antibody with IRDye800CW up to a substitution ratio of 2 only marginally 
affects the in vivo behavior of the antibody [17]. Next, the feasibility of dual-modality imaging 
was shown in an i.p. tumor model. Preoperative microSPECT/CT identified FRα-expressing 
intra-abdominal tumor lesions as small as 1 mm (Figures 3a and 3b). Intraoperative 
fluorescence imaging successfully guided resection of superficially located tumor lesions 
(Figure 4). Microscopic analyses confirmed that the resected lesions were tumor lesions 
(Figure 7) and a co-localization was seen between the radioactive and fluorescent signal 
and FRα-expression (Figures 6 and 7). Co-injection of an excess of unlabeled farletuzumab 
resulted in significant reduction of accumulation of dual-labeled farletuzumab in tumor 
tissue (Figure 8). This indicates that the uptake of dual-labeled farletuzumab in tumor lesions 
is mainly due to specific binding of farletuzumab to FRα. However, nonspecific tracer uptake 
may also contribute to tumor accumulation because of the enhanced permeability and 
retention effect (EPR) in tumor lesions.
 Since ovarian cancer mainly spreads within the abdominal cavity and lesions 
develop on the surface of abdominal organs, a clear contrast between tumors and the 
abdominal organs is a requirement for sensitive intraoperative detection of ovarian cancer 
lesions. In the current study, high accumulation of dual-labeled farletuzumab in tumor tissue 
was seen, while accumulation in the normal abdominal tissues was low as predicted by lack 
of farletuzumab’s crossreactivity to murine FRα. This led to a high tumor-to-normal contrast 
as shown in figure 3 and 4. Thus, fluorescence imaging could be a useful aid to improve surgery 
of advanced stage ovarian cancer patients. In addition, fluorescence imaging could also be 
used to improve staging of ovarian cancer patients. Accurate staging of lower stage ovarian 
cancer patients is important to decide if adjuvant therapy is indicated. After comprehensive 
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surgical staging approximately 30% of ovarian cancer patients are upstaged, since (micro)
metastases are found in the uterus and/or fallopian tubes, lymph nodes, and in peritoneal, 
omental, or adhesion biopsies [25]. Targeted intraoperative fluorescence imaging could 
guide the surgeon to tumor tissue and thereby improve staging and cytoreductive surgery. 
 A non-targeted fluorescence imaging approach based on the enhanced permeability 
and retention effect using indocyanine green has been investigated by Tummers et al. [26]. 
In this study, ovarian cancer lesions appeared fluorescent, but a false-positive rate of 62% 
was found [26]. Currently, several trials are ongoing that demonstrate the value of targeted 
intraoperative fluorescence imaging [5, 27-29]. The FRα is an ideal marker for targeted 
imaging in ovarian cancer patients, whereas the folate receptor beta has limited value, 
because it is expressed on activated macrophages and to a lesser extent on ovarian cancer 
lesions [9, 10, 30]. Recently it was shown that 16 to 29% additional lesions could be detected 
using FRα-targeted fluorescence imaging using folate-analogues (EC17 and OTL38) [31, 32]. 
A clear advantage of folate-analogues over using intact antibodies is the shorter time that is 
needed to obtain an optimal tumor-to-normal tissue contrast (several hours versus several 
days). However, false positive rates of 23% were found in both studies [31, 32]. With EC17, 
this can partly be attributed to autofluorescence of benign tissue in the 500 nm range. Near-
infrared fluorescence imaging with OTL38 has the advantage of lower autofluorescence and 
a higher tissue penetration depth, leading to a better tumor-to-normal tissue contrast, as 
shown previously [33]. Also, folate-analogues are not FRα specific, but may also bind the 
folate receptor beta on activated macrophages [31, 32]. 111In-farletuzumab-IRDye800CW has 
the advantages that farletuzumab only recognizes FRα and that imaging can be performed 
in the near-infrared range [34]. 
 However, even in the near-infrared range, the penetration depth of light restricts 
fluorescence imaging to superficially located tumor lesions. The advantage of using a 
radiolabel is that it can be visualized preoperatively with SPECT/CT imaging and that it can 
be used intraoperatively to localize deeply seeded tumors with a gamma probe or handheld 
SPECT camera. Using dual-labeled imaging, deeper tumors can first be localized with a 
gamma probe, and after surgical exposure fluorescence imaging can be used to guide tumor 
resection and assess the surgical cavity for residual disease. Due to the small size of a mouse, 
gamma probe detection was not feasible in this preclinical study.  Dual-modality imaging 
may be achieved using a dual-labeled probe or co-injection of two separate agents. The 
disadvantage of co-injection of two separate agents is the potentially different biodistribution 
and clearance of the agents. In a dual-labeled approach the radiosignal and the fluorescent 
signal originate from the same molecule. This has the advantage that both signals can serve 
as an internal control for each other, e.g. a positive radiosignal in tissue precludes that 
the fluorescent signal is due to autofluorescence. Another advantage of using a radiolabel 
in the preclinical setting is that it allows for easy quantification of the accumulation of 
111In-farletuzumab-IRDye800CW in tissues, whereas the quantification of a fluorescent signal 
can be challenging [35]. When combining fluorescent dyes with radioisotopes, radiolysis 
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of the fluorescent molecule may occur, a phenomenon that can be prevented by adding 
reactive oxygen scavengers like ascorbic acid [36]. Considering that radiolysis is limited with 
Indium-111-labeled compounds that are injected shortly after radiolabeling [36], no specific 
precautions were taken in the current study. 
 When translating the current results to the clinical situation, one has to consider 
that the sensitivity of the imaging systems used in the clinical situation differs from the 
ones used in preclinical studies. Furthermore, in the clinical setting tumors may be more 
heterogeneous in terms of FRα expression and tumor physiology compared to the tumors 
in this mouse model. These factors may lead to more variation in the tumor uptake of the 
tracer. The feasibility of FRα-targeted dual-modality imaging was shown in an i.p. IGROV-1 
tumor model, but feasibility should be shown in additional FRα-expressing tumor models. 
Also, the tumor-targeting characteristics of our tracer could be further assessed by using 
bioluminescence imaging in a luciferase expressing IGROV-1 tumor model. Other limitations 
in the current study included the lack of farletuzumab’s crossreactivity to murine FRα which 
may be present in normal tissue, as well as that dual-modality imaging was performed in a 
non-ascitic tumor model. Patients with advanced stage ovarian cancer often develop ascites 
in which circulating tumor cells will be present. This may lead to an increased background 
signal in preoperative SPECT images due to accumulation of dual-labeled farletuzumab in 
the ascites. However, this did not appear to be a problem in the previous studies where FRα-
targeted imaging has been performed [5, 14]. Since ascites is removed at the start of surgery, 
this phenomenon will not hamper intraoperative fluorescence imaging.  
CONCLUSION
In conclusion, this study shows the feasibility of FRα-targeted SPECT/fluorescence imaging 
using 111In-farletuzumab-IRDye800CW in ovarian cancer in vivo. The next step will be to 
evaluate the value of dual-modality imaging and fluorescence-guided surgery in advanced 
stage ovarian cancer patients. 
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ABSTRACT
Purpose: 
Intraoperative dual-modality imaging can help the surgeon distinguish tumor from normal 
tissue. This technique may prove particularly valuable if small tumors need to be removed 
that are difficult to detect with the naked eye. The humanized anti-carcinoembryonic antigen 
(anti-CEA) monoclonal antibody, labetuzumab (hMN-14), can be used as a tumor targeting 
agent in colorectal cancer (CRC), since carcinoembryonic antigen (CEA or CEACAM5) is 
overexpressed in approximately 95% of CRC. Dual-labeled labetuzumab, labeled with both 
a near-infrared fluorescent dye (IRDye800CW) and a radioactive label (Indium-111), can 
be used as a tracer for dual-modality imaging. This study aimed to assess whether dual-
modality imaging using Indium-111-DTPA-labetuzumab-IRDye800CW can detect pulmonary 
micrometastases in a mouse model. 
Methods: 
Pulmonary GW-39 human colonic carcinoma microcolonies were induced in athymic 
BALB/c mice by intravenous injection of 100 µL of a GW-39 cell suspension. After 1, 2, 3, and 
4 weeks of tumor growth dual-modality imaging was performed 3 days after i.v. injection of 
Indium-111-DTPA-labetuzumab-IRDye800CW (10 µg, 25 MBq). Micro single-photon emission 
computed tomography (SPECT) images and optical images were acquired and image-
guided surgery was performed. Finally, the biodistribution of the dual-labeled tracer was 
determined. Formalin-fixed sections of the lungs were analyzed using fluorescence imaging, 
autoradiography and immunohistochemistry. 
Results: 
Sub-millimeter pulmonary tumor colonies could be visualized with both microSPECT and 
fluorescence imaging from the first week of tumor growth, before they became visible with 
the naked eye. Furthermore, dual-modality imaging could be used to guide resection of 
tumor lesions. Mean uptake of the dual-labeled tracer in tumor lesions was 17.2 ± 5.4 %ID/g 
and 16.5 ± 4.4 %ID/g in weeks 3 and 4, respectively. Immunohistochemical analysis of the 
tumorous lungs showed that the distribution of the radioactive and fluorescent signal co-
localized with CEA-expressing tumor lesions. 
Conclusion: 
Dual-modality imaging after injection of Indium-111-labetuzumab-IRDye800CW can be used 
to detect sub-millimeter CEA-expressing pulmonary tumor lesions, before they become 
visible with the naked eye, supporting the added value of this technique to the resection of 
small tumor lesions. 
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INTRODUCTION
Radical tumor resection is crucial for optimal prognosis of cancer patients [1-6]. However, 
during surgery small tumor lesions or positive surgical margins can be difficult to detect 
with the naked eye. Sensitive intraoperative imaging techniques could help the surgeon 
visualize these small tumor lesions that otherwise could be missed. Targeted dual-modality 
image-guided surgery using monoclonal antibodies tagged with both a fluorescent and a 
radioactive label combines the advantages of radioguided and fluorescence-guided surgery 
[7-14]. The monoclonal antibody assures adequate targeting of a tumor-associated antigen. 
The radioactive label allows localization of both deeply and superficially located tumor 
lesions, while the fluorescent label enables the surgeon to visualize, delineate and resect the 
tumors with fluorescence-guided surgery. 
 Labetuzumab (hMN14) is a humanized monoclonal antibody that specifically 
recognizes carcinoembryonic antigen, which is overexpressed in approximately 95% of 
CRC [15]. CEA is considered to be the preferred biomarker for in vivo targeting of colorectal 
cancer [15]. In CRC incomplete tumor resection has a clearly negative effect on patients’ 
prognosis [16]. A special surgical challenge are those patients with multiple small metastases 
limited to the peritoneal cavity (peritoneal carcinomatosis). In these patients long term 
control of disease can be achieved by cytoreductive surgery (resect all visible tumor tissue) 
in combination with hyperthermic intraperitoneal chemotherapy  [17-21]. However, the 
presence of tumor residue after cytoreduction negatively effects patients’ prognosis [18, 20, 
21]. Intraoperative imaging can help the surgeon limit residual disease.  Rijpkema et al. have 
shown the feasibility of image-guided surgery with 111In-labetuzumab-IRDye800CW in mice 
with intraperitoneal, CEA-positive, LS174T tumors [14]. However, to be of optimal benefit 
in the operating room, dual-modality imaging should be able to detect very small tumor 
lesions that can be missed with the naked eye. 
 The aim of the current study is to assess the feasibility of CEA-targeted dual-
modality imaging to detect micrometastases. In this study, micrometastases were defined 
as tumor lesions smaller than 2 mm according to the 6th edition of the American Joint 
Committee on Cancer  Cancer Staging Manual for breast cancer [22]. For this aim, a model 
with CEA-expressing pulmonary tumor lesions was used, since it is an optimal model to study 
micrometastatic disease [23]. 
MATERIAL AND METHODS
All animal studies have been approved by the institutional Animal Welfare Committee of the 
Radboudumc and experiments were conducted in accordance with the principles as stated 
in the revised Dutch Act on Animal Experimentation (WOD 2014). 
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Study design
The feasibility of dual-modality imaging using Indium-111-labetuzumab-IRDye800CW to 
detect CEA-expressing pulmonary micrometastases was studied. Pulmonary lesions were 
induced in 28 athymic BALB/c mice by intravenous injection of a GW-39 cell suspension 
obtained by serial transplantation from subcutaneous xenografts. After 1, 2, 3, and 4 weeks of 
tumor growth microSPECT/CT, optical imaging and image-guided surgery were performed. 
Dual-modality imaging was performed 3 days after i.v. injection of Indium-111-DTPA-
labetuzumab-IRDye800CW (10 µg, 25 MBq, 7 mice per timepoint). Biodistribution studies and 
immunohistochemical analysis of the lungs were performed. 
Animal model
The experiments were performed in 28 female BALB/c nu/nu mice (6-8 weeks old, Janvier, le 
Genest-Saint-Isle, France). Mice were climatized to laboratory conditions for at least 1 week 
before use.  Mice were housed in individually ventilated cages with ad libitum access to food 
and water. The CEA-expressing GW-39 cell line was obtained from Immunomedics, Inc. (Morris 
Plains, NJ). Subcutaneous GW-39 xenografts were grown to 1 cm3 and serially transplanted 
in BALB/c nu/nu mice. Tumors were harvested, cut into pieces, filtered through a 400-µm 
mesh and resuspended to a 10% cell suspension in culture medium (Roswell Park Memorial 
Institute medium + penicillin/streptomycin) while kept on ice, as described by Sharkey 
et al.[23]. The first fifteen mice were injected i.v. with 100 µL of this cell suspension with a 
23-gauge needle to induce micrometastatic disease in the lungs. Three mice died during i.v. 
injection due to inadequate suspension of the tumor cells. Therefore, the cell suspension 
was filtered again through a 200-µm mesh. The remaining 13 of the total of 28 mice were 
injected with 100 µL of this cell suspension without causing any health problems to the mice. 
Mice injected with different cell suspensions were equally distributed over the experimental 
groups. The cell concentration in both cell suspensions was counted by adding ZAP-OGLOBIN 
II lytic reagent (Beckman Coulter) to a sample, vortexing the mixture and moving the cells up 
and down through a 23-gauge needle. Subsequently the nuclei were counted using a Burker 
Turk counting chamber. The cell suspensions before and after extra filtration contained 3.7 
and 3.5 million cells per mL, respectively. All animals developed pulmonary tumor lesions. 
Animal health was monitored on a daily basis and body weight was measured three times 
a week. Two weeks after injection of tumor cells, one mouse had to be taken out of the 
experiment prematurely because of dyspnoea and weight loss originating from excessive 
pulmonary tumor growth. For the same reason one animal from week 4 was scanned 2 days 
(instead of 3 days) after injection of the tracer. In total, 6, 7, 6, and 5 animals were used in the 
experiment in weeks 1, 2, 3, and 4, respectively.
Dual-labeled antibody production
Humanized labetuzumab (Immunoglobulin G type 1) was kindly provided by Immunomedics 
Europe (Darmstadt Germany). The fluorophore IRDye800CW-NHS ester was purchased from 
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LI-COR biosciences (Lincoln, NE, USA). The bifunctional chelator ITC‐DTPA was purchased 
from Macrocyclics (Dallas, TX, USA). First labetuzumab (10 mg/mL) was incubated in 0.1 
M NaHCO3, pH 8.5, with a 3-fold molar excess of the IRDye800CW-NHS ester (RT, 1 h). Then 
the mixture was incubated in 0.1 M NaHCO3, pH 9.5, with a 20-fold molar excess of the ITC‐
DTPA (RT, 1 h). To remove the unconjugated IRDye800CW and ITC-DTPA, the reaction mixture 
was transferred into a Slide-A-Lyzer cassette (molecular weight cut-off: 20,000 Da, Thermo 
Scientific, Rockford, IL, USA) and extensively dialyzed against 0.25 M NH4Ac, pH 5.5, for three 
days with buffer changes. The average substitution ratio (SR) of IRDye800CW molecules 
was 1.2/antibody as was determined by the Ultrospec 2000 UV/Visible spectrophotometer 
(Pharmacia Biotech, Sweden). Since GW-39 cells cannot be cultured in vitro, the 
immunoreactive fraction of dual-labeled labetuzumab was determined after 6 h incubation 
with CEA-expressing LS174T cells, essentially as described by Lindmo [24], and was 90 %. 
DTPA-labetuzumab-IRDye800CW was stored in the dark at 4 ˚C until use.
Radiolabeling of DTPA-labetuzumab-IRDye800CW
DTPA-labetuzumab-IRDye800CW was incubated with 0.5 M 2-(N-morpholino)ethanesulfonic 
acid (MES) (30 min, RT) and 111InCl3 (Mallinckrodt Pharmaceuticals, ‘s Hertogenbosch, 
The Netherlands). Then unincorporated Indium-111 was chelated by adding 50 mM 
ethylenediaminetetraacetic acid  to a final concentration of 5 mM. Radiochemical purity was 
determined by Instant Thin Layer Chromatography on silica gel strips, using 0.1 M sodium 
citrate buffer, pH 6.0, as the mobile phase. Radiochemical purity always exceeded 95 %. 
Standards of the injected dose (ID) were prepared in triplicate to be able to quantify antibody 
accumulation, corrected for radioactive decay for biodistribution studies. 
Dual-modality imaging
Groups of mice were injected via the tail vein with Indium-111-labetuzumab-IRDye800CW 
(10 µg, 25 MBq 111In) (n=7 per time point). Three days later (after 1, 2, 3, or 4 weeks of tumor 
growth), dual-modality imaging was performed. First, mice were euthanized using O2/CO2 
and the lungs were fixed by intratracheal injection of 4% formalin with a 21-gauge needle. 
Then microSPECT/CT images were obtained by scanning mice in supine position with the 
U-SPECT II scanner (MILabs, Utrecht, The Netherlands), using a 1.0 mm diameter multi-
pinhole Ultra High Sensitive (UHS-M) collimator tube. Total scan time was 50 minutes per 
animal (2 time frames, 24 bed positions, scan mode: fast) for SPECT acquisition and 3 minutes 
for CT imaging. Subsequently, the thoraco-abdominal wall was removed surgically and 
mice were placed in supine position in the IVIS Lumina closed-cabinet fluorescence imager 
(Caliper Life Sciences, recording time 1-5 min; binning factor small or medium; F/stop 2-4; 
excitation filter 745 nm; emission filter ICG; Field of view C; autofluorescence [675 nm] and 
background correction). Fluorescence imaging was performed before and after resection of 
tumor lesions. Thereafter lungs were resected and scanned ex vivo in the IVIS (Field of view 
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A) and with the Odyssey CLx flatbed fluorescence scanner (LICOR Biosciences, recording time 
± 5 min; 800 nm channel; focus 1.0 mm). 
Biodistribution
After dual-modality imaging the biodistribution of the radiolabel was determined. Therefore, 
blood, muscle, heart, spleen, kidney, pancreas, liver, stomach, duodenum, and tumors 
were resected and weighed. Subsequently, the amount of Indium-111 in these tissues was 
determined in a gamma counter (2480 WIZARD2, Perkin Elmer). To correct for radioactive 
decay, samples were measured along with standards of the injected dose (in triplicate). 
The organ accumulation of Indium-111-DTPA-labetuzumab-IRDye800CW was expressed as 
percentage of the injected dose per gram tissue (% ID/g). Values are represented as mean 
uptake ± standard deviation. Statistical analyses were performed using IBM SPSS Statistics 
22.0. Tissue uptake at the different timepoints was tested for significance using a one-way 
ANOVA test with post-hoc Bonferroni corrections. An alpha of 0.05 was used in all analyses.
Immunohistochemical analysis 
Formalin-fixed, paraffin-embedded, 5-µm sections of the lungs were cut and analyzed 
autoradiographically after 1.5 weeks exposure to a phosphor imaging plate. This plate was 
developed using the Typhoon FLA 7000 Phosphor Imager and analyzed with Aida Image 
Analyzer v. 4.21. Next, fluorescence imaging of the pulmonary sections was performed with 
the Odyssey CLx flatbed fluorescence scanner (800 nm channel, recording time 1-5 min, 
focus 1.0 mm). Subsequently, sections were stained for CEA with humanized labetuzumab, 
as described previously by Schoffelen et al. and counterstained with Hematoxylin [25]. 
Furthermore, on adjacent tissue sections a standard Hematoxylin & Eosin staining was 
performed. 
RESULTS
Dual-modality imaging
Sub-millimeter pulmonary tumor lesions could be visualized with dual-modality imaging in 
all animals that were imaged from the first week of tumor growth onwards (Fig. 1 and 2). 
MicroSPECT/CT showed uptake of dual-labeled labetuzumab in pulmonary tumor lesions 
and limited uptake in the liver, spleen and lymph nodes (Figs. 1A and 1B). After resection 
of the thoraco-abdominal wall, no tumor lesions were visible with the naked eye after one 
week of tumor growth (Fig. 1C). However, superficially-located tumor lesions smaller than 
1 mm were identified with fluorescence imaging (Figs. 1D and 1E). The presence of these 
CEA-expressing tumor lesions was confirmed by immunohistochemistry and the distribution 
of the radioactive and fluorescent signal in tissue sections (autoradiography and flatbed 
fluorescence imaging) co-localized with CEA-expressing tumor lesions (Fig. 3-5). Pulmonary 
tumor lesions became visible by macroscopic inspection after two weeks of tumor growth. 
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However, CEA-targeted dual-modality imaging revealed additional pulmonary tumor lesions 
that had been missed by macroscopic inspection (Fig. 6). No metastases outside the lungs 
were seen. After 3 or 4 weeks of tumor growth, tumor lesions were clearly visible by the naked 
eye and were visualized by dual-modality imaging.
Figure 1: 
Example of dual-modality imaging in a mouse one week after tumor cell injection. Pulmonary tumor lesions 
could be visualized with microSPECT/CT (coronal view A, sagittal view B). Some physiologic uptake of the tracer 
in the liver and lymph nodes is observed. After resection of the thoraco-abdominal wall, no tumor lesions were 
visible with the naked eye (C). Fluorescence imaging with the IVIS lumina closed cabinet fluorescence camera 
system could identify the superficially located tumor lesions (D). Fluorescence imaging with the Odyssey flatbed 
fluorescence scanner of the resected lungs could visualize numerous pulmonary lesions (E). L = lung, H = heart. 
Figure 2: 
Overview of dual-modality imaging (upper row microSPECT/CT, lower row Odyssey fluorescence imaging of 
resected lungs) in mice after 2 (A,D), 3 (B,E) and 4 (C,F) weeks of tumor growth.
A
A
D
B
E
C
F
B C
E
D
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Figure 3: 
Autoradiography (A), fluorescence 
imaging (C), and immunohistochemistry; 
CEA (B) and H&E (D) of 5-µm paraffin-
embedded pulmonary sections 
confirmed the presence of sub-millimeter 
tumor lesions in the lungs after one week 
of tumor growth. The fluorescent (C) and 
radioactive signals (A) co-localize with 
CEA-expressing tumor lesions (B). 
Figure 4: 
Representative examples of sets 
(fluorescence imaging, autoradiography 
and CEA-staining) of adjacent slices 
of pulmonary metastases from mice 
from week 2 (A-C), week 3 (D-F) and 
week 4 (G-I). Fluorescence imaging with 
a flatbed fluorescence scanner and 
autoradiography of 5-µm sections of lung 
tissue show the co-localization of dual-
labeled labetuzumab in CEA-expressing 
tumor lesions. During the experiment, 
the tumors showed increasing central 
necrosis and therefore uptake of dual-
labeled labetuzumab was mainly in 
the periphery of the tumor lesions (see 
Figure 5).
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Figure 5: 
Autoradiography shows mainly uptake of dual-labeled labetuzumab in the periphery of the tumor lesion (A). 
Extensive central necrosis is seen after 3 weeks of tumor growth on the corresponding H&E-staining (B). 
Figure 6: 
Ex vivo example of the resected lungs and heart after 2 weeks of tumor growth. Pulmonary tumor lesions are 
now visible with the naked eye (white circles); however, CEA-targeted fluorescence imaging reveals multiple 
additional superficial pulmonary tumor lesions (histologically confirmed).
Fluorescence-guided surgery
Superficially-located pulmonary lesions identified with fluorescence imaging were 
subsequently resected based on their fluorescent signal (Fig. 7 and 8). In this example (three 
weeks after tumor induction), the lungs were imaged again after resection of the tumor 
lesions to confirm that a radical tumor resection had been performed (compare Figs. 7C 
and 7D). Autoradiography of the tissue sections and immunohistochemistry did not identify 
remaining tumor lesions (Fig. 7E).
A
A
B
B
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Figure 7: 
Image-guided surgery using dual-
labeled labetuzumab in week 3. In this 
example microSPECT/CT (A) did not 
reveal any pulmonary lesion, probably 
due to their location close to the liver. 
Fluorescence imaging revealed one 
superficial pulmonary nodule (D), while 
fluorescence imaging of the resected 
lungs revealed a second nodule behind 
the lung (B). Both lesions were resected 
using fluorescence-guided surgery (C), 
and CEA staining of lung sections did not 
reveal remaining lesions (E).
Figure 8: 
Image-guided surgery after 4 weeks of tumor growth: microSPECT/CT (A), fluorescence imaging (B), fluorescence 
imaging after partial resection of tumor nodules (C). Due to the high tumor density, a complete resection of all 
tumor nodules was not possible in this case.
Biodistribution
One and 2 weeks after tumor induction, quantification of tumor uptake was unreliable 
because the tumor weight could not be determined accurately. In weeks 3 and 4, mean 
uptake of the dual-labeled tracer in tumor lesions was 17.2 ±  5.4 %ID/g and 16.5 ±  4.4 %ID/g, 
respectively. Blood levels of the dual-labeled tracer decreased from 16.5 ± 2.8 %ID/g in the 
group that was imaged 1 week after tumor induction to 7.7 ± 1.3 %ID/g in the group that was 
imaged 4 weeks after tumor induction. Tracer uptake in the other organs is shown in figure 9 
and Table 1 and expressed as mean ± standard deviation. Apart from the liver, uptake in all 
organs was significantly lower at week 4 compared to week 1.
A B C
A
D
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Figure 9: 
Biodistribution of Indium-111-DTPA-labetuzumab-IRDye800CW at 72 hours after injection at 1, 2, 3, and 4 weeks 
after tumor induction. One and 2 weeks after tumor induction, tumors were too small for reliable quantification, 
since the tumor weight could not be determined accurately. Apart from the liver, uptake in all organs was 
significantly lower in week 4 compared to week 1. Tissue uptake is expressed as % ID/g. Values represent mean 
± SD.
Table 1: 
Biodistribution of Indium-111-labetuzumab-IRDye800CW.
Week 1 Week 2 Week 3 Week 4
Blood 16.5 (2.8) 12.1 (3.4) 9.3 (1.8) 7.7 (1.3)
Muscle 1.3 (0.1) 0.9 (0.3) 0.7 (0.1) 0.6 (0.3)
Heart 6.8 (2.0) 6.3 (2.4) 4.8 (0.8) 3.2 (1.5)
Spleen 14.6 (3.5) 9.4 (3.0) 9.0 (2.6) 7.6 (3.8)
Pancreas 2.3 (0.4) 1.9 (0.6) 1.5 (0.3) 1.1 (0.5)
Kidney 6.7 (1.0) 5.5 (1.0) 4.2 (0.9) 3.7 (1.7)
Liver 10.0 (2.0) 9.6 (2.6) 9.6 (2.7) 10.5 (5.1)
Stomach 2.5 (0.3) 1.8 (0.4) 1.5 (0.3) 1.2 (0.6)
Duodenum 5.3 (1.1) 3.9 (1.3) 3.5 (0.9) 2.8 (1.3)
Tumor N.A. N.A. 17.2 (5.4) 16.5 (4.4)
Values are expressed as mean (+SD) % ID/g. Tumor uptake could not be reliably quantified after 1 and 2 weeks 
of tumor growth. 
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DISCUSSION
This study shows the potential of CEA-targeted dual-modality imaging using dual-labeled 
labetuzumab to detect CEA-expressing micrometastases before they become visible with the 
naked eye. Furthermore, it shows that dual-labeled labetuzumab can be used to perform 
image-guided surgery of very small tumor lesions. These results support the added value of 
dual-modality imaging to visualize and resect small tumor lesions. 
 Labetuzumab is a humanized monoclonal antibody that specifically recognizes 
CEACAM5. Clinical studies have shown the potential of radiolabeled anti‐CEA antibodies 
for SPECT imaging and radioimmunotherapy, but image‐guided surgery with dual-labeled 
labetuzumab still awaits clinical translation [26, 27]. In a previous study, we showed the 
feasibility of image-guided surgery with 111In-labetuzumab-IRDye800CW in mice with 
intraperitoneal CEA-positive LS174T tumors [14]. In the current study, we show the added 
value of dual-modality imaging by assessing the feasibility of detecting micrometastases. 
For this purpose, the GW-39 model was chosen, since it is a well established CRC model for 
studying CEA-expressing micrometastatic disease in the lungs [23]. The finding that dual-
modality imaging can detect micrometastatic disease is very promising. Although the role 
for surgery in pulmonary metastases of colorectal cancer origin is limited, the current results 
could also apply to other CEA-expressing cancers or, when using a different tumor-targeting 
agent, to other types of cancer; e.g., dual-labeled farletuzumab (anti-folate receptor alpha) in 
ovarian cancer surgery. The main role for surgery in metastasized CRC patients is in patients 
with metastases that are limited to the peritoneal cavity, and in a subgroup of patients with 
limited liver metastases. Patients with peritoneal carcinomatosis represent a specific surgical 
challenge, since lesions can be very small and numerous and difficult to differentiate from 
scar tissue from previous surgery. In this study we have demonstrated that CEA-expressing 
micrometastases can be detected sensitively with the dual-modality imaging agent. In 
peritoneal carcinomatosis, tumor lesions are located superficially on the abdominal organs 
instead of distributed within a solid organ, such as in our pulmonary model. Together with 
the mobility of the intra-abdominal organs (e.g., intestines), this may simplify the use of dual-
modality imaging in the abdominal setting compared to the pulmonary setting. The high liver 
uptake of Indium-111-labetuzumab-IRDye800CW and the prolonged retention of Indium-111 
in the liver may limit the role of the dual-labeled agent in the detection of micrometastases in 
or near the liver. Clinical trials with Indium-111-labeled antibodies in other tumor types have 
shown that imaging of liver metastases with Indium-111-labeled monoclonal antibodies is 
feasible [28, 29]. However, the addition of a fluorescent label (IRDye800CW) may reduce the 
tumor-to-liver contrast, due to the enhanced uptake in the liver [30]. Therefore, dual-modality 
imaging using Indium-111-labetuzumab-IRDye800CW may not be useful for intraoperative 
detection of small liver metastases. 
 In the current study sub-millimeter pulmonary tumor colonies could be visualized 
with dual-modality imaging before they became visible with the naked eye. After 3 and 4 
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weeks of tumor growth, image-guided resection of tumor lesions was performed. Figure 7 
demonstrates that dual-modality imaging can be used to check if a complete tumor resection 
has been performed. Since most of the mice had numerous pulmonary tumor nodules, 
resection of all tumor lesions was challenging in this tumor model. Biodistribution studies 
showed that the mean uptake of dual-labeled labetuzumab in tumor lesions was 17.2 ±  5.4 
%ID/g and 16.5 ±  4.4 %ID/g in weeks 3 and 4, respectively. Mean blood levels of dual-labeled 
labetuzumab decreased gradually from week 1 to week 4 after tumor induction (16.5, 12.1, 
9.3 and 7.7 %ID/g in week 1, 2, 3, and 4, respectively). An explanation might be that there is 
increased shedding of CEA into the blood by tumors in mice with a higher tumor load and 
therefore faster clearance of the dual-labeled antibody as was described previously [31, 32]. 
Sharkey et al. reported that in the presence of high plasma CEA levels (> 400 ng/ml), there 
is significant complexation of the antibody and that patients with elevated CEA levels have 
faster blood clearance of radiolabeled labetuzumab [33]. Complexation could be reduced 
by increasing the protein dose [33]. This phenomenon has to be considered when applying 
CEA-targeted imaging with dual-labeled labetuzumab in patients. An alternative is to exclude 
patients with very high plasma CEA levels.
 The advantage of a dual-labeled tracer is that the same tracer can be used 
for preoperative and intraoperative imaging. Preoperative CT and/or Fluorine-18 
fluorodeoxyglucose positron emission tomography fail to detect peritoneal carcinomatosis 
in approximately 9% and 17% of patients, respectively [34]. The Indium-111-labetuzumab-
IRDye800CW SPECT/CT might be used to detect CRC metastases preoperatively. Intraoperatively 
tumors can be localized with a gamma probe and subsequently a fluorescence camera can 
be used to guide and facilitate tumor resection and to assess the surgical cavity for remnant 
disease. That both techniques are complementary to each other is illustrated in figures 1 
and 7. Due to the limited penetration depth of light, only superficially located tumor lesions 
can be detected with fluorescence imaging (Figs. 1D,E and 7B,D). However, the preoperative 
SPECT/CT reveals that tumor load is more extensive and in the human situation a gamma 
probe can be used together with a fluorescence camera for intraoperative tumor detection. 
The dual-labeled approach ensures that both signals originate from the same molecule in 
contrast to co-injection of a radiolabeled and a fluorescently-labeled agent.    
 Although this study demonstrates the feasibility of dual-modality imaging of very 
small CEA-expressing tumors, there are some limitations that have to be considered. Since 
imaging was performed in euthanized animals, direct translation of these results to the 
human situation is premature. Also, one should consider that the sensitivity of real-time 
fluorescence imaging systems used in the clinic differs significantly from the systems that 
were used in this study. Several reports have shown the feasibility of targeted fluorescence 
imaging of cancer in humans [8, 35, 36]; however, the technique is still in its infancy and has 
to be optimized before it can be used in clinical practice. Another consideration is that the 
spatial resolution of images acquired with clinical PET scanners is higher than the resolution 
of SPECT scanners. Therefore, for preoperative imaging purposes, the use of a positron-
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emitting radionuclide, e.g., Zirconium-89, could be beneficial. However, the 511 keV gamma 
rays are less suitable for intraoperative detection with a standard gamma probe. Therefore, 
the optimal tracer has to be selected depending on the clinical question. 
CONCLUSION
In summary, this study shows the potential of CEA-targeted dual-modality imaging using 
dual-labeled labetuzumab to detect and resect CEA-expressing micrometastases. These 
data support the initiation of a feasibility study of dual-modality image-guided surgery with 
Indium-111-DTPA-labetuzumab-IRDye800CW in patients with peritoneal carcinomatosis of 
colorectal origin. 
The detection of micrometastases using CEA-targeted dual-modality imaging
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ABSTRACT
Context: 
With more complex kidney tumors treated by nephron sparing surgery (NSS), complete 
tumor resection is becoming increasingly challenging. Intraoperative imaging techniques 
may improve the establishment of negative surgical margins.
Objective: 
To discuss intraoperative imaging techniques that may help to achieve complete tumor 
resection in NSS of renal tumors.
Evidence acquisition: 
PubMed was searched for English articles on intraoperative imaging in renal cell carcinoma 
published after 2005 and a reference search of retrieved articles was performed. 
Evidence synthesis: 
Included studies reported about ultrasonography, fluorescence imaging, augmented reality, 
optical coherence tomography and ex vivo MRI. The number of patients included in these 
studies is limited and randomized controlled trials have not been performed. Ultrasonography 
is a well-established technique to assess tumor localization, and may be used to evaluate 
the surgical margins of the resected specimen. Fluorescence imaging with Indocyanine 
green may help to differentiate tumor from normal kidney tissue. It is yet unclear whether 
fluorescence imaging can detect positive surgical margins. Augmented reality is best studied 
in robotic laparoscopic surgery and may be useful for tumor localization and resection, if the 
problem of tissue deformation during surgery can be solved. More results have to be awaited 
about optical coherence tomography and ex vivo MRI.  
Conclusions: 
Ultrasonography is a widely used technique to assist the surgeon in partial nephrectomy 
nowadays, while the use of fluorescence imaging and augmented reality is emerging. 
Although various techniques can be used during NSS, the added value of intraoperative 
imaging to support negative surgical margins remains to be demonstrated.
Patient summary: 
In this review we discuss the value of various intraoperative imaging techniques that may 
support the urologist to achieve complete tumor resection in nephron-sparing surgery for 
kidney tumors. Ultrasonography, fluorescence imaging and augmented reality have been 
studied best, but their added value needs further investigation.
 Intraoperative imaging in nephron-sparing surgery
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INTRODUCTION
Nephron-sparing surgery (NSS) is widely used to treat renal cell carcinoma (RCC). For small 
renal tumors oncological outcomes are comparable to radical nephrectomy, while more 
renal function can be preserved [1]. There is a trend that more complex renal tumors are 
treated by NSS, where it can be challenging to perform a complete tumor resection [2, 3]. 
The fraction of patients with positive surgical margins (PSM) after NSS varies from 0-7%, but 
in imperative indications for NSS, e.g. a single kidney or bilateral tumors, PSM are seen in 
up to 18% of interventions [4]. Frozen section analysis of the tumor bed is time-consuming 
and its accuracy is a matter of debate [4]. However, in spite of contradictory results of the 
impact of PSM on recurrence, complete tumor resection in patients with RCC should always 
be pursued. Intraoperative imaging may help to perform oncologically safe NSS, as it can 
be used for tumor localization, to differentiate tumor from normal kidney parenchyma, and 
to assess the surgical cavity and margins of the resected specimen. The aim of this review 
is to provide an overview of the current and emerging intraoperative imaging techniques 
to aid complete tumor resection in NSS of RCC. The additional value and limitations of 
ultrasonography, fluorescence imaging, dual-modality imaging, augmented reality, optical 
coherence tomography and ex vivo MRI are discussed. 
EVIDENCE ACQUISITION
PubMed was searched for articles on intraoperative imaging to aid in complete resection of 
RCC published after 2005. The database was searched using the terms RCC and/or partial 
nephrectomy together with the terms (intraoperative) imaging, fluorescence imaging, 
intraoperative ultrasonography, augmented reality, optical coherence tomography or MRI. 
A reference search of relevant articles was performed manually. Articles that reported in 
English about the use of intraoperative imaging techniques to support complete tumor 
resection during NSS were included.
 
EVIDENCE SYNTHESIS
Intraoperative ultrasonography
Intraoperative ultrasonography (US) has long been used for real-time intraoperative imaging 
during PN [5-7]. It can be used to obtain relevant information during surgery, including 
information about tumor localization, tumor characteristics, tumor border delineation, and 
renal perfusion during clamping [7-13]. Furthermore, it may alter surgical management by 
revealing findings absent on preoperative imaging (e.g. multifocal disease) [10, 11, 14-16]. 
Recent developments in US of the kidney are the use of Doppler modes, contrast-enhanced 
ultrasound (CE-US) and elastography for the improved visualization of kidney tumors [17]. 
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Furthermore, Doppler modes and CE-US can be used to assist in selective ischemia, where 
CE-US has the advantage that it is not prone to movement artifacts [8, 9, 18, 19]. Since robot 
laparoscopic surgery is increasingly applied, imaging techniques should be compatible with 
robotic surgery too. Laparoscopic US probes can be used by the assistant during robot-
assisted partial nephrectomy (RAPN), but the advantage of specific robotic US probes is that 
the surgeon remains autonomic [12, 20]. Preferably US images are projected onto the console 
screen, so the surgeon can implement them without leaving the console to see the images 
on an external screen [21]. Although many studies describe the use of US in RCC surgery, only 
a few studies report on the intraoperative assessment of surgical margins with US [22-25]. 
Ex vivo US
In 2011 Doerfler et al. studied the ex vivo use of US in 33 patients who underwent a PN [23]. 
After resection the tumor specimen was kept in saline and surgical margins were assessed 
with US by a radiologist [23]. Two specimens showed a positive margin on US and one 
positive margin was confirmed on final histology (as a gold standard). Veeratterapillay et al. 
confirmed these encouraging results in 2015 [25]: Ex vivo US was performed by a uroradiologist 
in 45 surgical specimens that were kept in US gel. In one specimen a PSM was correctly 
identified with US, while false-positive resection margins were not seen. Furthermore, there 
was a positive correlation between the thickness of the uninvolved margin in millimeters as 
measured on US and final histology (Pearson’s r=0.86, p<0.001) [25]. Desmonts et al. showed 
that a comparable accuracy can be obtained when US is performed by the urologist [22]. Ex 
vivo US was performed in 41 patients in a mean US duration of one minute. Of the two PSM 
on US, one was confirmed on final pathology. 
 The disadvantage of ex vivo assessment of surgical margins for laparoscopic surgery 
is that the pneumoperitoneum will be lost and a re-resection will be difficult to perform when 
a PSM is found [24]. Furthermore, re-clamping can be harmful for the kidney function. 
In vivo US
In 2014 Doerfler et al. described a method for in vivo US control of the surgical margin during 
laparoscopic PN for T1 tumors (n=12) [24]. Immediately after resection and before hemostasis 
the tumor was placed in an endobag filled with saline. Then US was used to evaluate whether 
the tumor’s pseudocapsule was intact (Figure 1). In one patient a PSM was detected by US 
and an extra rim of tissue was removed. US evaluation of the surgical margin matched with 
final histology. Mean US examination time during warm ischemia time was 42 ± 9 seconds. 
The disadvantage of this approach is that ischemia time will be prolonged, albeit to a limited 
extent. Recently, the same group confirmed these promising results in a larger cohort of 
147 open PN and 30 laparoscopic PN. The final pathology revealed only one false PSM (75% 
specificity) and one false NSM (99% sensitivity) [26]. However, it has not been mentioned 
whether the surgeon assumed a positive margin or not. Therefore it is unclear whether US 
assessment of the surgical specimen outperforms macroscopic inspection by the surgeon.
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Fluorescence imaging
A relatively new development in renal cancer surgery is intraoperative fluorescence imaging. 
In 2009 Hoda et al. reported about fluorescence-guided laparoscopic PN four hours after 
oral administration of 5-aminolevulinic acid (5-ALA) in 77 patients [27]. During surgery a 
fluorescent red signal (635 nm) was observed in 58 of 61 RCCs (95%) after excitation with 
light of 390 to 440 nm, while one angiomyolipoma showed false positive red fluorescence 
(sensitivity 95%, specificity 94%). Furthermore, two PSM were correctly identified with 5-ALA 
fluorescence imaging (100% accuracy) [27]. 
 Since then, most research has focused on fluorescent dyes that emit light in the 
near-infrared (NIR) range (700-1000 nm), since the penetration depth of NIR light in tissue 
is higher (up to approximately 1 cm) compared to dyes in the visible light range (390-700 
nm) [28]. The NIR signal must be detected with a NIR fluorescence camera system since NIR 
light is invisible to the human eye. During surgery the urologist can switch between visible 
light and NIR light or use the merged view that shows the fluorescent signal projected over 
the visible light view (overlay view, not available in all imaging systems). Several near-
infrared fluorescence imaging (NIRF) systems have become available for clinical use in open, 
laparoscopic or robotic surgery, either as stand-alone fluorescence cameras or integrated in 
robotic surgical systems. 
Figure 1: 
Margin control of the resected specimen 
with US imaging after the specimen has 
been placed in an endobag [24]. 
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Fluorescence imaging using ICG
The most commonly used NIR fluorescent dye in renal cancer surgery is Indocyanine Green 
(ICG) [29-34]. ICG can be used to confirm adequate ischemia (hypofluorescence) during 
selective clamping of renal artery branches and thereby reduce the proportion of renal 
parenchyma that is subjected to ischemia [33, 35]. Furthermore, ICG has been investigated 
as a negative contrast agent to differentiate the tumor from normal kidney parenchyma: after 
i.v. injection of ICG RCCs appear hypofluorescent compared to normal kidney parenchyma 
[29-32, 36]. It is hypothesized that ICG is retained by normal kidney parenchyma, because 
it is transported by bilitranslocase in renal proximal tubule cells [29]. The majority of RCC 
cells lack this protein, while oncocytomas do express bilitranslocase and therefore appear 
isofluorescent [37]. Because ICG is not cleared via the kidneys, it can be used in patients 
suffering from renal insufficiency and during renal ischemia in the operating room. 
 Seven studies have reported on fluorescence imaging with ICG to differentiate 
tumor from normal tissue (in total 287 partial nephrectomies); two during open PN [29, 31] 
and five during (robot-assisted) laparoscopic PN [30, 32, 34, 36, 38]. ICG was injected i.v. after 
exposure of the renal hilum and resection of Gerota’s fascia and the perirenal fat, shortly 
before arterial clamping. Fluorescence of the parenchyma was observed several minutes 
after injection, extending for at least one hour (Figure 2). Successful differentiation of tumor 
tissue from normal kidney parenchyma ranged from 73% to 100% [33]. Entirely endophytic 
tumors could not be detected with fluorescence imaging, due to overlying fluorescent 
normal parenchyma. The variable success rates probably originate from differences in dosing 
regimens which ranged from 0.5 to 25 mg of ICG. In 2013 Angell et al. reported a 92% accuracy 
of successful tumor differentiation in a two-step dosing regimen (test-dose and re-dose) to 
prevent inadequate fluorescence due to under- or overdosing of ICG [32]. Although these 
results suggest proof of principle that fluorescence imaging can be used to differentiate 
tumor tissue from normal kidney parenchyma, the reliability to differentiate malignant from 
benign lesions (PPV 84%, NPV 57%) has been questioned [38].
Figure 2: 
A ccRCC appears hypofluorescent 
compared with normal (n) renal 
parenchyma after intravenous ICG 
injection [31]. 
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Mitsui et al. investigated whether fluorescence imaging could be useful to assess resection 
margins in the surgical cavity [29]. In 6 out of 16 patients low fluorescent regions were 
found in the surgical cavity, warranting additional investigation of possible remnant tumor 
tissue. However, in all cases the low fluorescence was caused by adipose tissue around the 
hilum. Ex vivo examination of surgical margins using fluorescence imaging revealed NSM in 
all specimens (n=16), as indicated by a rim of normal fluorescent tissue around the tumor 
[29]. This correlated with histopathological evaluation. The only study that compared NIRF 
imaging in RCC to a control group was performed by Krane et al. [34] comparing a cohort of 
47 RAPN performed with NIRF imaging using ICG with 47 previous historical RAPN that were 
performed without NIRF imaging. They found no significant difference in the percentage of 
positive margins (NIRF 6%, versus control 8.5%, P = 0.69). 
Tumor-targeted fluorescence imaging
A promising new approach is tumor-targeted fluorescence imaging [39]. In this approach, a 
fluorescent dye is conjugated to a cancer-specific targeting molecule, e.g. a receptor binding 
ligand or a monoclonal antibody. With intact antibodies the optimal timing to perform 
imaging (with high tumor-to-normal contrast) is several days after tracer injection, but this 
interval can be shortened by using small molecules or (engineered) antibody fragments, 
e.g. Fab-fragments, minibodies, diabodies or single-chain antibodies, allowing for imaging 
on the day of the injection [40]. A specific disadvantage of smaller molecules for imaging 
RCC is that their size is below the limit for glomerular filtration (60 kDa), resulting in a high 
background signal in the kidneys hampering visualization of kidney tumors [41, 42].
 The potential of targeted fluorescence imaging has already been shown in other 
tumor types, but in RCC it is still in its infancy. Folate receptor alpha targeted imaging in RCC 
has shown conflicting results. Guzzo et al. described a positive tumor-to-normal fluorescent 
contrast intraoperatively in 2 out of 4 clear cell RCC (ccRCC) using folate-FITC [43]. In contrast, 
Shum et al. reported a negative tumor-to-normal tissue contrast in all 3 studied RCC patients 
using the tracer OTL38 [44]. A probably more suitable antigen that is commonly used to 
target ccRCC is carbonic anhydrase IX (CAIX) [45, 46]. CAIX is expressed at high levels in more 
than 95% of ccRCCs and not in normal kidney parenchyma. Girentuximab is a monoclonal 
antibody that specifically recognizes CAIX. Tagged with a NIR dye this tracer can be used as 
an imaging probe for ccRCC and accurate real-time tumor delineation during surgery. This 
approach is currently under investigation in a clinical trial (clinicaltrials.gov: NCT 02497599, 
see below). Since chromophobe and papillary RCCs do not express high levels of CAIX, this 
limits the use of CAIX-targeted imaging to ccRCC.
Tumor-targeted dual-modality imaging
The main drawback of fluorescence imaging is the limited tissue penetration depth of the 
NIR signal, only allowing imaging of superficially located tumors [39]. Gamma radiation, on 
the other hand, has a very high tissue penetration depth. Therefore, radiolabeled tumor-
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targeting agents may be useful for intraoperative localization of endophytic tumors with a 
gamma probe. A case report showed that Iodine-124-girentuximab can be used for accurate 
intraoperative tumor localization and confirmation of complete tumor removal [47]. 
 Targeting molecules like girentuximab can be tagged with both a fluorescent dye 
and a radiolabel (dual-labeled probe). Dual-modality imaging combines the advantages of 
radio-guided and fluorescence-guided surgery and compensates for the disadvantages of 
each detection method. Tumors can be localized with a gamma probe and real-time imaging 
can be performed with a fluorescence camera. Furthermore, a dual-labeled probe has the 
advantage that the same tracer can be used for preoperative imaging (PET/CT or SPECT/CT) 
and intraoperative imaging. A recent ex vivo study in perfused tumorous kidneys showed that 
targeted dual-modality imaging using dual-labeled girentuximab is feasible (Figure 3) [48]. 
A clinical trial that investigates the feasibility of intraoperative imaging using dual-labeled 
girentuximab is currently ongoing. Efforts have been made to fasten pharmacokinetics and 
therefore shorten the time between injection and imaging by using smaller CAIX-targeting 
molecules. The dual-motif CAIX-ligands 111In-XYIMSR-01 and 64Cu-XYIMSR-06 have been 
evaluated in preclinical studies, but clinical studies have not been initiated yet [49, 50]. A 
recently published clinical trial with a CAIX-targeting small molecule PET-tracer (18F-VM4-037) 
showed that visualization of primary ccRCC with this tracer was challenging due to a high 
background signal in the kidneys [42]. This problem of small molecule imaging agents has to 
be overcome before it may be applied for intraoperative imaging of primary renal tumors.
Figure 3: 
Morphological image (A), fluorescent image (B) and autoradiography (C) showing high and specific uptake of 
dual-labeled girentuximab in a ccRCC after ex vivo kidney perfusion. A satellite ccRCC lesion (**) was identified 
by fluorescence imaging [48].
Augmented reality 
In augmented reality (AR) preoperative or intraoperative images are superimposed onto the 
surgical field (Figure 4). For a PN, roughly two phases can be distinguished: the preparation 
phase during which the kidney is mobilized and the tumor localized, and the phase of actual 
A B C
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tumor resection. In the preparation phase an inaccurate image overlay of several millimeters 
may not be crucial. However, for AR to be useful in supporting the surgeon during tumor 
resection, image overlay needs a very high accuracy and a submillimeter precision [51].
Figure 4: 
3D model image of the renal tumor 
(green) superimposed onto the 2D 
laparoscopic image with manual image 
fusion [53]. 
Several studies have shown the feasibility of AR using preoperative images for tumor 
localization in PN [51-54]. When preoperative images are used, the most challenging aspects 
in adequate image overlay technology are organ movements and tissue deformation [51]. The 
segmental branches of the renal artery can shift up to 11 mm when comparing intraoperative 
flank position and the supine position used for preoperative imaging [55]. Application of 
organ trackers to correct for real-time organ movements due to surgery and respiration may 
(partly) solve this problem [51]. However, the lack of a viable solution to tissue deformation 
represents the major holdback to use preoperative imaging during tumor resection in an 
AR environment. Several factors play a role in tissue deformation, such as arterial clamping, 
surgical dissection, bleeding, respiration, the pneumoperitoneum and the tumor itself. 
Current computer models can only partly predict these deformations [56]. 
 The problem of tissue deformation can be avoided by using real-time intraoperative 
images instead of preoperative images for image overlay. The first use of registered 
intraoperative US overlay in two patients has shown the feasibility of the technique [57, 
58]. However, since the US probe has to stay in close contact with the kidney surface, this 
impairs the ability of the surgeon to perform resection at the same time. Another possible 
real-time imaging modality is intraoperative cone beam CT (CBCT) [51]. Simpfendörfer et al. 
have shown the feasibility of CBCT during laparoscopic PN in 10 patients [55]. They used 
intraoperative contrast-enhanced CBCT combined with fluoroscopy and marker-based 
AR navigation for intraoperative tumor delineation and resection. The intervention was 
prolonged with approximately 15 minutes due to imaging and the radiation dose to the 
patient was acceptable. The estimated effective dose was around 7 mSv, which was slightly 
higher than a noncontrast-enhanced CT and comparable to the widely accepted radiation 
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exposure during kidney stone surgery [55]. The renal function did not deteriorate, despite the 
use of a  contrast agent. The major disadvantage in the current era of robotic surgery, is the 
interference of the C-arm of the CBCT with the robots’ arms which would require temporary 
disconnection of the robot. Furthermore, intraoperative CBCT requires a hybrid operating 
room with expensive and dedicated imaging technology.
Optical coherence tomography
An upcoming technique that may become useful in the future to differentiate tumor from 
normal kidney parenchyma during PN is optical coherence tomography (OCT). OCT uses 
reflected light comparable to US. The OCT probe emits coherent light of a certain wavelength 
into the tissue. Next, the part of the light that is reflected by the tissue can be detected by 
the OCT probe and used to obtain a detailed image of the microstructure of the tissue [59]. 
OCT can be obtained with needle-sized probes, in a laparoscopic probe, or in a hand held 
probe [60, 61]. With NIR light, images to a depth of 1-2 mm and a resolution of 10-30 µm can 
be obtained [59, 61]. The resolution can be further increased to achieve cellular resolution 
imaging by combining OCT with confocal microscopy (optical coherence microscopy) [60]. 
 Several studies have demonstrated that OCT can be used ex vivo to differentiate 
normal renal parenchyma from renal tumors and to differentiate benign from malignant 
tumors [60-63]. Barwari et al. quantified the attenuation of the OCT signal in a phase I in vivo 
study in patients. The image acquisition time was approximately 5 minutes per patient and 
the attenuation coefficient of the OCT signal in normal renal parenchyma was significantly 
lower than in renal tumors [62]. These studies showed the potential of OCT to be a real-
time intraoperative imaging technique to distinguish tumor from normal tissue. Current 
research focuses mainly on the application of OCT as an alternative to or extension of the 
percutaneous biopsy to diagnose kidney cancer (clinicaltrials.gov: NCT02073110). The value 
of OCT in the assessment of the resection margins has not been investigated yet.
Ex vivo MRI
Another new tool that might be useful to evaluate the surgical margins after PN is ex vivo 
MRI. Ex vivo MRI was previously used in breast cancer and prostate cancer specimens to 
visualize the extension of the tumor in the resected tissue [64, 65]. The advantage of MRI is 
that it produces high resolution images of the resected specimen (Figure 5). Recently, the ex 
vivo assessment of surgical margins using MRI was reported [66]. Anatomical T1-, T2- and 
diffusion weighted images of 6 resected specimens were obtained in a 7T horizontal wide 
bore (200 mm) ClinScan animal scanner immediately after PN. In this pioneering study, MRI 
results and pathological results were concordant. Although these first results are encouraging 
further research should evaluate whether results are reproducible with more widely available 
3T MRI scanners. Furthermore, ex vivo assessment of the surgical specimen has inherent 
disadvantages, as previously mentioned in the section about ex vivo US.
 Intraoperative imaging in nephron-sparing surgery
71
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 8
Ch
ap
te
r 8
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
Figure 5: 
Ex vivo assessment of the resected specimen with MRI (A) revealed negative surgical margins and this correlated 
to final pathology (B, tumor delineated with green) [66]. 
CONCLUSION
In this review an overview is provided of intraoperative imaging techniques to improve 
complete tumor resection in NSS for RCC (Table 1). Ultrasonography is a widely used technique 
to assist the surgeon in partial nephrectomy, while the use of fluorescence imaging and 
augmented reality is emerging. But, it remains to be proven whether intraoperative imaging 
has added value to support NSM and improve tumor resection. To date, no randomized trials 
have been performed to compare PN with or without intraoperative imaging. 
 A rough distinction can be made between real-time imaging during surgery, versus 
imaging of the resected specimen. With real-time imaging during tumor resection, significant 
extension of the period of renal ischemia should be avoided. Clear advantages of US are the 
wide availability, low costs, and ease of use. However, live imaging during tumor resection is 
not feasible, since the probe interferes with the resection as it has to stay in close contact with 
the tissue. Fluorescence imaging can be used for enhanced visualization of the renal tumor-
to-normal kidney interface in exophytic tumors. However, the limited tissue penetration 
depth of light limits its use in endophytic tumors. Dual-modality imaging with both a 
radiolabel and a fluorescent label might compensate for the limited tissue penetration depth 
of light, but results of the clinical trial have to be awaited. If the challenges regarding tissue 
deformation can be resolved, AR could be a valuable tool to guide resection of endophytic 
tumors or tumors that are located near vital structures. More data have to be awaited to 
judge the value of OCT and MRI.  
 All techniques have their own additional value and limitations and none of 
the techniques will fit every patient. Preferably preoperative evaluation should address 
whether specific challenges are to be expected during surgery. For NSM in tumors with a 
low complexity score, intraoperative imaging may have limited relevance. However, currently 
larger and complex tumors are increasingly treated by NSS. Since especially these patients 
are at risk for PSM, it is likely that intraoperative imaging will be beneficial in this particular 
clinical setting [4]. 
A B
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Table 1: 
Overview of imaging techniques that can be used during partial nephrectomy.
Technique Application Strengths Weaknesses
In vivo US
[5-15, 18-20, 
24, 26]
✓ Tumor localization and 
delineation
✓ Margin assessment of 
resected specimen
✓ Guide selective ischemia 
when Doppler or CE-US is 
used.
• Widely available
• No contrast agent 
needed
• High tissue penetration 
depth
• Probe has to stay in 
contact with tissue, not 
practical for realtime 
guidance during 
resection. 
• In vivo assessment 
of surgical margins 
may slightly prolong 
ischemia time
Ex vivo US 
[22, 23, 25]
 ✓ Margin assessment of 
resected specimen
• Quick and simple 
assessment of surgical 
specimen
• No real-time guidance
• A PSM would require re-
entering the abdomen 
and  
re-clamping the kidney
Fluorescence/
dual-modality 
imaging 
[27, 29-34, 36, 
38, 43, 44, 47, 
48]
 ✓ Tumor localization and 
delineation
 ✓ Realtime guidance during 
tumor resection
 ✓ Assessment of surgical 
cavity 
 ✓ Margin assessment of 
resected specimen
 ✓ Guide selective ischemia 
(ICG)
• Real-time imaging 
before, during and after 
tumor resection
• Dual-modality imaging: 
Radiolabel has high 
tissue penetration depth
• Targeted imaging 
approaches: high and 
specific accumulation in 
tumor tissue 
• Fluorescence has 
a limited tissue 
penetration depth, 
therefore not suitable 
for endophytic tumors
• Contrast agent needed
• Interval required 
between tracer 
injection and imaging 
timepoint depending 
on pharmacokinetics 
of the tracer (ICG quick 
versus antibodies slow)
AR
 [51-58]
 ✓ Tumor localization and 
delineation
• Accurate visualization of 
tumor localization and 
vital structures
• No contrast agent 
needed
• Tissue deformation 
currently limits it use 
during tumor resection 
OCT 
[60-63]
score
 ✓ Differentiate between 
tumor and normal kidney 
parenchyma
 ✓ In the future maybe 
assessment of surgical 
margins
• Submillimeter resolution • Limited data available
• Limited field of view 
and depth penetration 
• No real-time guidance
Ex vivo MRI [66]  ✓ Margin assessment of 
resected specimen
• High resolution images • No real-time guidance 
• Limited data available
• A PSM would require re-
entering the abdomen 
and re-clamping the 
kidney
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ABSTRACT
Purpose: 
Antibodies labeled with both a near-infrared fluorescent dye and a radionuclide can be 
used for tumor-targeted intraoperative dual-modality imaging. Girentuximab is a chimeric 
monoclonal antibody against carbonic anhydrase IX (CAIX), an antigen expressed in 95% of 
clear cell renal cell carcinoma (ccRCC). This study aimed to assess the feasibility of targeted 
dual-modality imaging with 111In-girentuximab-IRDye800CW using ex vivo perfusion of 
human tumorous kidneys.
Experimental design: 
Seven radical nephrectomy specimens of ccRCC patients were perfused during 11-15h with 
dual-labeled girentuximab and subsequently rinsed during 2.5–4h with Ringer’s Lactate 
solution. Then, dual-modality imaging was performed on a 5-10-mm thick lamella of 
the kidney. Fluorescence imaging was performed with a clinical fluorescence camera set-
up as applied during image-guided surgery. The distribution of Indium-111 in the slice of 
tumor tissue was visualized by autoradiography. In two perfusions an additional dual-
labeled control antibody was added to demonstrate specific accumulation of dual-labeled 
girentuximab in CAIX-expressing tumor tissue. 
Results: 
Both radionuclide and fluorescence imaging clearly visualized uptake in tumor tissue and 
tumor-to-normal tissue borders, as confirmed (immuno)histochemically and by gamma 
counting. Maximum uptake of girentuximab in tumor tissue was 0.33 % of the injected dose 
per gram (mean 0.12 %ID/g, range 0.01 – 0.33 %ID/g), while maximum uptake in the normal 
kidney tissue was 0.04 %ID/g (mean 0.02 %ID/g, range 0.00 – 0.04 %ID/g).   
Conclusion: 
Dual-labeled girentuximab accumulated specifically in ccRCC tissue, indicating the feasibility 
of dual-modality imaging to detect ccRCC. A clinical study to evaluate intraoperative dual-
modality imaging in ccRCC patients has been initiated.
Targeted dual-modality imaging in ccRCC - an ex vivo kidney perfusion study
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STATEMENT OF TRANSLATIONAL RELEVANCE
Intraoperative dual-modality imaging may provide the surgeon with valuable information 
about tumor localization and resection margins, and therefore may improve locoregional 
control and patient outcome. In the current study we bridge the gap between preclinical 
studies and the clinical application of intraoperative dual-modality imaging using 
radiolabeled and fluorescently labeled tumor-targeting antibodies. In an ex vivo perfusion 
study of human kidneys with renal cell carcinoma dual-modality imaging was tested in a 
translational setting. Real-time fluorescence images acquired with a clinical fluorescence 
camera system clearly visualized uptake in tumor tissue and tumor-to-normal tissue borders, 
as confirmed (immuno)histochemically and by gamma counting. These results demonstrate 
the clinical potential of dual-modality imaging and have lead to the initiation of the first 
targeted dual-modality image-guided surgery study in clear cell renal cell carcinoma patients 
(NCT02497599). Targeted dual-modality imaging has the potential to revolutionize oncologic 
surgery.
INTRODUCTION
In oncological surgery, radical tumor resection is crucial for treatment outcome and patient 
survival [1-6]. During surgery, differentiation of tumor tissue from non-tumorous tissue with 
the naked eye may be challenging. Intraoperative imaging techniques that can distinguish 
tumor from normal tissue will help the surgeon to achieve complete tumor resection. 
 One of these techniques, radio-guided surgery, has already been implemented 
in clinical practice, for example to detect sentinel lymph nodes [7-9]. The high tissue 
penetration depth of gamma radiation allows accurate localization of tumors, almost 
regardless of tissue depth. However, exact tumor delineation with a gamma probe is difficult 
and for precise real-time tumor delineation during surgery an optical signal may be more 
beneficial. For this purpose, a fluorescent probe can be used, but since the penetration 
depth of light in biological tissue is limited, fluorescence imaging is mainly useful for the 
detection of superficially located tumors [10, 11]. Therefore, dual-modality image-guided 
surgery, combining the advantages of radioguided and fluorescence-guided surgery may be 
a synergistic combination [12-15]. A dual-labeled tumor-targeting imaging probe could allow 
intraoperative tumor detection, tumor delineation, and assessment of resection margins and 
remnant disease. Results from preclinical studies are promising [16-19] and tumor-targeted 
dual-modality imaging is awaiting its first use in patients.
 Monoclonal antibodies against tumor-associated antigens tagged both with a 
radiolabel and a fluorophore may be used as probes during image-guided surgery [20]. 
Girentuximab, a chimeric monoclonal IgG1 antibody, is an excellent vehicle to target clear 
cell renal cell carcinoma (ccRCC). It specifically recognizes carbonic anhydrase IX (CAIX), a cell 
surface antigen that is expressed abundantly in more than 95 percent of ccRCC and is absent 
CHAPTER 5
82
in normal kidney tissue [21, 22]. Previous research has shown that after administration of 
radiolabeled girentuximab both primary tumors and metastases can be detected by PET/
CT or SPECT/CT in patients [23-25]. Animal studies using 111In-girentuximab-IRDye800CW 
have illustrated the potential of dual-modality imaging [17, 18]. Dual-labeled girentuximab 
accumulates highly and specifically in CAIX-expressing SK-RC-52 subcutaneous tumors [18]. 
Next, a proof-of-principle study was performed to show the feasibility of image-guided surgery 
using an intraperitoneal tumor model [17]. After administration of dual-labeled girentuximab 
submillimeter CAIX-expressing tumor nodules could be detected preoperatively with SPECT/
CT. Subsequently, during surgery superficially located tumor nodules could be visualized and 
resected based on the fluorescent signal.  
 However, animal studies only partly reflect the clinical situation. To test the 
translation of dual-modality imaging to the clinic, models using clinical imaging systems and 
intact tumors obtained from patients are required. In the present study, tumorous kidneys 
resected from ccRCC patients were connected ex vivo to a perfusion system via the renal 
artery as has been described previously [26]. Subsequently, the tumorous kidneys were 
perfused with dual-labeled girentuximab and investigated using the clinical imaging system 
to be used during image-guided surgery. In preparation of the first targeted dual-modality 
image-guided surgery study in patients, this study aimed to show the feasibility of tumor-
targeted dual-modality imaging in renal cell carcinoma using dual-labeled girentuximab in 
an ex vivo kidney perfusion model.
MATERIAL AND METHODS
Study design
The aim of this study was to assess the feasibility of DMI in ccRCC patients in an ex vivo kidney 
perfusion study. Patients suspected of ccRCC and scheduled for a radical nephrectomy that 
signed informed consent were included. Exclusion criteria were a known subtype other than 
ccRCC or the administration of a radioisotope within ten physical half-lives prior to surgery. 
The first human tumorous kidney was perfused with DOTA-girentuximab-IRDye800CW 
not labeled with Indium-111, to estimate the radiation safety risks of the procedure. Next, 
four human tumorous kidneys were perfused ex vivo with dual-labeled girentuximab. 
To demonstrate specific binding of girentuximab two additional tumorous kidneys were 
perfused with a mixture of dual-labeled 131I-girentuximab-IRDye800CW and a 125I-labeled 
control antibody-IRDye800CW. After perfusion, radionuclide and fluorescence imaging 
were performed performed on a 1-cm lamella of the specimen using clinical and preclinical 
imaging systems. Subsequently, samples of tumor and normal tissue were taken for further 
analysis; quantification of antibody accumulation, fluorescence imaging, autoradiography, 
CAIX-staining and H/E-staining. The primary outcome measure was the ability to detect a 
fluorescent and radioactive signal in tumor tissue. Secondary outcome measures were 
the antibody accumulation in tumor and normal kidney tissue expressed as percentage 
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of injected dose per gram (%ID/g) and as the tumor-to-kidney tissue ratio. This study was 
approved by the regional ethical review board (CMO, region Arnhem-Nijmegen). 
Dual-labeled antibody production
Chimeric girentuximab (IgG1) was a kind gift from Wilex AG, Munich Germany. The isotype-
matched control human Immunoglobulin (IgG1) was purchased from Biotrend Chemikalien, 
Köln, Germany. The fluorophore IRDye800CW-NHS ester was purchased from LI-COR 
biosciences (Lincoln, NE, USA). IRDye800CW is a near-infrared dye that can be stably coupled 
to monoclonal antibodies [27]. It emits 789-nm photons when excited at 774 nm. Near-infrared 
fluorescent dyes (700-1000 nm) have a higher tissue penetration depth compared to dyes in 
the visible light range [28]. The chelator DOTA-NHS ester (1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid mono-N-hydroxysuccinimide ester) was purchased from Macrocyclis 
(Dallas, TX, USA). 
 DOTA-girentuximab-IRDye800CW was produced under metal free conditions 
as described previously [29]. In short, girentuximab (5 mg/mL) was incubated in 0.1 M 
NaHCO3, pH 8.5 at room temperature (RT) for one hour with a 3-fold molar excess of the 
IRDye800CW-NHS ester. Then the mixture was incubated in NaHCO3 , pH 9.5 for one hour 
with a 10 to 20-fold molar excess of the DOTA-NHS ester. After conjugation, the reaction 
mixture was transferred into a Slide-A-Lyzer cassette (molecular weight cut-off: 10,000 or 
20,000 Da, Thermo Scientific, Rockford, IL, USA) and extensively dialyzed against 0.25 M 
ammoniumacetate, pH 5.5 for three days with buffer changes to remove the unconjugated 
IRDye800CW and DOTA. The average number of IRDye800CW molecules that was conjugated 
to the antibody (substitution ratio or SR) was determined spectrophotometrically with the 
Ultrospec 2000 UV/Visible spectrophotometer (Pharmacia Biotech, Sweden) and ranged 
from 1.3 to 1.5. The immunoreactive fraction of dual-labeled girentuximab was determined 
as described by Lindmo [30], within two weeks of each experiment and always exceeded 70 
%. DOTA-girentuximab-IRDye800CW was stored in the dark at 4 ˚C until use.
 For the control experiments girentuximab-IRDye800CW and control IgG-IRDye800CW 
were prepared as describe above. The SR of girentuximab-IRDye800CW and the irrelevant 
control IgG-IRDye800CW were 2.0 and 2.1 respectively.
Radiolabeling of antibodies
On the day of the experiment 1.2 mg DOTA-girentuximab-IRDye800CW was labeled with 3.5 
– 7.0 MBq 111InCl3 (Mallinckrodt Pharmaceuticals, ‘s Hertogenbosch, The Netherlands) in two 
volumes of 0.5 M 2-(N-morpholino)ethanesulfonic acid (MES). After 40 minutes of incubation 
at 45 °C 50 mM ethylenediaminetetraacetic acid (EDTA) was added to a final concentration 
of 5 mM to chelate unincorporated Indium-111. Preparations were purified on a PD10 
disposable gelfiltration column eluted with phosphate-buffered saline (PBS). Radiochemical 
purity was determined by Instant Thin Layer Chromatography (ITLC) on silicagel, using 0.1 
M sodiumcitrate buffer, pH 6.0 as mobile phase. Radiochemical purity of the Indium-111-
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labeled preparations exceeded 95 %. After purification the DOTA-girentuximab-IRDye800CW 
amount was adjusted to a total protein amount of 1.2 mg. Standards of the injected dose 
(ID), were prepared in triplicate to be able to quantify antibody accumulation corrected for 
radioactive decay. The injected activity dose was determined in a dose calibrator and ranged 
from 3.4 to 5.1 MBq. 
 In the two dual-isotope experiments 100 µg of girentuximab-IRDye800CW was 
radiolabeled with 10 to 15 MBq Iodine-131 (PerkinElmer, Milano, Italy) and 100 µg of control 
IgG-IRDye800CW was labeled with 5 to 7 MBq Iodine-125 (PerkinElmer, Milano, Italy) [31]. 
Briefly, 100 µg of antibody conjugate was added to 10  µL of 0.5 M sodium phosphate, pH 7.4 in 
a vial coated with 100 µg iodogen. After adding the radioactivity the volume was adjusted to a 
total volume of 100 µL with 50 mM sodium phosphate, pH 7.4. After 10 minutes of incubation 
at RT, the reaction mixture was transferred to a clean Eppendorf vial together with 100 µL of 
saturated tyrosine. After purification on a PD10 column radiochemical purity exceeded 95 
%  and the amount of both antibodies was adjusted to 1.2 mg of protein with cold antibody. 
Standards of the injected dose were prepared in triplicate. Both Iodine-131-girentuximab-
IRDye800CW (1.2 mg, ID 4.6 and 4.1 MBq) and Iodine-125-control IgG-IRDye800CW (1.2 mg, ID 
1.0 and 1.2 MBq) were added to the perfusion reservoir.
Kidney perfusion model
At the operation theatre a vessel cannula was inserted on the bench in the renal artery and 
connected to a flushing system with Ringer’s Lactate solution to rinse blood (see fig. 1, 2). In 
case of multiple renal arteries, the two largest arteries were connected and any others were 
left open. Also the renal vein was left open. Then, the kidney with the vessel cannula(s) in 
situ was connected to a recirculating perfusion system, which included a peristaltic pump 
(30 mL/min).  The flow in the system (30 ml/min) is considerably lower than the human renal 
blood flow (500 mL/min). This flow rate was selected based on our experience that at this 
maximum flow rate the risk of leakage of the arterial connection was minimal. After ensuring 
the leakage-free connection to the kidney, the afferent and efferent hoses of the pump (fig. 
1) were placed in a reservoir with 350 mL Ringer’s Lactate solution containing 0.1 % Bovine 
Serum Albumin (BSA). This reservoir was cooled with ice (0-4 °C) and protected against light. 
Subsequently, the dose of Indium-111-DOTA-girentuximab-IRDye800CW (1.2 mg, 3.6 – 5.2 
MBq Indium-111) was added to the 350 mL reservoir resulting in an antibody concentration 
of 3.4 mg/L. This concentration was chosen to mimic the serum concentration in patients 
that receive radiolabeled girentuximab in clinical studies [22-24]. 
 The tumorous kidney was perfused during 11 – 15 hours with dual-labeled antibody. 
After this period, the kidney was rinsed with 5 to 7 litres of non-recirculating Ringer’s Lactate 
solution (2.5 – 4 h) to wash out unbound antibody. For safety reasons the first experiment was 
performed without radioactivity, and therefore antibody uptake was not quantified in this 
first kidney.
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Figure 1: 
Schematic overview of the different steps of the perfusion experiment.
Figure 2: 
Photograph of an ex vivo tumorous 
kidney during a perfusion experiment. 
In this kidney, two renal arteries were 
connected to the perfusion system. 
During perfusion, the kidney was kept at 
0-4 °C and protected from light.
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Dual-modality imaging
A central coronal slice (5-10 mm thick) of the perfused kidney containing both tumor and 
normal tissue was obtained for further analysis. Fluorescence imaging was performed 
using a real-time clinical imaging system (Storz D-light P laparoscopic setup). Furthermore, 
fluorescence imaging was performed with two non-clinical imaging systems, the IVIS Lumina 
closed-cabinet fluorescence imager (Caliper Life Sciences, recording time 5-10 min; binning 
factor medium; F/stop 2; excitation filter 745 nm; emission filter ICG; FOV C; autofluorescence 
(675 nm) and background correction) and the Odyssey CLx flatbed fluorescence scanner 
(LICOR biosciences, recording time 20-30 min; 800 nm channel; focus 1.0 mm). Subsequently 
the kidney slice (kept on ice) was exposed for one hour to a phosphor imaging plate for 
autoradiography. This plate was developed using the Typhoon FLA 7000 Phosphor Imager 
and analyzed with Aida Image Analyzer v. 4.21. 
Tissue processing
After dual-modality imaging 1 cm3 samples of tumorous and normal tissue were taken from 
the kidney slice and fixed in 4% formalin for further analysis. The amount of Indium-111-
DOTA-girentuximab-IRDye800CW in tissue was determined quantitatively by measuring 
these samples in a gamma counter (2480 WIZARD2, Perkin Elmer) together with the standards 
of the injected dose. In the control experiment a dual-isotope protocol was used (Iodine-125 
35 keV (window 15 - 85 keV), Iodine-131 360 keV (window 260 – 430 keV), spillover correction 
was applied). The tracer uptake was expressed as percentage of the injected dose per gram 
tissue (%ID/g). In addition, the tumor-to-normal antibody uptake ratio was calculated. 
 Then, formalin-fixed, paraffin-embedded 5-µm sections were cut and were analyzed 
autoradiographically (2 weeks exposure to a phosphor imaging plate) and fluorescence 
imaging (Odyssey CLx flatbed fluorescence scanner, 800nm channel, recording time 1-5 
min, focus 1.0 mm). Subsequently, sections were stained for CAIX with the murine anti-CAIX 
antibody M75 (cell line HB-11128 obtained from the ATCC). Also a classic Hematoxylin & Eosin 
(H/E) staining was performed on all slices. 
Statistics
Statistical analysis were performed using IBM SPSS 20.0. For each separate experiment the 
antibody accumulation was expressed as %ID/g (maximum, mean and standard deviation). 
All samples that consisted macroscopically at least partly of tumor, also border, central 
cystic or necrotic tumor regions, were considered as tumor tissue samples. Only samples 
macroscopically consisting of normal tissue were considered as normal tissue samples. 
Differences in accumulation between tumor and normal tissue samples were tested for 
significance within the single experiment using t-tests. Furthermore, in the two control 
experiments the difference between tumor accumulation of girentuximab compared to 
tumor accumulation of control IgG was tested for significance using the paired t-test. 
Differences were considered significant at p<0.05, two-sided. Tumor-to-normal (T:N) ratios 
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were calculated by dividing the mean %ID/g in tumor tissue by the mean %ID/g in normal 
tissue. Furthermore, a range was given for the T:N ratio: minimum and maximum antibody 
accumulation in tumor tissue in relation to the mean antibody accumulation in normal 
tissue. 
RESULTS
Experiment characteristics
Between June 2014 and July 2015 seven radical nephrectomy specimens from ccRCC 
patients were perfused ex vivo with dual-labeled girentuximab in Ringer’s Lactate solution 
(experiment 1 was performed without Indium-111). Histopathology confirmed that all seven 
kidneys contained a CAIX-expressing ccRCC. Basic characteristics of these perfusions are 
shown in table 1.
Table 1: 
Characteristics of the seven perfusion experiments.
# Histology Fuhrman 
grade
Type of 
surgery
T-stage Kidney 
weight 
(kg)
Tumor 
diameter 
(cm)
No. of 
connected 
arteries
Perfusion/ 
washing 
(h)
111In-DOTA-girentuximab-IRDye800CW
1 ccRCC 2 Right LN pT1b 0.8 8 2 14/3
2$ ccRCC 3 Left ON pT3a 1.0 12 1 14/3
3 ccRCC 1 Left LN pT1a 0.5 4 1 14/3
4 ccRCC 3 Left LN pT2a 0.9 7 2 15/4
5* ccRCC 3 Left ON pT3a 1.5 9 1 11/3
Control experiments: 131I-girentuximab-IRDye800CW and 125I-IgG-IRDye800CW
6 ccRCC 4 Left ON pT3a 1.7 13 1 13/3
7 ccRCC 2 Right ON pT3a 0.5 7 1 13/3
# experiment number, ON: open nephrectomy, LN: laparoscopic nephrectomy.  $ Renal vein thrombus (level 0), 
also see fig 11, * ON + cavotomy for level 1 thrombus
Dual-modality imaging
Real-time fluorescence imaging of the lamella with the clinical fluorescence camera system 
revealed images in which the tumor was clearly delineated (fig. 3), while fluorescence in 
normal tissue was hardly detectable (fig. 4). Subsequently, non real-time fluorescence 
imaging was performed with the Odyssey fluorescence flatbed scanner (fig. 5 D and fig. 6 B) 
and the IVIS Lumina fluorescence imager (fig. 5 B). Fluorescence imaging showed preferential 
accumulation of dual-labeled girentuximab in tumor tissue, and low accumulation in 
normal kidney parenchyma. As a result, a clear contrast was obtained between tumor and 
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normal tissue. These results were consistent throughout all experiments. Most importantly, 
in one of the perfused kidneys, a small satellite tumor lesion was detected by fluorescence 
imaging that had not been recognized by macroscopic inspection, but proved to be ccRCC at 
histopathological evaluation (fig. 6 A & 6 B). 
Figure 3: 
Representative images from a kidney lamella after perfusion made with the clinical laparoscopic fluorescence 
camera showing the tumor margin (A): visible light image (B): corresponding fluorescence image.
Figure 4: 
Images from a kidney lamella after perfusion made with the clinical laparoscopic fluorescence camera showing 
normal kidney parenchyma (A): visible light image (B): corresponding fluorescence image.
After the fluorescence measurements, the accumulation of Indium-111-girentuximab-
IRDye800CW in tumor tissue could be clearly visualized by autoradiography of the 1-cm 
lamella (fig. 5 C and 6 C, 1 h exposure to a Phosphor imaging screen). Visual assessment 
revealed excellent co-localization of the fluorescent and radioactive signal in regions 
macroscopically designated as tumor tissue (fig. 5 and 6).
A
A
B
B
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Figure 5: 
High accumulation of dual-labeled 
girentuximab in tumor tissue can be 
visualized with both fluorescence and 
radionuclide imaging. A. Macroscopy, 
B. Fluorescence image acquired with 
the IVIS Lumina fluorescence imager, 
C. Autoradiography, D. Odyssey 
fluorescence flatbed scanner image.
Figure 6: 
(A) Macroscopic image of the tumorous kidney tissue slice after ex vivo kidney perfusion, (B) corresponding 
fluorescence image (Odyssey) and (C) autoradiography, showing high and specific uptake of the dual-labeled 
tracer in the tumor region.  ** histologically confirmed satellite ccRCC focus.
A
C
A
B
D
B C
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Quantitative analysis of antibody accumulation
The accumulation of Indium-111-girentuximab-IRDye800CW in tumor and normal tissue 
kidney samples is shown in table 2. Indium-111-girentuximab-IRDye800CW accumulated 
preferentially in tumor tissue (mean 0.12 %ID/g, range 0.01 - 0.33 %ID/g). Accumulation in 
normal kidney parenchyma was low (mean 0.02 %ID/g, range 0.00 – 0.04 %ID/g). In the first 
kidney perfusion no radioactivity was used and therefore antibody accumulation could not 
be quantified. In experiment 2 antibody accumulation in tumor tissue was not significantly 
higher than in normal tissue, most likely because the tumor tissue was largely necrotic. In 
that experiment high antibody accumulation (0.15 %ID/g) was found in the renal vein tumor 
thrombus. In the other five kidney specimens accumulation of girentuximab in tumor tissue 
was significantly higher than in normal kidney tissue (p<0.05). The mean tumor-to-normal 
ratio ranged from 4 to 14. 
 Perfusion of two radical nephrectomy specimens (#6 and #7) with a mixture of 
girentuximab-IRDye800CW and a control antibody-IRDye800CW labeled with 131I and 125I, 
showed specific accumulation of dual-labeled girentuximab in tumor tissue. Uptake of Iodine-
131-girentuximab-IRDye800CW in tumor tissue (mean 0.14 %ID/g, range 0.01 - 0.31 %ID/g) 
was significantly higher than uptake of the irrelevant control Iodine-125-IgG-IRDye800CW in 
tumor tissue (mean 0.02 %ID/g, range 0.01 – 0.03 %ID/g, p < 0.001). The latter concentration 
was in the same range as the concentration of girentuximab in normal kidney parenchyma 
(mean 0.02 %ID/g, range 0.01 – 0.02 %ID/g) (table 2, figure 7 and 8).
Figure 7: 
Photograph (A) and autoradiographic 
image (B) of the second control 
experiment showing high uptake of 
Iodine-131-girentuximab-IRDye800CW 
in tumor tissue. The low energy gamma 
radiation of Iodine-125 is not visible in 
this autoradiography. 
A B
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Figure 8:
Biodistribution of Iodine-131-girentuximab-IRDye800CW and  the irrelevant control Iodine-125-IgG-IRDye800CW 
in tumor and normal tissue samples. Left: first control experiment (#6). The mean tumor-to-normal-ratio for 
girentuximab and the irrelevant control antibody were 6 and 1, respectively. Right: second control experiment 
(#7). The mean tumor-to-normal-ratio for girentuximab and the irrelevant control antibody were 10 and 1, 
respectively.
Table 2: 
Accumulation of dual-labeled antibodies in tissue samples (%ID/g).
Tumor tissue Normal tissue T:N
ratio
Mean
(range)#
ID
(MBq) Max Mean (SD) No. Max Mean (SD) No. p$$
1* - - - 11 - - 2 - -
2 3.4 0.13 0.04 (0.03) 16 0.02 0.01 (0.00) 4 0.118 4 (2 – 13)
3 3.8 0.33 0.15 (0.09) 7 0.04 0.02 (0.01) 9 0.001 8 (4 – 17)
4 3.5 0.31 0.14 (0.09) 12 0.02 0.01 (0.01) 5 0.005 14 (1 – 31)
5 5.1 0.33 0.15 (0.08) 16 0.03 0.01 (0.01) 6 <0.001 8 (1 – 17)
Control experiments: 131I-girentuximab-IRDye800CW and 125I-IgG-IRDye800CW
Tumor tissue Normal tissue
p**131I/125I
Girentu- 
ximab Control No.
Girentu- 
ximab Control No. p$$
6 4.6/1.0 0.08 (0.05) 0.01 (0.01) 15 0.01 (0.01) 0.01 (0.01) 5 <0.01 <0.001
7 4.1/1.2 0.20 (0.06) 0.02 (0.00) 17 0.02 (0.00) 0.02 (0.00) 9 <0.001  <0.001
* Performed without radioactivity. # experiment number. ID: injected dose. T:N ratio: tumor to normal ratio. No: 
Number of tissue samples. $$ T-test comparing uptake of dual-labeled girentuximab in tumor vs. normal tissue. 
** Paired t-test comparing uptake of dual-labeled girentuximab and dual-labeled control antibody in tumor 
tissue.
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Microscopic analysis 
Finally, microscopic analysis of the tissue sections confirmed that the intratumoral 
distribution of the radioactive signal was congruent with that of the fluorescent signal. 
Most importantly, both signals co-localized with CAIX expression (fig. 9). In normal kidney 
parenchyma the dual-labeled girentuximab was barely detectable (fig. 10). H&E staining of 
the sections showed that cell morphology after perfusion was normal, indicating that the 
continued perfusion did not lead to cell damage (fig. 10-11).
Figure 9: 
Tissue section of tumor thrombus in the renal vein and several small veins showing the overlap between the 
fluorescent and radioactive signals and CAIX-expression in tumor tissue. A. H&E staining, B. fluorescence image 
(Odyssey), C. CAIX staining with DAB of CAIX-expressing tumor tissue, D. autoradiography.
A
C
B
D
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Figure 10: 
Tissue section of normal kidney parenchyma showing the absence of CAIX-expression (A) and corresponding 
absence of a radioactive (B) and fluorescent (C) signal in normal tissue. In the H&E staining detail (D) normal 
glomeruli are present lacking CAIX-expression (E) as seen in tumor tissue.
Figure 11: 
Overview of the results of perfusion experiment #2. High uptake of dual-labeled girentuximab was observed in 
two foci (*) of tumor thrombus in the renal vein (A, B). The central region of the tumor largely consists of necrosis, 
with little and inhomogeneous uptake of dual-labeled girentuximab. Histology confirms that the tumor center 
consists of fibrosis and necrosis (H&E staining detail, C), without CAIX expression (D).
A
A B D
C
B E
D
C
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DISCUSSION
This study demonstrated the feasibility of tumor-targeted dual-modality imaging in clear 
cell renal cell carcinoma using dual-labeled girentuximab ex vivo. Tumors were clearly 
distinguishable from normal kidney parenchyma both by fluorescence and radionuclide 
imaging when tumor-bearing kidneys were perfused with dual-labeled girentuximab. The 
specific localization of the dual-labeled antibody in CAIX expressing tumor tissue allowed 
excellent tumor visualization. Co-localization was observed between the fluorescent signal, 
the radioactive signal and CAIX expression in tumor tissue. These results, in a system closely 
resembling the clinical application, bridge the gap between preclinical research and clinical 
application of dual-labeled girentuximab and have lead to the initiation of the first targeted 
dual-modality image-guided surgery study in ccRCC patients (clinicaltrials.gov NCT02497599). 
 As more complex renal tumors are increasingly treated by partial nephrectomy 
nowadays [32, 33], intraoperative dual-modality imaging can be useful to improve 
intraoperative tumor detection and improve radical tumor resection. Particularly in more 
complex tumors the percentage of positive surgical margins can be as high as 18% [34]. 
Although no consensus exists about the prognostic impact of positive surgical margins, 
the uro-oncological surgeon should aim for radical tumor resection [34, 35]. Targeted dual-
modality imaging using dual-labeled girentuximab may be a valuable imaging technique 
during surgery of ccRCC patients. The high tissue penetration depth of gamma radiation 
for tumor localization combined with fluorescence imaging for real-time precise tumor 
delineation form a powerful combination to improve surgical outcome. The advantage of the 
dual-labeling strategy over co-injection of separate radio- and fluorescently labeled probes, 
is that both imaging signals originate from the same tracer molecule [20, 36].
 Preclinical studies have already demonstrated the feasibility of dual-modality 
imaging using various monoclonal antibodies in several animal tumor models; e.g. cetuximab 
(anti-EGFR) [29], panitumumab (anti-HER1) [37], trastuzumab (anti-HER2) [37, 38], TRC105 
(anti-CD105) [39], D2B (anti-PSMA) [16] and girentuximab (anti-CAIX) [17, 18, 29]  in head and 
neck cancer, breast cancer, prostate cancer, and renal cell carcinoma, respectively. However, 
extrapolation of results of these studies in mouse-tumor models to the clinical setting is 
cumbersome, because tumor models and the experimental setup used only partly reflect the 
clinical situation. To facilitate clinical translation of dual-modality imaging, in this study an ex 
vivo model was used to evaluate the in vivo targeting properties of dual-labeled antibodies 
[26, 40]. This model has several advantages compared to the mouse-tumor models. Because 
human tumor-containing tissue is used, the tumor size, antigenic make-up, vascularisation 
and growth pattern of the tumor reflect the clinical situation. Furthermore, as the sensitivity 
of clinical imaging systems differs from preclinical imaging systems, we used both types of 
imaging systems in this study (i.e. closed cabinet-type fluorescence imaging systems often 
used in preclinical research and a hand-held laparoscopic fluorescence camera system 
used for clinical applications). By selecting an antibody concentration of 3.4 mg/L (1.2 mg 
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in 350 mL of Ringer’s Lactate solution), we mimicked the initial plasma concentration in 
clinical trials (administration of 5 – 50 mg girentuximab per patient) [22-25]. Clearance of the 
non-bound antibody from the circulation was mimicked by washing with Ringer’s lactate. 
However, this does not reflect the complex clearance of antibodies in the human body. 
Nevertheless, we found a maximum accumulation of dual-labeled girentuximab of 0.3 %ID/g 
in tumor regions, which is in the same range as the accumulation that was found in clinical 
studies with radiolabeled girentuximab (up to 0.5 %ID/g) [22, 41]. Therefore our results may 
be a good predictor for the intensity of the dual-modality signal that can be expected during 
surgery. However, one must realize that real-time intraoperative imaging involves many 
challenges, that were not encountered in this imaging model of the lamella, for example the 
limited movability of a camera during laparoscopy, 3D optical imaging, gamma probing and 
an increased noise level because of tracer accumulation in the liver and blood. These aspects 
have to be evaluated in a clinical trial. 
  The kidneys included in this study contained large renal cell carcinomas, including 
tumor thrombi. This differs from the small renal masses where we envision that intraoperative 
dual-modality imaging might be particularly useful. However, inclusion of specimens with 
smaller tumor masses was not possible as in these cases usually partial nephrectomy is 
indicated, and partial nephrectomy specimens lack the renal artery to perform the perfusion. 
However, the added value of dual-modality imaging for tumor detection and resection was 
elegantly illustrated after perfusion of specimen #5. In this kidney lamella a small satellite 
ccRCC lesion was identified by fluorescence imaging (see fig. 6 B), that had not been 
recognized on primary macroscopic inspection. Histopathological analysis confirmed that 
this was a ccRCC lesion. According to literature satellite lesions are found in approximately 
7% of patients, depending on tumor stage [42]. 
 A challenge for the clinical application of targeted imaging techniques will be 
intratumoral heterogeneity. Large variation in antibody accumulation was seen within tumors. 
This might be attributable to differences in CAIX expression, tumor viability, vascularization 
and/or perfusion [41]. We found an excellent spatial overlap between CAIX-expression 
and the fluorescent and radioactive signal of dual-labeled girentuximab. Furthermore, 
antibody accumulation was found to be high at the tumor borders, which are clinically the 
most relevant regions. Another concern was that the accumulation of girentuximab could 
be partly due to the enhanced permeability and retention (EPR) effect, because of the 
enhanced vascular permeability in tumor tissue [43]. Therefore, we performed a dual-isotope 
(131I and 125I) control experiment in two resected tumorous kidneys. Since accumulation of 
the control IgG in tumor tissue was much lower than accumulation of girentuximab (table 
2), we conclude that the girentuximab accumulation is mainly due to specific interaction 
of girentuximab with the CAIX antigen in the tumor tissue. Since the concentration of the 
dual-labeled antibody is similar to the plasma concentration and since the concentration in 
tumor tissue ex vivo and in vivo are in the same order of magnitude, the accumulation of the 
antibody in the tumor due to the EPR effect is expected to be similar ex vivo and in vivo. This 
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also implies that targeted imaging using girentuximab can only be used in CAIX-expressing 
tumors. However, with a suitable tumor-targeting agent, dual-modality imaging can be used 
in any type of cancer surgery. 
 The first clinical trials using fluorescently labeled tumor-targeting probes (folate-
FITC [11], cetuximab-IRDye800CW [44] and GE-137 [45]) have clearly demonstrated the 
potential of targeted intraoperative fluorescence imaging for improved intraoperative or 
endoscopic tumor visualization, which may lead to improved surgical outcome in clinical 
oncology. Furthermore, improved delineation of tumor margins may improve locoregional 
control, shorten duration of surgery and reduce morbidity since a more limited resection 
may be performed [44]. Fluorescence imaging is particularly useful for superficially located 
tumors, since the penetration depth of the fluorescent signal is limited [28]. Deeper located 
tumor lesions, for example intraparenchymal tumors or metastatic lymph nodes covered 
with fat, may be missed by fluorescence imaging. For these applications the addition of 
a radiolabel to the imaging probe can be valuable. When the tumor has been localized 
intraoperatively using the signal emitted by the radionuclide, resection can be performed 
using fluorescence-guided surgery [12]. Finally, the surgical cavity can be examined for 
remnant disease with dual-modality imaging. Another advantage of dual-modality imaging 
is that a PET/CT or SPECT/CT can be obtained preoperatively. This gives the surgeon an 
indication of the location of the primary tumor and/or metastases. Hence preoperative and 
intraoperative imaging can be performed with the same imaging probe. Thus, targeted dual-
modality imaging could revolutionize surgical oncology. 
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ABSTRACT
Introduction: 
Intraoperative imaging with antibodies labeled with both a radionuclide for initial guidance 
and a near-infrared dye for adequate tumor delineation may overcome the main limitation of 
fluorescence imaging: the limited penetration depth of light in biological tissue. In this study, 
we demonstrate the feasibility and safety of intraoperative dual-modality imaging with the 
carbonic anhydrase IX (CAIX)-targeting antibody 111In-DOTA-girentuximab-IRDye800CW in 
clear cell renal cell carcinoma (ccRCC) patients. 
Methods: 
A phase I protein dose escalation study was performed in patients with a primary renal mass 
who were scheduled for surgery. 111In-DOTA-girentuximab-IRDye800CW (5, 10, 30, or 50 mg, 
n=3 ccRCC patients per dose level) was administered intravenously and after 4 days SPECT/
CT imaging was performed. Seven days after antibody injection, surgery was performed with 
the use of a gamma probe and near-infrared fluorescence camera. 
Results: 
In total, fifteen patients were included (12 ccRCC, 3 CAIX-negative tumors). No study-related 
serious adverse events were observed. All ccRCC were visualized by SPECT/CT and localized 
by intraoperative gamma probe detection (mean tumor-to-normal kidney (T:N) ratio 2.5 ± 
0.8), while the T:N ratio was 1.0 ± 0.1 in CAIX-negative tumors. CcRCC were hyperfluorescent 
at all protein doses and fluorescence imaging could be used for intraoperative tumor 
delineation, assessment of the surgical cavity and detection of (positive) surgical margins. 
The radiosignal was crucial for tumor localization in case of overlying fat tissue. 
Conclusion: 
This first in man study shows that tumor-targeted dual-modality imaging using 
111In-DOTA-girentuximab-IRDye800CW is safe and can be used for intraoperative guidance of 
ccRCC resection.
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INTRODUCTION
Intraoperative fluorescence imaging has proven to be valuable in cancer surgery to enhance 
tumor visualization in challenging situations such as multifocal disease [1] or organ-sparing 
surgery [2]. It can be used to differentiate tumor from normal tissue. By conjugating a 
fluorescent dye to a monoclonal antibody against a tumor-specific antigen, a tumor-targeting 
fluorescent tracer can be created. Several studies have already shown the feasibility of this 
tumor-targeted approach for intraoperative fluorescence imaging [3-5].  However, the major 
pitfall of fluorescence imaging is the limited penetration depth of light in tissue, restricting 
detection to superficial tumors. This inherent problem can be overcome by combining 
fluorescence imaging with radiodetection, as gamma radiation has a high penetration depth 
in tissue. By dual-labeling monoclonal antibodies with a radionuclide for initial guidance 
and a near-infrared dye for real-time tumor delineation, the advantages of radiodetection 
and fluorescence imaging are combined. Due to specific accumulation of the antibody in 
tumor tissue, tumor-targeted dual-modality imaging may guide the surgeon to perform a 
complete tumor resection. We now describe the first in man study using this tumor-targeted 
dual-modality imaging technique during surgery. 
 Approximately 115,000 patients are diagnosed with renal cell carcinoma (RCC) in 
Europe every year [6]. A large proportion of these patients is treated by nephron-sparing 
surgery (NSS) with a trend towards NSS of larger or more complex tumors [7, 8]. Positive 
surgical margins (PSM) after NSS are seen in up to 7% of patients, but percentages up to 15% are 
reported in NSS for imperative indications (e.g., solitary kidney) [9]. Improved intraoperative 
tumor visualization by dual-modality imaging may help to perform oncologically safe NSS. 
Girentuximab is a monoclonal antibody that recognizes carbonic anhydrase IX (CAIX) that 
has been used extensively to target clear cell RCC (ccRCC), since more than 95% of ccRCC 
express CAIX [10-13]. Preclinical studies with dual-labeled girentuximab have shown the 
feasibility of tumor-targeted dual-modality imaging [14-17]. Thus, this technique may be 
useful during surgery to localize, visualize and delineate ccRCC. Furthermore, it may be used 
to detect residual tumor tissue or PSM and thereby improve the outcome of surgery. 
 The aim of this clinical trial was to evaluate the safety of 111In-DOTA-girentuximab-
IRDye800CW and to demonstrate the feasibility of preoperative as well as intraoperative 
detection of ccRCC with this CAIX-targeted dual-modality imaging agent.
MATERIAL AND METHODS
Study design
This was a single center phase I protein dose escalation study in adult patients with a primary 
renal mass who were scheduled for partial or radical nephrectomy. The focus of the trial 
design was to collect safety data and to collect data that support the intended clinical use 
and indication statement [18]. Written informed consent was obtained from all patients. 
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Patients with a known non-ccRCC subtype were excluded. Because preclinical data in 
primates suggested that another antibody-IRDye800CW conjugate influenced corrected 
QT (QTc) intervals, a measurement for electrical depolarization and repolarization of the 
hearts’ ventricles [19], patients with a pre-existent prolonged QTc interval were excluded. 
111In-DOTA-girentuximab-IRDye800CW (5, 10, 30, or 50 mg, n=3 ccRCC patients per dose level) 
was administered intravenously and after 4 days SPECT/CT imaging was performed. Seven 
days after antibody injection, surgery was performed with the use of a gamma probe and 
near-infrared fluorescence camera. The aim of this study was to demonstrate the safety and 
feasibility of intraoperative dual-modality imaging with the carbonic anhydrase IX (CAIX)-
targeting antibody 111In-DOTA-girentuximab-IRDye800CW in clear cell renal cell carcinoma 
(ccRCC) patients. Safety was scored by the number of adverse events (AE) according to the 
common terminology criteria for adverse events version 4.0 (CTCAE v4.0). Feasibility was 
defined as the ability to detect a discriminatory fluorescence and/or radioactive signal in 
ccRCC tumor tissue compared to normal kidney tissue. Patients with a CAIX-negative tumor 
on final histology were only included in the safety analysis. The study was approved by the 
regional Medical Ethics Committee of the region Arnhem-Nijmegen and was registered on 
clinicaltrials.gov (NCT: 02497599). A study flowchart of the design of the study is shown in 
Fig. 1.
Figure 1: 
Flowchart study protocol. PK = pharmacokinetics. p.i.= post injection. In addition, blood sampling for safety 
analysis was performed 2 to 3 weeks after surgery. 
Targeted dual-modality imaging in ccRCC - a first in man study
107
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 8
Ch
ap
te
r 8
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
Preparation of 111In-DOTA-girentuximab-IRDye800CW
DOTA-girentuximab-IRDye800CW was produced under metal free conditions and protected 
from light and production complied with Good Manufacturing Practice quality. Chimeric 
girentuximab 5 mg/mL (Wilex AG, Munich, Germany) was incubated with a 2−2.5-fold molar 
excess (preferred conjugation ratio 0.5-2.0) of IRDye800CW-NHS ester (LI-COR biosciences, 
Lincoln, NE, USA) and next with a 25-fold molar excess (preferred conjugation ratio of 0.5-3.0) 
of the chelator DOTA-NHS ester (Macrocyclics, Dallas, TX, USA) in a 1.25 M NaHCO3 buffer pH 
8.5. Excess IRDye800CW-NHS ester and DOTA-NHS ester were removed by dialysis against 
0.25 M ammoniumacetate pH 5.5 for 3 days. The integrity of the dual-labeled antibody 
conjugate was checked before i.v. administration. Radiochemical purity after radiolabeling 
was determined by high-performance liquid chromatography analysis. The integrity of 
the antibody-dye conjugate was checked by measuring the amount of free IRDye800CW 
in the preparation by high-performance liquid chromatography. To confirm the tumor-
specific binding of the dual-labeled antibody, the immunoreactive fraction of 111In-DOTA-
girentuximab-IRDye800CW was determined as described by Lindmo [20] and exceeded 70%. 
DOTA-girentuximab-IRDye800CW was stored in the dark at 4 °C until use.
 Radiolabeling was performed by incubating DOTA-girentuximab-IRDye800CW 
during 30 min at 45 °C with 100-120 MBq of Indium-111 (Mallinckrodt Pharmaceuticals, 
‘s Hertogenbosch, The Netherlands). Unlabeled DOTA-girentuximab-IRDye800CW was 
added to obtain the required protein dose. Radiochemical purity was determined by high-
performance liquid chromatography. 100 MBq of the final product was diluted in NaCl 0.9% 
to a final volume of 10 mL and pulled up in a syringe shortly before injection. Two patients 
received only 75 MBq instead of 100 MBq due to technical problems. Standards of the 
injected dose (ID) were prepared in triplicate to be able to quantify antibody accumulation in 
surgically obtained tissue samples.
Dual-labeled girentuximab injection
Seven days before surgery, patients were injected intravenously with 111In-DOTA-
girentuximab-IRDye800CW (100 MBq). Previous studies with radiolabeled girentuximab have 
shown an optimal protein dose of 5-10 mg [10, 12]. Since this was the first clinical trial with 
111In-DOTA-girentuximab-IRDye800CW and conjugation of IRDye800CW slightly changes the 
biodistribution of girentuximab [15], the dose escalation study was repeated. The rationale 
for the dose escalation schema was to determine the dose with the highest tumor-to-normal 
tissue ratio and the best intraoperative signal for both imaging modalities. Protein doses of 
5, 10, 30 or 50 mg were chosen in the current study. At each protein dose level three patients 
were included. When final histology revealed a CAIX-negative tumor, the patient was replaced 
by a subsequent patient at that dose level. Patients were monitored for AE for three hours 
and ECG-monitoring with measurement of the QTc interval was performed before and after 
injection. Blood samples were taken for pharmacokinetic and safety analyses. 
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SPECT/CT imaging
Four days after injection whole body anterior and posterior gamma camera images and 
SPECT/CT imaging of the abdomen were performed with a dual-head Symbia T16 Truepoint 
SPECT/CT scanner (Siemens Healthcare, The Hague, The Netherlands). After acquisition 
of a low dose, non-contrast enhanced CT, scintigraphic imaging was performed clockwise 
continuously from 0-180°, with 64 views, 19 s per view with medium energy all-purpose 
parallel-hole collimators. Accumulation of 111In-DOTA-girentuximab-IRDye800CW in tumors 
was scored as absent or present by an experienced nuclear medicine physician (WO). 
Dual-modality image-guided surgery
Standard of care surgery was performed, supplemented with gamma probe detection and 
near-infrared fluorescence imaging (NIRF) to assess accumulation of 111In-DOTA-girentuximab-
IRDye800CW in the tumor. Intraoperative scintillation counting was performed with the SOE 
311-AL laparoscopic gamma probe with a lateral window (diameter 10 mm, length 38.7 
cm) or the Europrobe 1 for open surgery (Eurorad, Strasbourg, France). An intraoperative 
tumor-to-normal kidney tissue ratio (T:N) was calculated by dividing the maximum counts 
per second (cps) in tumor by the maximum cps in adjacent ipsilateral normal kidney tissue. 
NIRF was performed with the Karl Storz NIR/ICG System (Karl Storz GmbH & co, Tuttlingen, 
Germany) for laparoscopic surgery, or the QMI Spectrum NIR fluorescence camera for both 
laparoscopic and open surgery (Quest Medical Imaging, Middenmeer, The Netherlands). In 
addition, ex vivo dual-modality imaging of the resected specimens was performed. 
Tissue analyses
NIRF and autoradiography were performed on a tissue slice of the resected specimen as 
described previously [17]. In short, a 5-10 mm thick slice of the resected specimen containing 
tumor and normal kidney tissue was obtained from the pathology department. First, NIRF 
was done using the Odyssey flatbed fluorescence scanner (800 nm channel, focus 1.0 mm) (LI-
COR biosciences, Lincoln, NE). Next, autoradiography was performed by exposing a phosphor 
imaging plate for approximately one hour to the tissue slice. This plate was developed using 
the Typhoon FLA 7000 Phosphor Imager and analyzed with Aida Image Analyzer v. 4.21. To 
quantify tissue accumulation of 111In-DOTA-girentuximab-IRDye800CW, samples of tumor and 
normal kidney parenchyma from the tissue slice and samples of blood were taken, weighed 
and measured in a gamma counter (2480 WIZARD2, Perkin Elmer, Boston, MA) together with 
aliquots of the injected dose. Tracer accumulation was expressed as percentage of the 
injected dose per gram of tissue (%ID/g). Next, the 5-10 mm thick tissue slice was fixed in 
formalin and embedded in paraffin. In case of partial nephrectomy specimens, the tissue 
slice was embedded in its entirety to be able to compare signal distribution in the tissue 
slices with the tissue sections. Fluorescence imaging of the tissue sections was done using the 
Odyssey flatbed fluorescence scanner (800 nm channel, focus 1.0 mm). Finally, hematoxylin 
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and eosin staining and M75-staining for CAIX-expression were performed on 4 µm formalin-
fixed paraffin-embedded tissue sections and interpreted by a uropathologist
Statistics
Statistical analyses were performed using IBM SPSS Statistics 22.0. One-way ANOVA testing 
with post-hoc Bonferroni correction was performed to test for significant differences between 
the different protein dose levels in T:N ratios. Independent sample t-tests were performed 
to compare mean T:N ratios and tracer accumulation (%ID/g) between ccRCC and CAIX-
negative tumors and a paired t-test to compare tracer accumulation between tumor and 
normal kidney tissue. Values are expressed as mean with standard deviation (SD). An alpha 
of 0.05 was used in all analyses and p<0.05 was considered significant. The biological half-
life of 111In-DOTA-girentuximab-IRDye800CW was calculated using bi-exponential regression 
analysis in MATLAB version R2014b. Graphs were made using GraphPad Prism 5.03. 
RESULTS
Patient population
Written informed consent was obtained from 17 patients with a primary renal mass who were 
scheduled for partial or radical nephrectomy. Two of these patients were excluded before 
injection of 111In-DOTA-girentuximab-IRDye800CW because of a prolonged QTc-interval. Three 
patients with a CAIX-negative tumor were replaced. An overview of patient characteristics is 
given in Table 1 and a study flowchart can be found in Fig. 1.
Safety analysis
All 15 patients were monitored for three hours after antibody injection and no infusion-related 
(serious) adverse events ((S)AE) nor any significant changes in vital signs were observed. ECG-
analysis before and one hour after antibody injection showed no prolongation of the QTc 
interval. Blood samples that were taken for pharmacokinetic and safety analysis revealed no 
significant abnormalities in blood values after antibody injection. Five possibly related grade 
1 AE were observed, while all other AE were related to surgery (Table 2). 
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Table 1: 
Patients characteristics.
No # Dose 
(mg)
Age Sex Tumor 
size 
(cm)
Surgery T-stage Pathological 
margin
Histology CAIX
1 5 67 F 6.0 RALN pT1b R0 ccRCC +
2 5 71 F 3.6 RALPN pT1a R0 ccRCC +
3 5 76 F 8.0 LN pT1b R0 ccRCC +
4 10 59 M 3.3 RALPN pT1a R0 ccRCC +
5 10 75 M 5.0 LN pT1b R0 ccRCC +
6 10 76 M 6.0 LN pT1b (M1) R0 ccRCC +
7 30 69 M 2.5 RALPN pT1a R0 Papillary ccRCC +
8# 30 76 M 2.5 RALPN pT1a R0 ccRCC +
9 30 55 F 2.8 OPN pT1a R0 ccRCC +
10 50 58 M 5.7 RALPN pT1b R0 ccRCC +
11 50 57 F 5.4 OPN pT3a R1* ccRCC +
12 50 65 M 3.7 RALPN pT1a R0 ccRCC +
13 30 64 M 1.5 RALPN - R0 Pseudocyst -
14 50 63 M 3.2 & 1.8 RALPN - R1 Angiomyo- lipomas -
15 50 76 V 2.5 RALPN pT1a R0
Clear cell 
papillary 
RCC
-
LN: laparoscopic nephrectomy; OPN: open partial nephrectomy; RAL(P)N: robot-assisted laparoscopic (partial) 
nephrectomy. #Due to logistical reasons, surgery in patient 8 was performed 6 days after injection (instead of 7). 
*Tumor tissue was present in the deep surgical margin of the primary resected specimen and further resection 
contained vital tumor tissue. Since the tumor was not resected en bloc, unequivocal assessment of the surgical 
margin was not possible.
Table 2: 
Overview of AE that were possibly related.
Patient 
#
Protein 
dose
Duration 
of hospital 
admission 
(days)
Adverse event Intervention CTCAE 
Grade
2 5 2 Increased creatinin day 4 p.i.** - I
6 10 4 Malaise day after injection - I
9 30 6 Thrombocytosis day 4 p.i.** - I
11 50 4 Increased amylase day 7 p.i. - I
14* 50 2 Increase amylase day 4 p.i. - I
Blood for safety analyses was tested for the following parameters; hemocytometry (Hb, Ht, leucocytes, 
thrombocytes), kidney function and electrolytes (creatinin, sodium, potassium, phosphate and calcium), liver 
chemistry (ALAT, ASAT, GGT LDH, ALP, bilirubin, amylase),  albumin and C-reactive protein. p.i.= post injection. All 
lab changes were transient.*Patient with a CAIX-negative tumor. ** Unlikely to be related.
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Preoperative SPECT/CT imaging
All CAIX-expressing tumors were visualized preoperatively by SPECT/CT, while no uptake 
was seen in CAIX-negative tumors (patients #13-15). Some physiological liver uptake 
was observed. False positive accumulation of 111In-DOTA-girentuximab-IRDye800CW was 
observed by SPECT/CT in a CAIX-negative adrenal adenoma and a cyst in the contralateral 
kidney in patient #12. In patient #6, accumulation of 111In-DOTA-girentuximab-IRDye800CW 
was visualized by the SPECT in a known bone metastasis (first lumbar vertebra). Unfortunately, 
this lesion was not accessible for intraoperative imaging during surgery (not in the surgical 
field). The other patients did not have metastatic disease.
Intraoperative dual-modality imaging
During surgery, all 12 ccRCC could be localized by gamma probe measurements with a mean 
(T:N) ratio of 2.5 ± 0.8 (Fig. 2 and Movie S1), while the T:N ratio in the 3 CAIX-negative tumors 
was significantly lower (1.0 ± 0.1, p<0.05). The highest T:N ratio (3.3 ± 0.6) was observed in 
the 10 mg dose group. T:N ratios did not differ significantly between the various protein 
doses (p=0.22). Radioactive probe guidance proved to be essential for intraoperative tumor 
localization, especially when fat covered the tissue of interest, since the fluorescence signal 
was significantly attenuated by the perinephric fat.
Figure 2: 
Intraoperative gamma probe measurements (T:N ratios). Each dot represents one patient and the horizontal 
line represents the mean per dose level. The highest T:N ratios were observed after administration of 10 mg 
111In-DOTA-girentuximab-IRDye800CW, but differences between the dose levels were not statistically significant. 
The T:N ratio in the CAIX-negative tumors was significantly lower than in the CAIX-positive tumors (p<0.05).
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After tumor localization and exposure of the tumor, NIRF was used for real-time tumor 
visualization and differentiation of tumor from normal kidney tissue (Fig. 3, Fig. 4 and Movie 
S2). Hyperfluorescence of tumors was observed during surgery and/or on the bench in all 
ccRCC at all protein dose levels. Fluorescence of normal kidney parenchyma was low (Fig. 3). 
Fluorescence imaging during open surgery was straightforward, but for laparoscopic surgery 
a perpendicular approach of the tumor with the fluorescence camera proved to be essential 
for accurate NIRF imaging. This was a complicating factor in laparoscopic surgery, especially 
in posterior tumors. Iso- or hypofluorescence was observered in two out of three CAIX-
negative tumors (patients #14 and #15), while hyperfluorescence was observed in one CAIX-
negative pseudocystic lesion (patient #13), but since no radioactive signal was detectable, it 
was considered to be autofluorescence of the cyst content.
Figure 3: 
Intraoperative NIRF to guide complete tumor resection (patient #9). (A) Intraoperative NIRF before tumor 
resection: Hyperfluorescence of a ccRCC was seen after injection of 111In-DOTA-girentuximab-IRDye800CW. NIRF 
was successfully used for tumor border delineation. (B) Ex vivo NIRF of the resected specimen showed a rim 
of normal hypofluorescent tissue around the hyperfluorescent tumor indicating a negative surgical margin, 
as confirmed by histopathology. (C) Intraoperative NIRF of the surgical cavity after tumor resection indicated 
complete tumor removal.
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Figure 4: 
Dual-modality imaging after injection of 111In-DOTA-girentuximab-IRDye800CW (patient #11). (A) Preoperative 
SPECT/CT imaging confirmed the presence of a CAIX-expressing ccRCC and revealed that this tumor extended 
deep into this patients’ monokidney. (B) Intraoperative NIRF showed hyperfluorescence of the tumor. (C) 
Assessment of the resected tumor specimen with NIRF suggested tumor in the surgical margin (square), which 
was subsequently confirmed by histopathology. (D) NIRF demonstrated that further resection contained vital 
tumor, again confirmed by histopathology. (E) NIRF was used to assess the presence of tumor (square) in 
additional resected tissue fragments. Histopathology confirmed that the fragment consisted mainly of fibrotic 
tissue, but also a tumor fragment of 2 mm. Scale bars are an approximation.
One PSM was correctly identified by ex vivo NIRF of the resected specimens (patient #11). 
Additionally, resected tissue contained vital tumor, as confirmed by histopathology (Fig. 4). 
In all other ccRCC, a rim of hypofluorescent, normal kidney parenchyma was visible around 
the tumor and final histology confirmed negative surgical margins. 
Tissue analyses 
A high T:N fluorescence contrast was seen in all ccRCC by fluorescence imaging of the 5-10 
mm slices of the resected specimens (Fig. 5). Considerable intratumoral heterogeneity in 
the uptake of 111In-DOTA-girentuximab-IRDye800CW was observed macroscopically, with 
high uptake at the tumor borders and lower uptake in the tumor center, most likely due 
to perfusion differences limiting tumoral penetration of girentuximab. Histopathology of 
the tissue section showed homogeneous expression of CAIX in tumors coinciding with the 
distribution of the fluorescence signal (Fig. 6).
 Maximum tumor uptake of 111In-DOTA-girentuximab-IRDye800CW in ccRCC as 
measured with a gamma counter ranged from 0.04–0.58 %ID/g, while uptake was significantly 
lower in normal kidney tissue (mean 0.004±0.002 %ID/g, p<0.05). In CAIX-negative tumors, 
0.01±0.01 %ID/g 111In-DOTA-girentuximab-IRDye800CW was detected, possibly related to the 
enhanced permeability and retention effect. 
A B D
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Figure 5: 
Patient #1: Fluorescence imaging of a 
slice of a radical nephrectomy specimen 
visualized considerable intratumoral 
heterogeneity in the uptake of 
111In-DOTA-girentuximab-IRDye800CW. 
A high tumor-to-normal fluorescent 
contrast was seen at the tumor borders 
and lower uptake in the center of the 
tumor. (A) Macroscopic photograph. (B) 
Fluorescence image obtained with the 
Odyssey flatbed fluorescence scanner.
Figure 6: 
Tissue processing and tissue section analysis (patient #8). Thin (5-10 mm) tissue slices (A) of the resected 
specimens were analyzed by autoradiography (B) and near-infrared fluorescence imaging (C). Both the 
radioactive and fluorescence signals were localized in tumor tissue. Histopathology of a tissue section showed 
homogeneous expression of CAIX in tumors coinciding with the distribution of the fluorescence signal. (D) H&E 
staining with the tumor annotated. (E) M75-staining showed a high and homogenous expression of CAIX in the 
tumor, visually overlapping with the distribution of the fluorescence signal. (F) Fluorescence imaging of a tissue 
section showed that T:N contrast is high at the tumor borders.
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F
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Pharmacokinetic analyses
The average blood levels of 111In-DOTA-girentuximab-IRDye800CW were 0.024±0.009, 
0.019±0.007, 0.007±0.003 and 0.004±0.002 %ID/g at 5 min, 3 h, 4 d and 7 d post injection, 
respectively. When fitting the curves in a two-compartment model, the half-life in the 
distribution phase was 1.4±1.7 h (t1/2α) and in the clearance phase 73.5±17.0 h (t1/2β) (Fig. 7).
Figure 7: 
Blood clearance of dual-labeled 
girentuximab over seven days 
after injection (p.i.) fitted to a two-
compartment model. Inset: clearance 
during the first three hours is depicted 
in more detail. Values are expressed 
as mean ± SD of 14 patients, since 
pharmacokinetic data of patient #3 were 
incomplete. 
DISCUSSION
This study describes the first clinical application of tumor-targeted dual-modality imaging 
with a dual-labeled monoclonal antibody. It shows that this novel technique is safe and 
allows successful intraoperative visualization of tumors in patients with ccRCC. Combining 
a radiolabel for preoperative imaging and intraoperative probe-guided tumor localization 
and a fluorescent label for tumor delineation proved to be a powerful synergy. CcRCC could 
be localized intraoperatively by gamma probe detection, and after surgical exposure of the 
tumor, NIRF could be used to delineate tumors and detect PSM. This potential of targeted 
dual-modality imaging can also be exploited in many other cancer types, by replacing 
girentuximab by another tumor-targeting antibody. 
 Administration of 111In-DOTA-girentuximab-IRDye800CW was well tolerated, as 
expected based on previous extensive experience with radiolabeled girentuximab [11, 12, 
21, 22]. No prolongation of the QTc-interval was found and no study drug-related SAE were 
observed. In two patients (13%) hospital admission was prolonged due to complications 
of surgery (CTCAE grade III), which is in accordance with complication rates reported in the 
literature [23]. Thus, intraoperative dual-modality imaging with 111In-DOTA-girentuximab-
IRDye800CW is a safe procedure. 
 Considering the trend to treat larger and more complex tumors by NSS [8, 24, 25], 
there is an increasing need for tools to achieve complete tumor resection, while supporting 
oncologically safe NSS. The advantage of using NIR dyes over visible light dyes is that there 
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is less autofluorescence, less scattering and a slightly higher tissue penetration depth [26]. 
Furthermore, since the dye is not visible by the human eye, the dye does not change the 
appearance of the surgical field, in contrast to, for example, blue dye. This implies that a 
light source and a camera system with special filters are needed, which can be argued as 
a disadvantage. NIRF after injection of indocyanine green has been used to delineate renal 
tumors. Indocyanine green accumulates in normal kidney parenchyma, resulting in relative 
hypofluorescence of RCC [27-29]. Disadvantages of this approach are that it is non-specific and 
hypofluorescent fat tissue can be misinterpreted as residual tumor tissue [27]. By targeting 
tumor-associated antigens, a positive T:N contrast can be obtained. Folate-receptor alpha-
targeted NIRF has shown promise to detect superficial tumor lesions in ovarian cancer [1] 
and has also been explored in RCC, but conflicting results were reported [30, 31].
 Because of the high expression of CAIX on more than 95% of primary ccRCC, CAIX 
is a more promising target for targeted imaging of ccRCC. The current study shows that 
CAIX-targeted dual-modality imaging could sensitively detect and delineate ccRCC during 
surgery. NIRF has the additional advantage to assess the surgical margins ex vivo as well 
as the surgical cavity in vivo. The radiosignal allowed both preoperative evaluation of 
tumor extension with SPECT/CT and intraoperative tumor localization by gamma probe 
detection. The latter proved to be essential when perinephric fat covered the tumor and 
in largely endophytic tumors. An additional advantage of the radiolabel is that it allows 
accurate quantification (T:N ratio or %ID/g) of tracer accumulation, which is important 
as quantification of a fluorescence signal may be complicated due to scattering and 
attenuation of light in biological tissue. The main advantage of the dual-labeled approach 
over co-injection of two separate antibodies is that both signals originate from the same 
molecule. This may be important, as conjugating the antibody with fluorescent dyes may 
alter the in vivo behavior of the conjugate [15]. Previous analyses showed that radiolabeled 
girentuximab remained intact and could be visualized on tumor cells ex vivo [32-34]. Based 
on the ratios used, approximately 74% of the girentuximab molecules are truly dual-labeled 
(containing at least one DOTA and one IRDye800CW molecule) [15]. Thus, we assume that 
the quantification of the radiolabel is representative for targeting of the intact antibody. 
Indeed, we observed a perfect visual overlap between the fluorescence and radioactive 
image in ex vivo analysis (Fig. 6), substantiating that the antibody remained intact in the 
tumor. The very low accumulation of 111In-DOTA-girentuximab-IRDye800CW in CAIX-negative 
tumors is adding to the evidence that uptake is primarily mediated by CAIX expression and 
only slightly by the enhanced permeability and retention effect. Therefore, preoperative 111In-
DOTA-girentuximab-IRDye800CW SPECT/CT imaging also has great diagnostic value since 
it allows for noninvasive confirmation that the tumor is a CAIX-expressing ccRCC. PET and 
SPECT studies with Iodine-124 labeled and Indium-111 labeled girentuximab, respectively, 
have shown the feasibility of this approach [11, 12, 21]. Distinction of ccRCC from other renal 
lesions can be difficult, since studies have shown that in up to 25% of patients that undergo 
surgery for small renal masses, final histology shows benign disease [35].
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 Despite the heterogeneous uptake of 111In-DOTA-girentuximab-IRDye800CW in 
the tumor, a high T:N fluorescence contrast was observed at the tumor margins, which is 
essential for detection of tumor remnants and to subsequently guide additional resection 
of tumorous tissue. Van Driel et al. have shown that a minimum of 1 mm3 tumor tissue could 
be detected with the NIRF system that was used in the current study [36]. Recently, we have 
shown in an animal model that submillimeter micrometastases could be detected with 
dual-modality imaging with dual-labeled antibodies [37]. However, the detection of small 
lesions is dependent on several factors, such as tumor vascularization, antigen expression, 
background tissue signal and tumor location. The highest T:N gamma probe ratio (3.3±0.64) 
was found at the 10 mg dose level and a trend towards a lower T:N contrast at higher protein 
doses was seen. Although the highest absolute amount (in theory the highest signal intensity) 
of protein per gram of tumor tissue (% ID/g × protein dose) was found at the 30 mg dose level, 
this resulted in a slightly decreased T:N contrast (gamma probe). This is in accordance with 
results of the studies with 131I-girentuximab and may be attributed to antigen saturation at 
higher protein doses [10, 38]. Therefore, a protein dose of 10 mg was considered to be the 
optimal dose when taking into account both imaging modalities.
 Addition of fluorescent molecules to a radiolabeled antibody may affect its 
biodistribution and tumor-specific accumulation. Animal studies have shown that the 
addition of up to two fluorescent molecules per girentuximab molecule (substitution ratio) 
only slightly effects its biodistribution and specific tumor accumulation [15]. Since the 
substitution ratio in the current study was between 1.0 and 2.0, no decrease in specific tumor 
accumulation was expected and indeed tumor uptake was comparable to radiolabeled 
girentuximab [22]. In addition, pharmacokinetic analyses confirmed that blood clearance 
of 111In-DOTA-girentuximab-IRDye800CW is similar to that of 111Indium-DTPA-girentuximab 
(t1/2β 73.5±17.0 h versus t1/2 α+β 58±18 h) [39]. The required interval between tracer injection 
and tumor targeting of approximately 7 days implies that the surgeon should decide well 
before surgery if intraoperative imaging will be needed. Pharmacokinetics are faster with 
smaller molecules, but small molecules may have the disadvantage of high physiological renal 
clearance, thereby obscuring ccRCC tumors [40]. Besides low normal kidney uptake, a further 
advantage of IgG molecules over antibody fragments and small molecules is the convenient 
chemistry of radiolabeling and fluorescence labeling, without significantly compromising the 
immunoreactivity or altering the pharmacokinetics [15]. Previous studies with radiolabeled 
girentuximab have shown that high tumor-to-normal tissue ratios were obtained 4 to 7 days 
after injection [12, 41]. In the current study, we aimed to show the feasibility of dual-modality 
imaging and we preferred to perform both SPECT and fluorescence imaging between 4 to 
7 days after injection. The choice to perform SPECT/CT imaging 4 days after injection and 
fluorescence imaging 7 days after injection was mainly based on logistical reasons. Future 
studies may focus on optimizing this time interval for dual-labeled girentuximab.  
 In the current study, dual-modality imaging devices were not integrated in the 
standard set of surgical instruments and therefore switching between standard surgery and 
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dual-modality image-guided surgery took additional time. After introducing the standard 
surgical instruments and opening the retroperitoneum, the laparoscopic gamma probe 
was used to localize the tumor. After exposure of the tumor, the fluorescence camera was 
introduced. Subsequently, surgery was continued with the standard surgical instruments. 
Therefore, dual-modality imaging could only be performed before resection and after 
terminating the critical period of kidney ischemia and haemostasis, making deep surgical 
margins less accessible for NIRF. Integration of imaging devices into the standard surgical 
instruments would increase the convenient use of dual-modality imaging. Except for its use 
during NSS, the specific accumulation of 111In-DOTA-girentuximab-IRDye800CW in ccRCC 
implies that dual-modality imaging may also be advantageous for lymph node dissection 
or metastasectomy. Since this was a phase I first in man study with the objective to assess 
the safety and feasibility, the surgical strategy (radical or partial nephrectomy) could not be 
changed based on intraoperative imaging results alone. Whether targeted dual-modality 
imaging using 111In-DOTA-girentuximab-IRDye800CW reduces PSM or ccRCC recurrences 
needs to be studied in subsequent prospective studies.
The following supplemental movies are available online: 
Movie S1. Intraoperative gamma probe detection during radical nephrectomy 7 days after 
administration of 111In-girentuximab-IRDye800CW in a ccRCC patient.
Movie S2. Real-time intraoperative fluorescence imaging 7 days after administration of 
111In-girentuximab-IRDye800CW during open partial nephrectomy in a ccRCC patient.
ABBREVIATIONS
CAIX: carbonic anhydrase IX; ccRCC: clear cell renal cell carcinoma; T:N ratio; tumor-to-normal 
kidney ratio; PSM: positive surgical margin; NSS: nephron-sparing surgery; QTc interval: 
corrected QT interval; (S)AE: (serious) adverse event; CTCAE: common terminology criteria 
for adverse events; ID: injected dose; %ID/g: percentage of the injected dose per gram; NIRF: 
near-infrared fluorescence imaging; cps: counts per second; LN: laparoscopic nephrectomy; 
OPN: open partial nephrectomy; RAL(P)N: robot-assisted laparoscopic (partial) nephrectomy. 
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ABSTRACT
Background: 
The unambiguous detection of ccRCC can be valuable when conventional diagnostics are 
inconclusive. Based on the high expression of Carbonic Anhydrase IX (CAIX) on the cell surface 
of 95% of clear cell renal cell carcinoma (ccRCC), PET/CT with the anti-CAIX monoclonal 
antibody 89Zr-girentuximab can be used for the non-invasive detection of ccRCC. 
Objective: 
To explore the clinical value of 89Zr-girentuximab PET/CT imaging in patients suspected of 
primary, recurrent or metastatic ccRCC.
Design, Setting, and Participants: 
A phase I/II clinical study in 30 patients with a primary renal mass or a history of ccRCC in 
whom conventional imaging was inconclusive. 
Intervention: 
PET/CT imaging was performed 4 or 5 days after injection of 37 MBq 89Zr-girentuximab (5 mg).
Outcome Measurements: 
Clinical value of 89Zr-girentuximab PET/CT imaging in diagnostic challenges regarding ccRCC.
Results and Limitations: 
89Zr-girentuximab PET/CT imaging was a valuable aid in decision making (surgery versus active 
surveillance) in case of indistinct primary renal masses (n=16). In all patients follow-up data 
confirmed the decision made after PET/CT imaging: all resected PET-positive primary lesions 
proved to be ccRCC, while no lesion progression was seen in PET-negative masses, suggestive 
of a more benign or non-ccRCC mass. In patients suspected of recurrent or metastatic ccRCC 
(n=14), PET/CT with 89Zr-girentuximab was useful to confirm or exclude the presence of ccRCC, 
to evaluate the extent of the disease and to differentiate with other cancers. In this group 
89Zr-girentuximab PET/CT resulted in a major change in clinical management  in five patients 
(36%), while in three patients (21%) repeat biopsies could be avoided. 
Conclusions: 
89Zr-girentuximab PET/CT imaging is a valuable diagnostic tool to evaluate patients suspected 
of primary, recurrent or metastatic ccRCC. 
Patient summary: 
89Zr-girentuximab PET/CT imaging can be used to visualize ccRCC and can be a valuable 
diagnostic tool for the clinician.
89Zr-girentuximab PET/CT imaging in ccRCC
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INTRODUCTION
 
The incidence of kidney cancer has showed a steady increase, coinciding with an increased 
use of imaging [1]. However, a significant part of the detected renal masses are benign 
or indolent tumors, which raises the question if active surveillance is a safe alternative to 
surgical management, particularly in patients with relative contraindications for surgery 
[2, 3]. Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC. Considering 
the higher metastatic potential of ccRCC compared to papillary and chromophobe RCC [4], 
it is important to accurately diagnose ccRCC. Diagnosing ccRCC can be challenging with 
conventional diagnostic methods and studies report up to 26% of benign renal tumors 
on final histology after surgery [5]. The CT-based Bosniak classification provides a risk 
assessment for cystic renal masses; up to 62% of Bosniak 3 and 79% of Bosniak 4 lesions are 
malignant [6, 7], but a higher level of certainty is desirable. The use of biopsies is increasing, 
but this is an invasive procedure and especially in cystic lesions the diagnostic yield and 
sensitivity are limited [8]. Thus, imaging methods with higher diagnostic accuracy are needed 
to guide clinical decision making in patients with primary renal masses where conventional 
diagnostics leave a dilemma. 
 In addition, non-invasive confirmation of the presence or absence of ccRCC can 
be useful to guide clinical decision making in patients suspected of recurrent or metastatic 
ccRCC. Metastasectomy of oligometastatic disease can have a beneficial effect on patient 
survival, but is associated with significant complication rates and careful selection of patients 
is required [9, 10]. Knowledge about the presence or absence of ccRCC can aid the clinician to 
select the optimal treatment strategy.
 Non-invasive imaging techniques may target carbonic anhydrase IX (CAIX), an 
antigen abundantly expressed in more than 95% of ccRCC [11]. Previous clinical trials have 
shown that CAIX-targeted imaging using Iodine-124 (124I) and Indium-111 (111In) labeled 
girentuximab, a monoclonal antibody that specifically recognizes CAIX, can detect ccRCC 
with high accuracy [12-14]. A PET-tracer allows better contrast and spatial resolution and 
shorter acquisition time with PET as compared to SPECT. PET imaging studies in animals 
demonstrated that Zirconium-89 (89Zr)-girentuximab outperforms 124I-girentuximab in terms 
of tumor-to-normal tissue ratios [15, 16]. 
 As the high accuracy of imaging using radiolabeled girentuximab has been 
confirmed in multiple studies, the aim of this phase I/II study was to evaluate the clinical 
value of 89Zr-girentuximab imaging in patients suspected of primary, recurrent or metastatic 
ccRCC where conventional diagnostics are inconclusive. 
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MATERIAL AND METHODS
Study design
This is a single center phase I/II study evaluating the value of 89Zr-girentuximab PET/CT 
imaging in 30 patients in whom the clinician faced a diagnostic dilemma regarding the 
presence or absence of (recurrent) ccRCC defined as doubt about the best medical treatment 
despite conventional diagnostics. The indication to perform a 89Zr-girentuximab PET/CT was 
set in a multidisciplinary meeting. PET/CT imaging was performed 4 or 5 days after injection 
of 5 mg 89Zr-girentuximab (37 MBq). The results of the PET/CT were discussed in a second 
multidisciplinary meeting and were used to decide on the next step in the clinical process. 
This step was compared with the hypothetical next step without the information from the 
89Zr-girentuximab PET/CT to identify the effect on clinical management. A major change in 
management was defined as a change in one of the next step strategies; surgery (including 
surgical strategy), surveillance, or systemic therapy. Histological and follow-up data were 
used to assess the effect on clinical management. The study was approved by Regional 
Internal Review Board (CMO region Arnhem-Nijmegen) and was listed on clinicaltrials.gov 
(NCT02883153). 
Patient population
Two subgroups of patients were distinguished: 1. patients with a renal mass of unknown 
origin, or 2. patients with a history of ccRCC and a suspicion of recurrent or metastatic 
disease. All patients received at least contrast-enhanced CT, MRI and/or biopsy, were over 
18 years old and signed informed consent. Patients with a history of a CAIX-negative RCC 
were excluded. Patients that were on tyrosine kinase inhibitor (TKI) treatment within the 
last month were excluded, as treatment with TKI has demonstrated to decrease uptake of 
111In-girentuximab in tumor lesions [17].
Preparation of 89Zr-girentuximab
Conjugation of N-suc-desferal ester (VU Medical Center, Amsterdam, the Netherlands) 
to girentuximab (Wilex AG, Munich, Germany and Telix Pharmaceuticals, Melbourne, 
Australia) was performed as described previously [16]. At the day of injection 2 mg desferal-
girentuximab was radiolabeled with 37 MBq of Zirconium-89 (Perkin Elmer, The Netherlands). 
The radiolabeling process was performed at a pH of 7.2. To achieve the desired pH value, 
oxalic acid, sodium carbonate and HEPES buffer (adjusted to pH 7.3 by use of sodium 
hydroxide solution) were added. After addition of 2 mg desferal-girentuximab and HEPES 
buffer, radiolabeling was allowed to take place during 60 minutes at room temperature. Next, 
unbound 89Zr was complexed by the chelator EDTA by incubation for 15 minutes at room 
temperature. Then the product was purified using gelfiltration on disposable PD10 columns. 
To obtain a total protein dose of 5 mg, unlabeled girentuximab was added to lower undesired 
hepatic uptake of 89Zr-desferal-girentuximab. Radiochemical purity was determined by high-
89Zr-girentuximab PET/CT imaging in ccRCC
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performance liquid chromatography and exceeded 90%. The end product was diluted to a 
total volume of 10 ml with NaCl 0.9% and administered intravenously in ten minutes within 
4 hours after radiolabeling.
89Zr-girentuximab PET/CT imaging
Whole body PET and low-dose CT images (skull to upper legs) were obtained using a Siemens 
Biograph mCT time-of-flight PET/CT camera. Attenuation-corrected and non-attenuation-
corrected images of PET data were reconstructed and automatically fused with low-dose 
non-contrast-enhanced CT data. Central reading was performed by a clinician with extensive 
experience in radiolabeled girentuximab imaging (WO). Lesions of interest were considered 
PET-positive or negative based on a visual scale taking into account the background signal in 
surrounding organs and blood. 
RESULTS
Between December 2015 and May 2017 thirty patients were included. The mean duration of 
follow-up was 16.1 ± 5.3 months. 
Group 1: 89Zr-girentuximab PET/CT imaging in primary renal masses (n=16)
Sixteen patients with a primary renal mass were included (Table 1). In six patients uptake 
of 89Zr-girentuximab was seen in the renal mass and in five of them the decision moved 
towards surgery confirming ccRCC (Fig. 1). The sixth patient (#4) was known to have Von 
Hippel Lindau (VHL) syndrome. PET/CT imaging revealed numerous cystic lesions with 
high accumulation of 89Zr-girentuximab, whereas on MRI only two lesions were suspicious 
(Fig. 2). A bilateral nephrectomy was advised, but the patient was treated by cryoablation of 
the largest lesion for debulking purposes. 
Figure 1: 
A. Patient #11 was referred with a complex cystic renal mass in a pelvic kidney on MRI. Because of a 
glomerular filtration rate of 25 ml/min and extensive previous abdominal operations, the clinician preferred 
to obtain certainty about the presence of ccRCC. B. 89Zr-girentuximab PET/CT imaging visualized uptake of 
89Zr-girentuximab in the walls of the lesion and subsequent surgery confirmed the presence of ccRCC.
A B
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Figure 2: 
Patient #4 was known to have Von Hippel Lindau syndrome and had several primary ccRCC in the past. On MRI 
(A, C) two suspicious growing lesions were visualized, but PET/CT imaging revealed multiple lesions with high 
accumulation of 89Zr-girentuximab (B, D). The largest renal lesion was treated by cryoablation, but unfortunately 
the biopsy that was retrieved during of the procedure was not representative. Focal uptake in the myelum on 
the level of the fifth lumbar vertebra, the cerebellum and the epididymis was seen (E, circles), on conventional 
imaging matching with hemangioblastomas and cystadenomas respectively.
In nine patients no uptake of 89Zr-girentuximab was seen (Fig. 3). A biopsy in patient #3 
revealed oncocytomas. In patient #16 the benign etiology of the renal mass was confirmed 
by a marsupialisation because of pain complaints. In patient #5 MRI suggested an 
angiomyolipoma. The remaining of the patients were followed by active surveillance. Since 
in none of the PET-negative tumors progression was seen during 6-22 months of follow-
up, these lesions are considered most likely to be benign or indolent non clear cell tumors. 
However, longer follow-up is needed since average growth of renal tumors is 3 mm/year [18]. 
 In patient #12 a 0.9 cm solid 89Zr-girentuximab positive lesion was visualized in 
the left kidney, while a Bosniak 4 lesion in the right kidney was negative. Due to extensive 
previous abdominal surgery and the small size of the positive lesion, active surveillance 
of both lesions was initiated. Twelve months follow-up showed shrinking of the Bosniak 4 
lesion and no growth of the positive lesion.
A
C
B
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Figure 3: 
Patient #9 was diagnosed with 
a centrally located cystic lesion 
in the left kidney with thickened 
walls and enhancement of septa, 
classified as Bosniak 3-4 (CT; A 
coronal, C, transverse plane). 
Due to the central location of the 
tumor, a partial nephrectomy 
was considered not feasible. 
More certainty about the nature 
of the lesion prior to radical 
nephrectomy was desirable. Since 
the chance of malignancy was 
lowered due to the negative 89Zr-
girentuximab PET/CT (B coronal, 
D transverse plane), active 
surveillance was advised. Neither 
growth nor progression of the 
lesion was seen during 12 months 
of follow-up.  
Impact on clinical management: 
In all patients the clinician had one or more reasons to be reluctant with surgery. The 
hypothetical next step without PET/CT imaging could not be determined objectively, since 
treatment of small renal masses did not follow strict guidelines but was subject to preferences 
of both the clinician and the patient. The information from the 89Zr-girentuximab PET/CT was 
used to counsel patients in their decision towards either active surveillance or treatment.
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Table 1: 
89Zr-girentuximab PET/CT imaging in patients with renal masses.
# Age Dilemma/ 
contra-indication to 
surgery
Lesion of 
interest
Size 
(cm)
PET Action after 
PET/CT
Follow-up/ 
histology
1 76 Mono-kidney Bosniak 3 2.6 + PN ccRCC
2 63 Mono-kidney Bosniak 3 4.9 - FU SD
3 76 Multifocal disease, 
comorbidity
8 solid 
tumors, 
bilateral
1.5-9.5 - Biopsy/FU Oncocytoma
4 49 Multifocal disease,  
VHL syndrome 
Figure 2
Bosniak 3
Bosniak 3**
Myelum (L5)
Epididymis 
Cerebellum
2
1.32
1.2
< 1.0
<1.0
+
+
+
+
+
Cryoablation
FU
Biopsy inconclusive
SD
Hemangioblastoma
Cystadenoma
Hemangioblastoma
5 29 Multifocal disease, 
biopsy inconclusive DD 
angiomyolipoma.
Solid
Solid
3.5
5.3
-
-
FU
FU
SD
SD
6 66 Multifocal disease, 
DD with metastases of 
other malignancies*
Solid
Solid
1.2
2.2
-
-
FU
FU
SD
SD
7 64 DD with metastasis of 
other malignancies 
(Synchronous lung 
carcinoma)
Bosniak 3-4 3 + PN ccRCC
8 50 Central lesion, PNx not 
feasible
Bosniak 3 5.5 - FU SD
9 47 Central lesion, PNx not 
feasible
Figure 3
Bosniak 3-4 2.8 - FU SD
10 59 Central lesion, PNx not 
feasible
Bosniak 3 1.1 - FU SD
11 66 Extensive previous 
abdominal surgery
Figure 1
Bosniak 3 4.2 + RN ccRCC
12 49 Extensive previous 
abdominal surgery
Bosniak 3-4
Solid 
(Contralateral 
kidney)
4
0.9
-
+
FU Shrinking
SD
13 70 Comorbidity Bosniak 3 2.7 + PN ccRCC
14 63 Comorbidity Bosniak 3 9 - FU SD
15 65 Other; metastases? Bosniak 3
Adrenal 
3.7
3.7
+
-
PN 
LA
ccRCC
Adrenal adenoma
16 45 Other; Changing 
cystic lesion after 
marsupialisation; 
cystic ccRCC?
Bosniak 3 10 - Marsupiali-
sation 
because of 
symptomatic 
cyst
No malignancy 
* History of colorectal carcinoma, prostate cancer and urothelial cell carcinoma. Metastases unlikely due to low 
tumor markers. Patient refused biopsy. ** PET/CT imaging revealed accumulation of 89Zr-girentuximab in multiple 
cystic lesions. Based on the PET/CT a bilateral radical nephrectomy was advised. PN: partial nephrectomy; RN: 
radical nephrectomy; LA: laparoscopic adrenalectomy; FU: follow-up; SD: stable disease. 
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Group 2: 89Zr-girentuximab PET/CT imaging after a history of ccRCC (n=14)
Fourteen patients were included who were suspected of recurrent or metastatic ccRCC (Table 2). 
 Patients #17 – 24 were considered to be candidates for surgery with curative intent 
and 89Zr-girentuximab PET/CT imaging was used to confirm ccRCC prior to surgery and to 
exclude additional metastases. In patients #18, #21 and #23 high uptake in the lesion of 
interest was seen without significant uptake elsewhere and surgery with curative intent was 
performed confirming ccRCC (Fig. 4). In patient #17 surgery was performed despite a negative 
89Zr-girentuximab PET/CT due to a high clinical suspicion for malignancy and histology 
revealed a CAIX-expressing papillary growing ccRCC metastasis (false negative). In #22 surgery 
could be limited to an adrenalectomy, since no uptake was seen in the enlarged contralateral 
1.5 cm lymph node. No growth of the lymph node was seen during eight months follow-
up. In #19 and #20 89Zr-girentuximab PET/CT imaging revealed additional metastases that 
significantly changed clinical management; curative surgery was cancelled (Fig. 5). In both 
cases progression of lesions was seen during follow-up. Patient #24 was referred for radical 
nephrectomy due to a suspicion of local ccRCC recurrence after partial nephrectomy, but 
since no renal uptake of 89Zr-girentuximab was seen, surgery was cancelled. No change was 
seen on contrast enhanced CT imaging during ten months follow-up.
Figure 4: 
Patient #18 presented with a suspicious lesion in the inferior caval vein (ICV 10 mm) 6 months after nephrectomy 
(pT3a ccRCC with a positive surgical margin at the renal vein). CT and multiparametric MRI (A) could not 
distinguish with certainty between tumor thrombus and a blood clot, and furthermore mpMRI revealed several 
enlarged lymph nodes (B, short axis up to 12 mm) and a liver lesion (C, 7 mm). 89Zr-girentuximab PET/CT imaging 
showed uptake of 89Zr-girentuximab in the inferior caval vein (D) thereby non-invasively confirming the presence 
of recurrent ccRCC. No uptake of  89Zr-girentuximab in the lymph nodes (E) nor the liver lesion (F) was seen, 
making ccRCC metastases less likely. Surgery was performed with resection of the lesion in the ICV (ccRCC) and 
several enlarged lymph nodes (benign). No change of the liver lesion was seen over 15 months. The value of 
the 89Zr-girentuximab PET/CT was to confirm the local recurrence, and, prior to metastasectomy, provide more 
certainty about the enlarged lymph nodes and the liver lesion.
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Patients #25 – #30 had multiple suspicious lesions. In patients #25 to 28 
89Zr-girentuximab PET/CT imaging was used to confirm metastatic ccRCC as previous 
biopsies were inconclusive or considered to be too invasive to perform. In three patients 
uptake of 89Zr-girentuximab was seen in multiple lesions and patients were considered to 
have metastatic ccRCC avoiding (re-)biopsy. Progression of lesions was seen in patients #26 
and 27 (#25 was lost to follow-up). In patient #28 no uptake of 89Zr-girentuximab was seen in 
the pulmonary lesions. Under the suspicion of a secondary primary lung cancer, a lobectomy 
was performed that confirmed primary lung carcinoma (adenocarcinoma) with several 
benign granulomas (Fig. 6). Patients #29 and #30 were previously diagnosed with metastatic 
ccRCC and 89Zr-girentuximab PET/CT imaging was used to evaluate the extent of the disease.
Impact on clinical management: 
A major change in the clinical management occurred based on 89Zr-girentuximab PET/CT 
in five patients (36%): the diagnosis ccRCC recurrence was not confirmed by PET/CT or the 
metastatic load was substantially higher or lower than expected based on conventional 
imaging. In three patients (21%) repeated biopsies were avoided, since the 89Zr-girentuximab 
PET/CT was positive, highly suggestive for ccRCC.
 In eight patients (57%) additional lesions were detected on 89Zr-girentuximab PET/
CT imaging, and in five patients these lesions were considered to be metastases (ccRCC 
histology or progressive disease on follow-up). In three patients (21%) additional diagnostic 
procedures were performed because the findings on 89Zr-girentuximab PET/CT imaging were 
equivocal. In these patients the lesions were ultimately diagnosed as most likely benign or 
inflammation. In all cases 89Zr-girentuximab PET/CT imaging results were interpreted with all 
clinical data taken into consideration, and clinical management was never changed solely on 
89Zr-girentuximab PET/CT imaging results. In the remainder of the patients PET/CT imaging 
confirmed clinical practice, but provided more certainty to both the patient and the surgeon 
to decide on clinical management.
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Figure 5: 
Patient #20 underwent a radical nephrectomy for ccRCC six years earlier and now presented with a new 
renal tumor and a solitary adrenal metastasis on CT-thorax/abdomen(A). Prior to metastasectomy (radical 
nephrectomy + adrenalectomy), 89Zr-girentuximab PET/CT imaging was performed to confirm the diagnosis and 
to exclude other metastatic sites. Uptake of 89Zr-girentuximab in the primary renal mass and the adrenal lesion 
was seen (B), but also in the proximal radius (insert). The proximal radius was not in the field of view of the 
initial conventional imaging (CT-thorax/abdomen). Biopsy of the radius confirmed ccRCC metastasis which was 
treated with radiotherapy. If the bone lesion had not been detected, the patient would have undergone a radical 
nephrectomy and as a result would have been dependent on dialysis. This would have been futile surgery and 
a major decrease in quality of life. 
Figure 6: 
Patient #28 had a history of ccRCC 16 years earlier (nephrectomy and immunotherapy because of pulmonary 
metastases, followed by a partial response). Small residual lesions remained stable over the past years, except 
for slowly growing pulmonary lesions in the left lower lobe of the long, which had a differential diagnosis of a 
primary lung carcinoma (A). PET/CT imaging demonstrated no uptake of 89Zr-girentuximab in the growing lung 
lesion, nor in the small residual lesions (B). Under the suspicion of a secondary primary lung cancer, a lobectomy 
was performed, confirming the presence of a primary lung carcinoma and several granulomas.
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DISCUSSION
This study confirms the excellent imaging properties of 89Zr-girentuximab PET/CT for the 
detection of ccRCC, which were observed in earlier, preclinical studies [15, 16]. Non-invasive 
confirmation of the presence or absence of ccRCC with 89Zr-girentuximab PET/CT imaging was 
of significant value in patients suspected of ccRCC and a diagnostic dilemma. The imaging 
results were used to guide clinical management and a major change in management based 
on the 89Zr-girentuximab PET/CT scan was seen in 36% of patients suspected of recurrent or 
metastatic ccRCC. 
 In patients with a primary renal mass, 89Zr-girentuximab PET/CT imaging was used 
in the decision to either perform surgery or active surveillance and in all cases follow-up data 
confirmed the chosen treatment strategy. The confirmation of the presence or absence of 
ccRCC by 89Zr-girentuxumab PET/CT imaging results provided valuable information for clinical 
decision making in challenging cases, such as patients with a relative contraindication for 
surgery. Unfortunately, due to the highly specific targeting of an antigen expressed on ccRCC, 
89Zr-girentuximab does not target other RCC subtypes. However, a negative 89Zr-girentuximab 
PET/CT lowers the a priori chance of lesions with a high malignant potential, which also aids 
in clinical decision making. 
 Considering the variable nature of ccRCC and the unpredictable pattern of 
metastatic spread [19], diagnosing ccRCC can be challenging. In case of oligometastatic 
disease, surgery with curative intent can be considered, whereas in case of more extensive 
metastatic disease, systemic treatment options with a more palliative effect. Confirmation 
of oligometastases prior to metastasectomy is of utmost importance to avoid futile surgery, 
especially because this type of surgery can be associated with significant complication rates 
[9, 10]. Depending on the location, a biopsy can be considered, but the invasive nature of 
the procedure and the fact that it may provide inconclusive results, can make a biopsy less 
desirable. Because ccRCC metastases also show CAIX expression, 89Zr-girentuximab PET/CT 
imaging had great clinical value in patients with oligometastases. In this study, surgery in two 
patients was cancelled since 89Zr-girentuximab PET/CT imaging revealed additional ccRCC 
metastases. 
  Another diagnostic dilemma where 89Zr-girentuximab PET/CT imaging can be 
helpful is when conventional imaging detects suspicious lesions in patients with a history 
of both ccRCC and another malignancy. Identifying the nature of these lesions can be very 
challenging if not impossible with CT or MRI imaging. Tumor-targeted imaging using 89Zr-
girentuximab PET/CT visualizes the underlying tumor biology and can be used to distinguish 
ccRCC from other cancers, which is important since treatment strategies can be essentially 
different. CAIX expression has been described in other malignancies where it is hypoxia-
driven, but the mutational loss of VHL in ccRCC leads to a much higher expression of CAIX 
[11] and this makes 89Zr-girentuximab PET/CT imaging a valuable tool to differentiate ccRCC 
from other malignancies. 
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 An identical pattern of CAIX expression is described in hemangioblastomas, a tumor 
of the central nervous system that can occur sporadically or related to VHL syndrome [20]. In 
patient #4 who suffered from the VHL syndrome, focal uptake in the myelum, the cerebellum 
and the epididymis was seen, that matched with hemangioblastomas and cystadenomas, 
respectively on conventional imaging. Both are known to express CAIX in patients with VHL 
syndrome [20-22] and should not be confused with metastases during the reading of the PET/
CT scan. 
 Developments to improve classification of primary renal tumors by imaging 
modalities, such as multiparametric MRI [23, 24] and 99mTc-sestamibi SPECT/CT (uptake 
indicates oncocytoma) are ongoing [25]. An alternative target that is currently under 
investigation for ccRCC is prostate-specific membrane antigen (PSMA). The first (small) 
studies demonstrate that PSMA-tracers can visualize metastatic ccRCC [26, 27], but renal 
clearance of radiolabeled PSMA molecules may obscure primary renal tumors. With 89Zr-
girentuximab PET/CT imaging both primary ccRCC as well as metastases can be visualized. 
Additional advantages are that 89Zr-girentuximab is not nephrotoxic and that it can be used 
in patients with renal insufficiency. 
 The aim of the current study was to evaluate the value of 89Zr-girentuximab PET/
CT imaging in clinical practice. This broad aim led to the inclusion of a heterogeneous 
study population, which can be considered a limitation of this study. Another limitation is 
the absence of histopathological confirmation in some patients, which makes it impossible 
to adequately calculate the accuracy of this imaging modality. Previous clinical trials have 
shown the accuracy of imaging using radiolabeled girentuximab [12-14] and based on 
preclinical comparisons we expect the accuracy of 89Zr-girentuximab PET/CT to be higher 
than the previously used girentuximab tracers labeled with 111In or 124I [15, 16]. A limitation of 
89Zr-girentuximab PET/CT imaging is that due to the hepatic clearance of 89Zr-girentuximab, 
the excretion with the faeces and the expression of CAIX in the gastrointestinal tract [28], 
small intra-abdominal lesions may be obscured. Though, 111In-girentuximab could detect 
liver metastases before they became visible on CT-imaging [14]. The current study clearly 
demonstrates that 89Zr-girentuximab PET/CT imaging can be a valuable addition in patients 
were conventional diagnostics give inconclusive results or where invasive diagnostics are 
undesirable. A large phase III trial, that will provide more information about and confirm the 
diagnostic accuracy of 89Zr-girentuximab PET/CT imaging, is currently in preparation.
CONCLUSION
89Zr-girentuximab PET/CT imaging is a valuable non-invasive diagnostic tool to evaluate 
patients suspected of primary, recurrent or metastatic clear cell RCC. By indicating the 
presence or absence of these tumors, 89Zr-girentuximab PET/CT imaging can guide clinical 
decision making.
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THE FUTURE OF DUAL-MODALITY IMAGING  
Intraoperative dual-modality tumor detection can help the surgeon to establish complete 
tumor resection. The radioactive signal can be used for preoperative imaging and 
intraoperative tumor localization, while the fluorescent signal allows real-time tumor 
visualization, tumor border delineation, and evaluation of surgical margins. Since 
intraoperative dual-modality imaging is still in its infancy, optimal dosing and timing of 
dual-modality imaging after administration is unclear. Gamma radiation can be used for 
accurate quantification of tracer uptake, allowing measurement of tracer levels in tumor and 
background and allows assessment of the pharmacokinetics of the tracer. The fluorescent 
signal is more difficult to quantify due to the absorption and scattering of photons when 
they traverse through biological tissue. If reliable quantification of fluorescence can be 
achieved, it would be possible to set clear thresholds to differentiate tumor from normal 
tissue. Advancements have been made to quantify the fluorescent signal and set such 
thresholds [1, 2], but methods remain cumbersome. Although dual-modality imaging is a 
promising combination of two imaging modalities, the need for both signals may differ per 
tumor type, type of surgery, or may even differ per patient. In case of superficial tumors, a 
fluorescent signal may suffice, whereas a solitary lymph node metastasis may be detected 
solely based on the radio signal. Dual-modality imaging provides a powerful combination of 
two complementary imaging modalities, and several strategies can be used to improve its 
performance in clinical practice. 
Selecting the best targeting agent
In this thesis several tumor-targeting tracers are described at different stages of clinical 
development; girentuximab for clear cell renal cell carcinoma (ccRCC), labetuzumab for 
colorectal cancer and farletuzumab for ovarian cancer. Ideally, an intraoperative imaging 
tracer can be used in a broad range of cancer types. Therefore, the search for the ideal 
target continues and focuses on pancarcinoma markers, such as the epidermal growth 
factor receptor (EGFR) and vascular endothelial growth factor (VEGF). Promising results have 
been reported with intraoperative VEGF-targeted fluorescence imaging using Bevacizumab-
IRDye800CW in colorectal cancer [3], breast cancer [4] and dysplastic oesophageal lesions [5], 
while studies are ongoing in pancreatic cancer (clinicaltrials.gov: NCT02743975). However, 
for any pancarcinoma tracer concessions are inevitable as higher uptake and specificity may 
be obtained by selecting the optimal tracer for each tumor type. Therefore, one tracer that 
fits all cancer patients probably will remain an illusion.     
 All studies described in this thesis used monoclonal antibodies as targeting agents 
for molecular imaging. An important advantage of the large size of antibodies is that they can 
easily be labeled with both a radiolabel and a fluorescent molecule without compromising 
the affinity to their target antigen and without significantly changing the in vivo behavior 
of the antibody [6]. However, depending on the intended application, the relatively slow 
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pharmacokinetics of antibodies can be an important drawback. To obtain an optimal tumor-
to-normal tissue ratio, an interval of one or more days is required between antibody injection 
and imaging. This can be inconvenient for logistical reasons for both the patient and the 
hospital. Since rapid imaging is preferred, several investigators have tried the use of engineered 
antibody fragments [7] or small molecules [8-10]. Due to their quicker clearance however, 
tumor uptake of these smaller molecules is generally lower than with intact antibodies 
[11, 12]. Thus, although antibody fragments reduce the optimal interval between imaging 
and time of injection, the absolute uptake in the tumor may not be optimal for imaging. In 
addition, the renal clearance of smaller molecules may result in a high background signal 
hampering intraoperative detection of intra-abdominal tumors. Especially for ccRCC, a high 
tumor-to-normal kidney ratio is needed. Turkbey et al. demonstrated that PET imaging with 
the anti-CAIX small molecule tracer 18F-VM4-037 allowed visualization of metastatic ccRCC 
as early as one hour after injection, but that imaging primary ccRCC was problematic due to 
the high background signal in the kidneys [8]. Preclinical studies with a 99mTc-labeled ligand 
of CAIX [13] and the dual-motif CAIX ligand 64Cu-XYIMSR-06 [9], resulted in tumor-to-normal 
kidney ratios of 2.9 (6 h after injection) and 7.1 (24 h after injection) respectively, which may 
be sufficient for imaging of primary ccRCC, but clinical results have to be awaited. 
Radionuclides
For targeted imaging the half-life of the radionuclide should match the pharmacokinetics 
of the targeting agent. Radionuclides with a half-life of several days are required to enable 
targeted imaging with antibodies. When using radiolabels combined with fluorescent labels, 
radiobleaching, a radiation-induced loss of the fluorescence signal of the fluorescent label 
may occur, but preclinical studies have shown that this can be prevented by adding oxygen 
radical scavengers [14]. An alternative approach to dual-labeled tracers is a co-injection of 
both a radiotracer and a fluorescent tracer, but the biodistribution of both tracers may differ, 
complicating interpretation of the imaging results. 
 Next, it is important that the decay mode and radiation energy of the radionuclide 
matches the intended clinical application, e.g. SPECT, PET or radionuclide therapy. PET 
has distinct advantages over SPECT imaging in the clinical setting; it has a higher spatial 
resolution, faster 3D image acquisition and more straightforward quantification. Currently, 
89Zr-labeled monoclonal antibodies (PET-tracers) are the subject of extensive research in 
clinical trials [15-18]. 89Zr is a residualizing radionuclide: after intracellular degradation of the 
labeled antibody, free 89Zr is trapped in the tumor cells, which results in a higher tumor-to-
normal tissue contrast compared to a non-residualizing radionuclide like 124I [19]. Chapter 7 
demonstrates the excellent imaging properties of 89Zr-girentuximab PET/CT for the evaluation 
of patients suspected of ccRCC. 
 Although 89Zr is highly suitable for PET imaging, the high energy photons that are 
emitted during decay of 89Zr (909 keV, and after annihilation of the positron two 511 keV 
photons) complicate intraoperative tumor localization. This would require extensively 
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shielded gamma probes for accurate tumor localization and would expose both the patient 
and the surgical team to a relatively high radiation dose, making 89Zr-labeled probes less 
suitable for intraoperative guidance. For dual-modality imaging the medium energy photons 
of 171 and 245 keV that are emitted during decay of 111In, another residualizing radionuclide, 
are more useful for intraoperative radiodetection by gamma probe. 
Fluorescent dyes
In the design of a targeted imaging tracer for dual-modality imaging, one has to define 
the optimal conditions (e.g. dosing, substitution ratio, timing) for each label without 
compromising image quality and tumor-specificity of the other imaging modality. The 
sensitivity of intraoperative fluorescence imaging might be improved by enhancing the 
fluorescent signal through higher protein doses or by increasing the number of fluorescent 
molecules per antibody molecule (substitution ratio). As observed in the clinical trial with 
111In-DOTA-girentuximab-IRDye800CW (chapter 6), a subjective increase in fluorescence 
intensity was seen at higher protein doses, but this resulted in a decreased tumor-to-normal 
ratio as measured by intraoperative radiodetection by gamma probe and therefore this dose 
was considered suboptimal. The alternative, higher substitution ratios, is also problematic 
since a substitution ratio of more than 2 leads to quicker clearance, a decreased tumor uptake 
and increased liver uptake, subsequently resulting in a lower tumor-to-normal tissue ratio 
[6]. Furthermore, because random conjugation of fluorescent molecules to antibodies may 
interfere with antigen-binding, a high substitution ratio may alter the immunoreactivity and 
the affinity of the antibody. These limitations could be overcome by applying site-specific 
conjugation methods, for example by conjugating the fluorophore and/or chelate to the 
glycosyl side chains of the heavy chains of the antibody [20], preventing that the conjugation 
would compromise the immunoreactivity of the antibody molecule [21]. For nanobodies, it 
has been shown that site-specific conjugation of IRDye800CW affects the biodistribution and 
clearance, with higher tumor-to-muscle ratios compared to the randomly labeled tracer [22]. 
Alternatively, new dyes with better fluorescent properties might improve image quality. Dyes 
with a higher quantum yield, defined as the number of photons emitted per photon absorbed, 
together with a higher molar absorption coefficient leads to a stronger fluorescent signal 
[23]. Dyes that emit light in the near-infrared II range from 1000 to 1700 nm instead of the 
near-infrared I range (700-1000 nm) might also be beneficial. Photons at longer wavelengths 
are less prone to attenuation and scattering but at the cost of more autofluorescence [24]. 
However, these dyes generally have a lower quantum yield (0.01-1.4%) than near-infrared 
dyes (10-80%) [25]. The use of these near-infrared II dyes in clinical practice would require 
substantial adjustments in clinical imaging systems, in addition to in depth toxicity and 
biodistribution studies.
 In addition, photosensitizers (e.g. IRDye700DX), molecules that possess both 
fluorescent and phototoxic properties upon irradiation with near-infrared light (photodynamic 
therapy) are being developed. Although this technique has to be further investigated and 
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optimized, targeted photodynamic therapy (e.g. a photosensitizer coupled to a targeting 
molecule) may in the future be useful for both intraoperative fluorescence imaging and 
therapy to eradicate residual tumor cells by irradiating the surgical cavity with near-infrared 
light [26, 27].  
Improving clinical imaging systems
The performance of intraoperative fluorescence imaging may also be increased by 
improvements in the imaging systems. In our clinical intraoperative imaging study (chapter 
6), fluorescence imaging during open surgery was much more straightforward than during 
laparoscopic procedures. To obtain a reliable tumor-to-normal tissue fluorescent contrast, 
it was essential to approach the tumor perpendicularly with the imaging probe, but 
manoeuvrability of the probe was restricted in laparoscopy due to the fixed position of the 
trocars. Van Oosterom et al. demonstrated the use of a drop-in gamma probe prototype 
that can be completely inserted through a 12-mm trocar after which it can be picked up by 
the surgeon by laparoscopic or robotic instruments [28]. This drop-in technology maintains 
the autonomy of the surgeon, while simultaneously increasing the manoeuvrability of the 
gamma probe and might also be extended to other imaging modalities [28]. In addition, the 
increase in robot-assisted procedures requires imaging systems that are compatible with 
robotic surgery as well. 
 Most currently available clinical fluorescence imaging systems are designed to detect 
high concentrations of indocyanine green (ICG) in the blood, but in fluorescent imaging using 
a specific tumor-targeting molecule, concentrations of the fluorescent tracer are in general 
several orders of magnitudes lower [29]. This sets strict demands on the sensitivity of the 
imaging systems. Improvements in software systems, emission filters, background correction 
and charge-coupled device (CCD) cameras are expected to enhance the sensitivity of next-
generation fluorescence imaging systems [29]. Although the possibility to individually adjust 
fluorescence imaging settings during surgery is interesting for research and optimization of 
the technique, the introduction of fluorescence imaging as a standard of care would require 
an easy-to-use camera that maintains the autonomy of the surgeon. 
TOWARDS SUCCESSFUL CLINICAL IMPLEMENTATION
The development of new agents for diagnostic or therapeutic purposes in the clinical setting 
usually takes a long time. Many agents fail during development somewhere along the road 
from design to clinical use: during optimization and assessment of toxicity and biodistribution 
in animal studies, or during the first studies in humans/patients [30]. An important factor is 
that animal tumor models only partly reflect the clinical situation [31]. Animal studies are 
suitable for primary in vivo evaluation of a tracer, but compared to the patient situation major 
differences in tumor vascularization, antigen expression, tumor biology and size ratios exist. 
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Aside from differences in animal models, the sensitivity of preclinical and clinical imaging 
systems differs too.
 The use of human tumor material in an ex vivo setting may help to bridge the gap 
between preclinical and clinical research [27]. Incubation or perfusion of human tumor and 
normal tissues with a tracer can be used to study the binding and help to better estimate the 
translatability of tumor-targeted imaging or therapies [27]. In chapter 5 we studied targeted 
dual-modality imaging in a translational setting with ex vivo perfusion of radical nephrectomy 
specimens using preclinical and clinical imaging systems. This model proved to be a good 
predictor for tumor uptake and tumor-to-normal fluorescent contrast as observed in the 
clinical trial with ccRCC patients (chapter 6). This type of translational studies allows for 
the ex vivo characterization of new tracers and can provide valuable information about the 
feasibility of a technique in humans.
  
OTHER IMAGING MODALITIES
 
All intraoperative imaging systems have advantages and disadvantages, and a combination of 
several techniques probably provides the best information to optimize patient management. 
Chapter 4 describes several other techniques that can be used for intraoperative imaging 
in renal cell carcinoma surgery (ultrasound, optical coherence tomography and augmented 
reality). However, even more techniques are being developed. 
 A different approach to obtain both a radiosignal and an optical signal is Cerenkov 
Luminescence Imaging (CLI). CLI studies Cerenkov light that is produced when charged 
particles traverse a medium at superrelativistic speed [32, 33]. Ex vivo assessment of resected 
breast cancer specimens showed promise in the evaluation of surgical margins with CLI [33]. 
However, the low tissue penetration depth of the blue light of CLI is an important limitation. 
Furthermore, the low light yield of CLI requires imaging in a closed and light-protected 
scanner which currently limits its use for real-time image-guided surgery. 
 As discussed, the major drawback of fluorescence-guided surgery is the limited 
penetration depth of light in biological tissue. An interesting technique with a higher tissue 
penetration depth is optoacoustic imaging. In optoacoustic imaging, tissue is illuminated 
with (near-infrared) light, and the absorption of this light in tissue results in the production of 
ultrasound waves due to thermoelastic expansion [34]. These sound waves can be converted 
into an image. Since sound waves are less prone to scattering in tissue than photons, a 
higher in-depth resolution can be obtained with optoacoustics compared to fluorescence 
imaging. By illuminating with multiple wavelengths, the distribution of different molecules 
can be distinguished based on their absorption profile (multispectral optoacoustics or 
MSOT) [34]. Clinical trials have demonstrated that MSOT is able to identify sentinel lymph 
node metastases in melanoma patients [35] and can be used for 3D mapping of skin tumors 
[36], but this technology is still very novel and more research is needed.    
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CONCLUSION
In this thesis several applications of targeted imaging are described using radiolabeled and 
fluorescently labeled antibodies. The main focus of this thesis was to translate targeted 
dual-modality imaging to the clinic. Intraoperative dual-modality imaging was successfully 
achieved with dual-labeled girentuximab in ccRCC, while clinical studies in colorectal cancer 
and ovarian carcinoma are in preparation. Improvements in targeted tracers and imaging 
systems may further increase the value of intraoperative dual-modality imaging. There is not 
a single imaging technique that solves all problems that can be encountered during surgery. 
The choice of the intraoperative imaging technique depends on patient characteristics and 
the specific demands of the surgeon. In the future, the combination of several intraoperative 
techniques that provide information on both the macroscopic and the microscopic level, in a 
multimodal imaging approach, may deliver the best information to lead patient management 
in a personalized fashion.   
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SUMMARY
Sensitive non-invasive or intraoperative imaging techniques can improve the management of 
patients with cancer. In tumor-targeted imaging targeting vehicles like monoclonal antibodies 
are used that specifically recognize tumor-associated antigens. When a radionuclide or a 
fluorescent molecule is conjugated to a tumor-targeting monoclonal antibody, a tumor-
targeting imaging tracer is created that can be used to visualize the primary tumor or 
metastases with, for example, Positron Emission Tomography (PET), Single-Photon Emission 
Computed Tomography (SPECT) or fluorescence imaging. In this thesis several preclinical 
and clinical applications of radiolabeled and/or fluorescently labeled antibodies have been 
investigated aiming to translate tumor-targeted imaging to the clinic. 
Part I includes two chapters that describe FRα- and CEA-targeted dual-modality imaging in 
an ovarian cancer and a colorectal cancer model, respectively. In chapter 2 targeted dual-
modality imaging using 111In-farletuzumab-IRDye800CW, a tracer that specifically recognizes 
the folate receptor alpha (FRα), was applied in a preclinical setting. First, a protein dose-
escalation study (3, 10, 30, 100 µg) was performed in mice with subcutaneous FRα-expressing 
IGROV-1 xenografts. Highest tumor uptake (up to 43.6 ± 4.8 % ID/g) and highest tumor-to-
blood ratios (3.4 – 3.7) were found at protein doses ranging from 3 to 30 µg. Next, experiments 
were performed in a clinically more relevant model with mice bearing intraperitoneal IGROV-1 
tumors. Three days after injection of 10 µg 111In-farletuzumab-IRDye800CW, intraperitoneal 
tumors could be clearly visualized by microSPECT/CT imaging and subsequently resected 
with fluorescence-guided surgery. Dual-modality imaging using 111In-farletuzumab-
IRDye800CW can be valuable in ovarian cancer patients, since ovarian carcinomas highly 
overexpress FRα and many patients present in an advanced stage with intraperitoneal tumor 
deposits. Intraoperative dual-modality imaging may be useful to guide the surgeon towards 
small tumor deposits and help to reach complete tumor resection. 
 In chapter 3 the value of targeted dual-modality imaging was further investigated 
with the carcinoembryonic antigen (CEA) specific tracer 111In-labetuzumab-IRDye800CW in 
a colorectal cancer model. To be of optimal benefit in the operating room, dual-modality 
imaging should be able to detect tumors that could be missed by the naked eye. To 
evaluate whether this is feasible, mice were injected intravenously with CEA-expressing 
GW-39 colon cancer cells to induce micrometastatic pulmonary tumor lesions. As early as 
one week after tumor cell injection, microSPECT and fluorescence imaging after injection 
of 111In-labetuzumab-IRDye800CW detected submillimeter pulmonary tumor lesions that 
were not visible to the naked eye. Although the resolution and sensitivity of the imaging 
systems used in this preclinical study differ from the ones that are used in the clinic, this 
study shows the potential of targeted dual-modality imaging to detect and guide resection 
of micrometastases.
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Part II includes four chapters that describe the need for and the clinical implementation of 
targeted imaging using radiolabeled and dual-labeled girentuximab (specifically recognizing 
carbonic anhydrase IX) in clear cell renal cell carcinoma (ccRCC). 
 Chapter 4 provides a state-of-the-art overview of the current and upcoming imaging 
techniques that can be used during surgery of renal tumors. During partial nephrectomy it 
can be difficult to localize the tumor or to delineate tumor borders, especially in larger or 
more complex tumors. Intraoperative ultrasound is best embedded in the operating room 
due to its ease of use and the wide availability. It can be used to localize and delineate 
tumors intraoperatively. However, live imaging during tumor resection is not feasible, since 
the probe interferes with the resection as it has to stay in close contact with the tissue. 
Intraoperative fluorescence imaging with both non-targeted (Indocyanine green, 5-ALA) and 
targeted (OTL38, folate-FITC) tracers has been investigated in cancer patients, but the limited 
penetration depth of fluorescence is the major limitation. Augmented reality can be a valuable 
intraoperative aid during tumor resection, if tissue deformation issues can be overcome. In 
this review it was concluded that there is not yet one imaging technique that is ideal for all 
patients and that the added value of intraoperative imaging techniques still has to be proven 
in larger controlled trials. It shows that there is a need for sensitive intraoperative imaging 
techniques that can help the surgeon in nephron-sparing surgery.
 Targeted dual-modality imaging using dual-labeled girentuximab could be a 
valuable tool to guide resection of ccRCC. The feasibility of the technique was previously 
demonstrated in mice with ccRCC tumors, but several challenges can arise when results of 
animal studies are translated to the human situation. In chapter 5 targeted dual-modality 
imaging was investigated in a translational setting. Seven tumorous kidneys (resected from 
ccRCC patients) were perfused with 111In-girentuximab-IRDye800CW. Autoradiography and 
fluorescence imaging of a tissue slice with preclinical and clinical imaging systems showed 
high uptake of 111In-girentuximab-IRDye800CW in tumor tissue and a clear tumor-to-normal 
kidney contrast. The specific binding of girentuximab to CAIX was demonstrated in a dual-
isotope perfusion experiment in two tumorous kidneys that were perfused simultaneously 
with 131I-girentuximab and 125I-irrelevant control IgG. 
 These encouraging results warranted the initiation of the first in man tumor-targeted 
dual-modality imaging study with 111In-girentuximab-IRDye800CW in ccRCC patients. 
Results of this study are described in chapter 6. The aim of this study was to demonstrate 
the feasibility and safety of intraoperative dual-modality imaging with 111In-girentuximab-
IRDye800CW. Fifteen patients, twelve with a CAIX-positive ccRCC and 3 with a CAIX-negative 
tumor, were injected with escalating protein doses (5 to 50 mg) of 111In-girentuximab-
IRDye800CW seven days before surgery.  The injection was well tolerated by all patients. In all 
twelve ccRCC patients, the tumor could be visualized preoperatively with SPECT/CT imaging 
and subsequently localized intraoperatively by gamma probe (mean tumor-to-normal 
kidney ratio 2.5 ± 0.8). All ccRCC were hyperfluorescent and fluorescence imaging correctly 
identified one positive surgical margin intraoperatively. In the three patients with a CAIX-
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negative tumor, no discriminatory uptake of 111In-girentuximab-IRDye800CW in the tumor 
was detected (mean tumor-to-normal kidney ratio 1.0 ± 0.1). This study was the first to show 
that 111In-girentuximab-IRDye800CW can safely be used as a tumor-targeting contrast agent 
for the intraoperative guidance of ccRCC resection. 
 While Indium-111 is a suitable radionuclide for intraoperative radiodetection 
by gamma probe, positron-emitting radionuclides are preferred for imaging since in the 
clinical setting PET has distinct advantages over SPECT (higher spatial resolution, shorter 
acquisition time). The study presented in chapter 7 showed that girentuximab, when labeled 
with Zirconium-89, can be a valuable diagnostic tool in patients suspected for ccRCC. Thirty 
patients were studied in whom the clinician faced a diagnostic dilemma regarding the 
presence or absence of ccRCC defined as doubt about the best medical treatment based 
on conventional diagnostics. Sixteen patients with an indistinct primary renal mass were 
included and 89Zr-girentuximab PET/CT imaging was used for decision making (surgery/
active surveillance). Accumulation of 89Zr-girentuximab in the renal mass is indicative of 
ccRCC, whereas the absence of 89Zr-girentuximab uptake in the tumor is suggestive of a 
benign tumor or a non-clear cell and in general less aggressive subtype RCC.  All resected 
PET-positive primary lesions proved to be ccRCC, while no lesion progression was seen in 
PET-negative tumors. Fourteen patients with a history of ccRCC and suspicious lesions in 
the follow-up were also studied. In this group, 89Zr-girentuximab PET/CT imaging was useful 
to confirm or exclude ccRCC prior to surgery with curative intent, to evaluate the extent 
of the disease, and to differentiate ccRCC from other cancers. 89Zr-girentuximab PET/CT 
imaging lead to a major change in clinical management in five patients. We concluded that 
89Zr-girentuximab PET/CT is a valuable diagnostic tool that can guide clinical decision making 
in case of diagnostic dilemmas concerning ccRCC suspicion.
Overall, the studies described in this thesis have contributed to the clinical translation of 
targeted imaging using radiolabeled and fluorescently labeled antibodies. The preclinical 
studies have added to the evidence that dual-modality imaging can be feasible in colorectal 
and ovarian cancer and clinical trials with dual-labeled labetuzumab and farletuzumab are 
warranted. Furthermore, this thesis resulted in the clinical implementation of two different 
applications of targeted imaging with girentuximab; as a sensitive non-invasive whole body 
imaging tool to detect ccRCC (89Zr-girentuximab PET/CT imaging) and for intraoperative 
guidance of ccRCC resection (dual-modality imaging using 111In-girentuximab-IRDye800CW). 
Therefore, the studies in this thesis contribute to improving both the diagnosis and prognosis 
of oncology patients. Ultimately, the combination of several intraoperative techniques may 
deliver the best information to lead patient management in a personalized fashion.   
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SAMENVATTING
Sensitieve niet-invasieve preoperatieve of intraoperatieve beeldvormende technieken 
kunnen bijdragen aan een verbeterde behandeling van patiënten met kanker. Bij targeted 
imaging wordt gebruik gemaakt van moleculen, bijvoorbeeld monoklonale antilichamen, 
gericht tegen tumor-geassocieerde antigenen. Door het koppelen van een radionuclide of 
een fluorescent label aan een monoklonaal antilichaam, ontstaat een tumor-targeted tracer, 
die gebruikt kan worden om de primaire tumor en eventuele metastasen in beeld te brengen 
met Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography 
(SPECT) of fluorescentie imaging. In dit proefschrift worden verschillende toepassingen 
van radioactief en/of fluorescent gelabelde antilichamen onderzocht met als doel om 
beeldvorming met tumor-targeted tracers te implementeren in de kliniek.  
Deel 1 van dit proefschrift bevat twee hoofdstukken die FRα- en CEA-targeted dual-modality 
imaging beschrijven in preklinische modellen voor respectievelijk eierstok- en darmkanker. 
In hoofdstuk 2 wordt targeted dual-modality imaging met 111In-farletuzumab-IRDye800CW, 
een antilichaam dat specifiek bindt aan de folaat receptor alpha (FRα), onderzocht in een 
dierstudie. Als eerste werd een eiwit dosis-escalatie studie (3, 10, 30, 100 µg) uitgevoerd in 
muizen met subcutane IGROV-1 tumoren die  FRα tot expressie brengen. De hoogste tumor 
opname (tot 43.6 ± 4.8 % ID/g) en de hoogste tumor-tot-bloed ratio (3.4 - 3.7) werden gevonden 
na injectie van een eiwitdosis tussen de 3 en 30 µg. Vervolgens werden experimenten 
uitgevoerd in een model dat relevanter is voor de klinische situatie, namelijk in muizen 
met intraperitoneale IGROV-1 tumoren. Drie dagen na injectie van 10 µg 111In-farletuzumab-
IRDye800CW konden tumoren duidelijk zichtbaar worden gemaakt met de microSPECT/
CT. De tumoren konden vervolgens verwijderd worden op basis van fluorescentie imaging. 
Deze techniek zou waardevol kunnen zijn bij operaties van patiënten met eierstokkanker 
(ovariumcarcinoom). Deze tumor brengt namelijk veel FRα tot expressie en veel patiënten 
presenteren zich in een vergevorderd stadium met meerdere metastasen verspreid door de 
buikholte (peritonitis carcinomatosa). Intraoperatieve dual-modality imaging zou de chirurg 
kunnen helpen om deze metastasen op te sporen en compleet te verwijderen.
 In hoofdstuk 3 wordt de waarde van targeted dual-modality imaging verder 
onderzocht in een muizenmodel voor darmkanker (colorectaal carcinoom: CRC) met 
behulp van een carcino-embryonic antigeen (CEA) specifiek antilichaam (111In-labetuzumab-
IRDye800CW). Om optimaal te kunnen bijdragen tijdens de operatie, moet dual-modality 
imaging in staat zijn om tumoren te detecteren die gemist kunnen worden met het blote 
oog. Om dit te onderzoeken werden muizen intraveneus geïnjecteerd met CEA-positieve GW-
39 darmkanker cellen die vervolgens uitgroeiden tot micrometastasen in de longen. Reeds 
na één week tumorgroei waren microSPECT en fluorescentie imaging in staat om tumoren 
kleiner dan een millimeter in de longen zichtbaar te maken, die nog niet met het blote oog 
te zien waren. Hoewel de resolutie en sensitiviteit van de beeldvormende systemen die in 
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deze preklinische studie gebruikt werden verschillen van systemen die in de kliniek gebruikt 
worden, toont deze studie dat targeted dual-modality imaging een waardevolle techniek kan 
worden in de operatiekamer. 
Deel II van dit proefschrift bevat vier hoofdstukken die de noodzaak van en de klinische 
toepassing van targeted imaging met girentuximab in patiënten met een heldercellig 
niercelcarcinoom (Engels: clear cell renal cell carcinoma: ccRCC) beschrijven. Girentuximab 
is een monoklonaal antilichaam dat specifiek carbonzuur anhydrase IX herkent, een 
antigeen dat in hoge mate tot expressie komt bij ccRCC. Hoofdstuk 4 geeft een overzicht 
van de huidige beeldvormende technieken die gebruikt kunnen worden tijdens chirurgie 
van niertumoren. Tijdens een partiële nefrectomie kan het moeilijk zijn om de tumor te 
lokaliseren en af te grenzen van het normale nierparenchym, vooral bij grotere en complexere 
tumoren. Intraoperatieve echo wordt het meest gebruikt in de operatiekamer vanwege het 
gebruiksgemak en de brede beschikbaarheid. Echografie kan gebruikt worden om de tumor te 
lokaliseren en de overgang tussen tumor en normaal weefsel in beeld te brengen. Het nadeel 
van echo is dat de probe in nauw contact moet blijven met het weefsel, waardoor real-time 
imaging tijdens tumor resectie niet mogelijk is. Verschillende toepassingen van intraoperatieve 
fluorescentie imaging zijn onderzocht, zowel met non-targeted tracers (indocyanine groen, 
5-ALA) als targeted tracers (OTL38, folaat-FITC). Het beperkte doordringend vermogen van 
fluorescentie in weefsel vormt echter een belangrijke beperking voor de toepassing van deze 
techniek. Augmented reality zou een waardevolle ondersteuning kunnen zijn tijdens resectie 
van de tumor, mits het probleem van de vervorming van weefsel kan worden opgelost. De 
conclusie van dit overzichtsartikel is dat er nog geen universele beeldvormende techniek 
is die geschikt is voor alle patiënten en dat er meer studies nodig zijn om de toegevoegde 
waarde van intraoperatieve beeldvorming tijdens een partiële nefrectomie aan te tonen. Dit 
onderstreept de noodzaak voor nieuwe intraoperatieve beeldvormende technieken die de 
chirurg kunnen helpen bij niersparende chirurgie.   
 Targeted dual-modality imaging met radioactief en fluorescent gelabeld 
girentuximab (111In-girentuximab-IRDye800CW) zou gebruikt kunnen worden voor de 
intraoperatieve detectie van ccRCC. De toepasbaarheid van deze techniek werd eerder 
aangetoond in muizen met subcutane ccRCC tumoren, maar deze resultaten kunnen niet 
altijd rechtstreeks vertaald worden naar de humane situatie. In hoofdstuk 5 wordt targeted 
dual-modality imaging onderzocht in een translationele setting. Zeven chirurgische resectie 
preparaten van patiënten verdacht van een ccRCC werden via de nierarterie geperfundeerd 
met 111In-girentuximab-IRDye800CW. Met autoradiografie en fluorescentie imaging van een 
lamel van het preparaat met preklinische en klinische beeldvormende systemen was het 
mogelijk om hoge opname van 111In-girentuximab-IRDye800CW in tumorweefsel zichtbaar 
te maken en beide technieken toonden een groot contrast tussen de tumor en het normale 
nierweefsel. De specifieke binding van girentuximab aan CAIX-expresserend tumorweefsel 
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werd bevestigd in een dual-isotoop perfusie experiment met twee nieren die geperfundeerd 
werden met zowel 131I-girentuximab en een irrelevant controle antilichaam gelabeld met 125I. 
 Deze bemoedigende resultaten hebben geleid tot de start van de eerste klinische 
studie naar tumor-targeted dual-modality imaging in patiënten met ccRCC. De resultaten van 
deze studie worden beschreven in hoofdstuk 6. Het doel van deze studie was om de veiligheid 
en toepasbaarheid van intraoperatieve dual-modality imaging met 111In-girentuximab-
IRDye800CW aan te tonen. Vijftien patiënten, twaalf met een CAIX-positieve ccRCC tumor 
en drie met een CAIX-negatieve tumor, werden een week voor de operatie geïnjecteerd 
met 111In-girentuximab-IRDye800CW. De injectie werd door alle patiënten goed verdragen. 
In alle twaalf patiënten met een ccRCC was de tumor preoperatief duidelijk zichtbaar op 
de SPECT/CT en kon de tumor intraoperatief gelokaliseerd worden met een gamma probe 
(gemiddeld contrast tussen tumor en normaal nierweefsel 2.5 ± 0.8). In alle ccRCC patiënten 
werd verhoogde fluorescentie van de tumor ten opzichte van normaal nierweefsel gezien. Bij 
één patiënt werd met behulp van fluorescentie imaging een positief snijvlak gedetecteerd. 
In de drie patiënten met een CAIX-negatieve tumor werd geen verhoogde opname van 
111In-girentuximab-IRDye800CW in de tumor gemeten (gemiddeld contrast tussen tumor 
en normaal nierweefsel 1.0 ± 0.1). Dit is de eerste klinische studie die aantoont dat 
111In-girentuximab-IRDye800CW veilig gebruikt kan worden als tumor-targeted contrastmiddel 
voor de intraoperatieve detectie en resectie van ccRCC. 
 Hoewel Indium-111 een geschikt radionuclide is voor intraoperatieve radiodetectie 
met een gamma probe, zijn radionucliden die gedetecteerd kunnen worden met PET, 
geschikter voor klinische beeldvorming, omdat PET als voordeel heeft dat de resolutie hoger 
is vergeleken met SPECT. De studie beschreven in hoofdstuk 7 laat zien dat girentuximab 
gelabeld met Zirconium-89 een waardevol diagnosticum kan zijn voor patiënten verdacht 
van een ccRCC. Er werden dertig patiënten onderzocht waarbij er sprake was van een 
diagnostisch dilemma betreffende ccRCC, gedefinieerd als twijfel over de beste behandeling 
gebaseerd op conventionele diagnostische technieken. Zestien patiënten hadden een 
niertumor van onbekende origine en 89Zr-girentuximab PET/CT imaging werd gebruikt in 
de beslissing tussen opereren versus actief volgen. Stapeling van 89Zr-girentuximab in de 
tumor wijst op een ccRCC, terwijl afwezigheid van stapeling wijst op een benigne afwijking 
of een niet-ccRCC, die in het algemeen minder agressief zijn. Alle PET-positieve tumoren die 
verwijderd werden bleken inderdaad ccRCC, terwijl er tijdens het actief volgen van de PET-
negatieve tumoren geen groei van deze tumoren werd gezien. Er werden tevens veertien 
patiënten bestudeerd die bekend waren met een ccRCC in het verleden en die zich nu 
presenteerden met een voor ccRCC verdachte afwijking op conventionele beeldvorming. 
In deze groep was 89Zr-girentuximab PET/CT imaging bruikbaar om ccRCC te bevestigen 
of uit te sluiten voordat overgegaan werd tot in opzet curatieve chirurgie. Verder was 
89Zr-girentuximab PET/CT imaging bruikbaar om de uitgebreidheid van ziekte te bepalen 
en om ccRCC te differentiëren van andere vormen van kanker. 89Zr-girentuximab PET/CT 
imaging leidde tot een significante verandering in klinische besluitvorming bij vijf patiënten. 
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We concludeerden dat 89Zr-girentuximab PET/CT imaging een waardevol diagnosticum kan 
zijn bij de klinische besluitvorming in het geval van diagnostische dilemma’s bij patiënten 
verdacht van een ccRCC.   
Het doel van de studies beschreven in dit proefschrift was de klinische implementatie van 
beeldvorming met radioactief en fluorescent gelabelde antilichamen. De preklinische 
studies ondersteunen de hypothese dat targeted dual-modality imaging bruikbaar kan 
zijn voor patiënten met colorectaalcarcinoom en ovariumcarcinoom en dat klinische 
studies met dual-labeled labetuzumab en farletuzumab kunnen worden gestart. Daarnaast 
heeft dit proefschrift twee verschillende klinische toepassingen van targeted imaging met 
girentuximab laten zien: als een sensitieve non-invasieve manier om ccRCC door het hele 
lichaam te detecteren (89Zr-girentuximab PET/CT imaging) en als intraoperatief hulpmiddel 
voor de detectie en resectie van ccRCC (dual-modality imaging met 111In-girentuximab-
IRDye800CW). Samenvattend,  de studies in dit proefschrift laten zien dat de behandeling van 
patiënten met kanker door de ontwikkeling van gevoelige preoperatieve en intraoperatieve 
beeldvormende technieken verbeterd kan worden. Uiteindelijk kan een combinatie van 
verschillende intra-operatieve beeldvormende technieken de optimale informatie geven 
leidend tot individuele patiënt management.
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en buitenland, zoals de Vlietstraprijs voor beste presentatie op de vergadering van de 
Nederlandse vereniging voor urologie. Gedurende haar promotie-onderzoek was Marlène 
ook op organisatorisch vlak nauw betrokken, zoals bij de organisatie van de PhD retreat, het 
dagje uit van de afdeling urologie en de urologische research meetingen. 
In juli 2017 begon zij aan de specialisatie tot uroloog.
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DANKWOORD
It’s done! Dit proefschrift is het resultaat van ruim vier jaar onderzoek. Ondanks dat ik mijn 
hele geneeskunde opleiding gezegd heb dat ik echt geen onderzoek ging doen. Met heel veel 
plezier heb ik de afgelopen jaren aan mijn promotieonderzoek gewerkt op de afdelingen 
Urologie en Radiologie & Nucleaire geneeskunde. Dat ik het zo naar mijn zin heb gehad en 
dat dit boekje gevuld is geraakt, is mede dankzij vele personen!   
Ten eerste wil ik mijn promotoren, prof. dr. Mulders en prof. dr. Boerman, en co-promotoren, 
dr. Rijpkema en dr. Oosterwijk, bedanken. 
 Beste prof. Mulders, beste Peter, dank dat je me de kans gaf om op jouw afdeling 
onderzoek te doen. Gedurende onze wekelijkse overleggen wist je altijd de rode draad van 
mijn onderzoek te bewaken. Tijdens de nierkankerpoli, heb ik met bewondering gekeken, 
hoe je je patiënten hoop kon laten houden. Het vertrouwen dat je patiënten in je hebben, 
heeft eraan bijgedragen dat de inclusie van de klinische studies zo voortvarend liep. Dank 
daarvoor!   
 Beste prof. Boerman, beste Otto, jouw deur stond altijd open. Je was altijd 
geïnteresseerd in de details van mijn onderzoeksresultaten, maar wilde toch eerst weten of ik 
het weekend nog wat leuks had gedaan. Ik heb je sociale inbreng in de Nucmed groep altijd 
enorm bewonderd. Wat was het jammer dat je besloot om weg te gaan, maar wat fijn dat je 
mijn promotor wilde blijven. 
 Beste dr. Rijpkema, beste Mark, dank voor de fijne en motiverende begeleiding. 
Je hebt voor elkaar gekregen wat ik nooit voor mogelijk had gehouden; mij hele dagen op 
het lab laten doorbrengen. Met alle zinnige en minder zinnige vragen kon ik bij jou terecht. 
Je wist mij altijd weer op de juiste weg te helpen. Jouw chemische achtergrond was een 
waardevolle aanvulling op mijn klinische kennis. Dank voor het in detail nalezen van al mijn 
stukken! 
 Beste dr. Oosterwijk, beste Egbert, jij was altijd bereid om kritisch mee te denken 
over de basis van onze experimenten. Of het nou om preklinische of klinische studies ging, 
jij wist altijd wel een valide verklaring te bedenken waarom een experiment wel of niet 
gelukt was. Dankbaar maakte ik gebruik van jouw uitgebreide kennis over G250, cellijnen, 
biodistributies en nog veel meer. Ik heb nog geen vraag kunnen ontdekken die je niet wist te 
beantwoorden met een referentie waar ik het kon vinden. 
Graag wil ik alle patiënten bedanken die, door hun deelname aan de klinische studies met 
radioactief en fluorescent gelabeld girentuximab, hebben bijgedragen aan het implementeren 
van nieuwe diagnostische technieken voor patiënten met een heldercellig niercelcarcinoom. 
Graag wil ik de leden van de manuscriptcommissie, prof. dr. Massuger, prof. dr. De Jong en 
prof. dr. Bussink, bedanken voor het lezen en beoordelen van dit manuscript. 
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Beste prof. Oyen, beste Wim, jouw betrokkenheid bij de klinische studies met girentuximab 
hebben significant bijgedragen aan het succes ervan. Ongelooflijk hoe jij elke keer weer tijd 
wist te vinden om de scans binnen zo korte tijd te verslaan. Dank hiervoor.  
Beste dr. Langenhuijsen, beste Hans, dank voor het aandragen van patiënten voor de 
klinische studies en dank voor het kritisch nalezen van enkele manuscripten.
De afgelopen jaren waren een stuk minder gezellig geweest zonder mijn research collega’s. 
Allereerst mijn nucmed roommates in kamer 3, Wietske, Tessa, Willem, Inge, Stefanie, 
Selen, Wael, Charlotte, Susanne, Fortuné, Tom, Peter, Daphne L en Daphne D. Al luisterend 
naar het foute uur verschenen de manuscripten vloeiend op mijn scherm en werd alles 
aangegrepen als reden voor een borrel; daar houd ik van! Dames, bedankt voor de gezellige 
bieretentjes. Charlotte en Tessa, bedankt voor de mooie Amerika reis die we gemaakt 
hebben aansluitend aan de SNM. Het heeft me geleerd dat op tijd eten helpt voor positieve 
energie en dat je beren best kunt besluipen voor een foto. Sandra, bedankt voor de goede 
adviezen t.a.v. mijn experimenten. Erik, bedankt voor al je hulp bij de Zr-89-girentuximab 
patiënten. Fortuné, Robin en Jan-Marie, dank voor en succes met het voortzetten van de 
onderzoekslijnen uit dit proefschrift! Ook voor de rest van de researchgroep, Peter, Maarten, 
Marti, Mijke, Rian, Martin, Fokko, Eric en Antoi, zonder jullie was onderzoek nooit zo leuk 
geweest! Tot slot wil ik alle laboranten, AIOS en stafleden van de nucleaire geneeskunde 
bedanken voor de gezellige sfeer tijdens het werken op de afdeling en tijdens het dagje uit 
en het weekendje weg.
Verder wil ik alle analisten, Desirée, Janneke, Cathelijne, Gerben, Danny, Annemarie en 
Lieke, bedanken voor hun hulp bij mijn werk op het lab. Hoewel ik aan het begin van mijn 
onderzoek nog nooit van een ‘epje’ had gehoord, hebben jullie mij geholpen vertrouwd te 
raken op het lab. 1000x sorry dat ik op het lab altijd het foute uur aan had staan! Desirée, 
dank voor alle uren die je me geholpen hebt bij de dierexperimenten.  
Zonder de hulp van het trialbureau had ik de klinische studies nooit kunnen uitvoeren. 
Michel en Judith, bedankt voor het plannen van de patiënten en het coördineren van de 
uitdagende logistiek. Dank ook aan de radiofarmacie, Katja en Jolanda, voor de hulp bij het 
ontwikkelen en bereiden van de klinische preparaten. Verder was het Hotlab een letterlijke 
en figuurlijke centrale spil voor de klinische studies. Maichel, Natascha, Danny en Sandra, 
bedankt voor jullie enthousiasme en flexibiliteit bij het uitvoeren van alle labelingen. En niet 
te vergeten alle laboranten die geholpen hebben bij het scannen van de patiënten. 
Aan alle collega-onderzoekers van de urologie, Siebren, Tom, Max, Dick, Boy, Esther, 
Ruben, Rianne, Tim, Maarten, Hans, Allert, Caroline en Elle. Dank voor de vele gezellige 
momenten samen; de feesten, de borrels, en bovenal het koffiedrinken na de overdracht. 
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Tim, jij was mijn G250-mattie tijdens mijn onderzoek en liep net iets voor, waardoor ik met 
al mijn vragen bij je terecht kon. Rianne, tegelijk begonnen aan het onderzoek, tegelijk aan 
de opleiding en nu bijna tegelijk klaar. Samen hebben we heel wat congressen en feestjes 
afgestruind. Fijn dat jij 7 december naast mij staat! 
 Jack, Mirjam, Dorien, Onno, Kees, Gerald, Jeanette, Tilly en alle andere 
medewerkers van de experimentele urologie, dank voor jullie hulp bij het werken op het 
lab en de celkweek; iets wat mij toch niet echt op het lijf geschreven was. Mirjam, bedankt 
dat je me, ondanks je aanvankelijk scepsis, wilde helpen met het perfunderen van de nieren. 
Wat is het een mooi project geworden! 
In aansluiting hierop wil ik de pathologie, en in het bijzonder Arie, bedanken voor hun hulp 
bij het verwerken van de nierpreparaten.  
Ik wil alle medewerkers van PRIME bedanken voor hun hulp bij de dierexperimenten. Jullie 
goede zorg voor de muizen is van onschatbare waarde voor de dieren en voor het slagen van 
de experimenten. Bianca, bedankt voor je waardevolle aanvullingen op mijn experimenten 
en voor je uitmuntende technische vaardigheden. 
Het OK-team van de urologie, bedankt voor jullie inzet en enthousiasme rondom de 
perfusiestudie en de klinische studie met dual-labeled girentuximab. Anja, zonder jou waren 
de studies met dual-labeled girentuximab niet zo soepel verlopen. Dank voor je hulp met de 
logistiek op de OK. 
Dank aan alle stafleden, AIOS en medewerkers van de urologie voor de gezelligheid 
van de afgelopen jaren. Ondanks dat ik op papier bij Radiologie & Nucleaire geneeskunde 
hoorde, voelde ik me tevens als één van jullie. 
Alle collega’s van de heelkunde in het CWZ. Dank voor de leerzame 1,5 jaar die ik bij jullie heb 
gehad. Door jullie is mijn vooropleiding een prachtige tijd geweest. Op sommige momenten 
hebben jullie me bijna weten over te halen toch chirurg te worden.  
Jurre & Jorien, Hugo & Mariët (en Tess), hier is ie dan, mijn ‘schriftje’. Uiteindelijk is het toch 
best een boekwerk geworden. Dank voor alle gezelligheid van de afgelopen jaren. Wat waren 
we een goed team op de tennisbaan! Ik hoop dat we elkaar blijven zien, ondanks dat we nu 
allemaal in andere uithoeken wonen. 
Lieve pap en mam, dank dat jullie me hebben geholpen om te worden wie ik nu ben. Dank 
voor jullie onvoorwaardelijke steun en interesse. Dat heeft me enorm gestimuleerd om 
verder te komen. Ik had me geen betere ouders kunnen wensen. Lieve broer, beste Maarten, 
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dank dat je als paranimf naast mij wilt staan. Heel veel succes met je eigen carrière. Zoals je 
zelf altijd zegt; ‘Het komt wel goed!’.  
Lieve Stijn, je inspirerende verhaal op de NVU over image-guided surgery bij muizen bracht 
mij destijds naar Nijmegen. Dat wilde ik ook doen. Jouw 24/7 begeleiding in de vorm van 
gevraagd en ongevraagd advies hebben me geholpen om dit proefschrift tot een goed 
einde te brengen. De vele uren die we samen op de fiets of hardlopend in het bos hebben 
doorgebracht, waren een welkome afwisseling tijdens het schrijven van de manuscripten. 
Lief, ik kijk uit naar de vele jaren die voor ons liggen. Je maakt me enorm gelukkig.  

